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Deutsche Zusammenfassung 
Die Bakteriophagen Integrase PhiC31 stellt ein viel versprechendes Werkzeug zur Integration 
genetischen Materials im nicht viral-basierten Gentransfer dar. Die PhiC31 Integrase 
vermittelt die Rekombination von spezifische Erkennungssequenz attB enthaltenden 
Plasmiden mit natürlich vorkommenden attP Erkennungssequenzen innerhalb des Zielgenoms 
mit unterschiedlicher Integrationsfrequenz und -spezifität. Nebeneffekte der Integration in 
Form von insertioneller Mutagenese, wie z.B. große Deletionen und chromosomale 
Veränderungen im Genom der Zielzelle konnten beobachtet werden. 
Ziel dieser Dissertation war, die PhiC31 vermittelte Effizienz zu verbessern und die Spezifität 
zu adressieren. Als Ansatz wurde die Mutagenese der DNA-Bindungsdomäne der Integrase 
basierend auf Punktmutanten zur verbesserten Integrationseffizienz gewählt. 
Integrationsassays wurden in verschiedenen humanen Zelllinien durchgeführt. Etablierung 
von Doppelmutanten, sowie Dosisoptimierung des Integrase kodierenden Plasmids 
verbesserten die Integrationseffizienz mehr als dreifach, verglichen mit der Wildtypintegrase 
in den Zelllinien HeLa und HCT. Weitere Assays verglichen die Exzisionsaktivität der 
Integrasemutanten mit dem Wildtyp. Bei fünf Mutanten wurde eine etwa zweifach erhöhte 
Exzision gefunden. Die Beurteilung der Spezifität der Integrasemutanten erfolgte durch 
Substitution der Wildtyp-attP Sequenz mit drei Pseudo attP Erkennungssequenzen des 
Reporterplasmids, deren erhöhte Spezifität bereits dokumentiert war. Einzelne Mutanten 
zeigten eine zweifach erhöhte Exzisionsaktivität. Die Rekombinationsaktivität von 
Integrasemutanten wurde im Kontext chromosomaler DNA mittels einer stabil GFP-
exprimierenden Reporterzelllinie, in der die eGFP Expression mittels Integrase-vermittelter 
„Raus-Rekombination“ eines polyA Stoppsignals angeschaltet wird, untersucht. Auf 
chromosomaler Ebene wurde keine verbesserte Ausschneidungsaktivität erreicht. 
Zur Evaluierung der in vivo Effizienz zweier ausgewählter PhiC31 Integrasemutanten, die in 
vitro erhöhte Integrationsaktivität aufwiesen, wurden zwei Plasmide am C57BL/6 
Mausmodell getestet. Reportergen war ein für den humanen Koagulationsfaktor IX 
kodierendes Gen. In Abhängigkeit von der Integrationseffizienz der Mutanten und des 
Wildtyps, wurden im Zeitraum von einhundert Tagen ähnliche Expressionslevel gefunden. 
Die Mutanten zeigten keine Verbesserung der Langzeitexpression von humanem Faktor IX. 
Die hier durchgeführten Studien zur Mutationsanalyse der Phagenintegrase PhiC31 zeigten 
einen wirksamen Ansatz zur Verbesserung der PhiC31 Integrase-vermittelten 
Integrationseffizienz in vitro. 
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1. Introduction  
1.1 Gene therapy 
 
Historically, gene therapy can be defined as the treatment of hereditary and metabolic 
diseases or cancer by introducing therapeutic genes into the target cells of affected tissues 
(Friedmann and Roblin, 1972). The function of the inserted gene is thereby able to 
compensate for a genetic malfunction or deficiency of the mutated gene. Gene therapists 
distinguish between somatic gene therapy and germline gene therapy. Somatic gene therapy is 
considered to be the traditional treatment in gene therapy. This form of therapy addresses 
treatment of inherited and acquired genetic diseases within one individual by selective 
transfer of normal genes into certain somatic target cells. Germline based gene therapy deals 
with the genetic alteration of germ cells such as ovules and sperm cells and their progenitor 
cells. The latter therapy enables introducing genetic changes into the germ line, which are 
then passed on to future generations (Nielsen, 1997).  
 
a) Gene therapy trials 
The concept of somatic gene therapy has become accepted to date especially in animal 
models. Gene therapy vectors are applied to the patients target tissue by different methods. 
The in vivo based gene therapy refers to the transfer of a foreign gene into the targeted, living 
tissue of a whole organism. Ex vivo gene therapy involves the removal of living cells or 
tissues from an organism, subsequent manipulation such as foreign gene insertion in vitro and 
re-implantation into the organism. This form of gene therapy is used for treating inherited 
diseases or in bone marrow transplants. Gene therapy clinical trials have been approved and 
documented since 1989. During the last twenty years 1644 clinical trials had been 
documented. The four mostly diagnosed indications are presented in Table 1.1. 
 
Table 1.1. Number of gene therapy clinical trials. 1  
Indication Numbers of Trials 
Cancer     1060 (64.5 %) 
Cardiovascular disease  143 (8.7 %) 
Monogenic disease  134 (8.2 %) 
Infectious disease  131 (8.0 %) 
                                                 
1
 www.wiley.co.uk/genemed/clinical from the database of the Journal of Gene Medicine, updated 06/2010 
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Despite current difficulties, gene therapy has great potential to address, treat and cure 
infections and inherited diseases, based on monogenic malfunctions. The cure for cancer, in 
which several genes are affected (multi-genetic) by means of gene therapy, is still a big 
challenge. However, many questions remain open concerning risks and benefits of gene 
therapeutic approaches, which will be objectives for future investigations. 
 
b) Clinical trials: progress and problems 
Since the start of gene therapy trials the number of human genes associated with disease states 
and vector systems have been steadily increasing. Outstanding successes in human gene 
therapy in curing diseases such as SCID (severe combined immune deficiency) by retroviral 
vector-mediated gene transfer have been achieved. The treatment of X-linked SCID, an 
inherited disorder caused by γC cytokine receptor deficiency was first reported by Cavazzana-
Calvo et al. (2000). For the first time, alanine deaminase (ADA)-SCID, which provokes a 
defect in the purine metabolism by defective T and B cell function was successfully treated in 
ADA SCID patients (Aiuti et al., 2002). Currently, eight out of ten patients do not require 
enzyme-replacement therapy anymore since the patient’s blood cells express ADA by 
themselves (Aiuti et al., 2009).  
However, failures and severe side-effects during phase I clinical trials have raised concerns 
about safety issues due to immune inflammatory response and insertional mutagenesis leading 
to prompt death or leukaemia more than two years after the administration of adenoviral or 
retroviral vectors, respectively (Raper et al., 2003; Check, 2002; Hacein-Bey-Abina et al., 
2003a). The success of human gene therapy trials has been seriously queried upon a tragic 
setback. During a phase I clinical trial to test the safety of using a second-generation ∆E1/E4 
adenovirus vector, a young man died (Marshall, 1999; Bostanci, 2002; Thomas et al., 2003). 
The patient suffered from a partial deficiency of ornithine transcarbamylase (OTC), a liver 
enzyme needed for removal of excessive nitrogen from amino acids and proteins. This patient 
received the highest dose of vector (3.8 × 1013 particles) in the study via transduction of an 
adenovirus carrying the gene encoding for OTC. Within four days of treatment the patient 
died from multiorgan failure (Bostanci, 2002).  
The first ex vivo gene therapy study was performed to treat X-SCID in infants in Paris in 1999 
by means of retroviral vector transduction (Cavazzana-Calvo et al., 2000). A similar gene 
therapy phase I trial had started in the United Kingdom (Gaspar et al., 2004). Haematopoietic 
stem cells were transduced ex vivo with replication deficient recombinant murine leukaemia 
virus (MLV) vectors carrying the therapeutic gene encoding common cytokine-receptor chain 
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(γc) to restore the missing IL-2 receptor γ (IL2RG). Yet, the clinical benefit of gene therapy 
trials was hampered by the development of leukaemia in four out of nine young patients more 
than 2.5 years after initial retrovirus-based gene delivery (Hacein-Bey-Abina et al., 2003b; 
Hacein-Bey-Abina et al., 2008). Retroviral vector integration near or into the proviral 
integration site, LIM domain only 2 (LMO2), or into different proto-oncogenes activated 
transcription of cancer related genes and lead to chromosomal translocations (Hacein-Bey-
Abina et al., 2008). Recently, a 3-year-old boy treated in a hospital in London, also developed 
a chronic bone marrow disease two years after retrovirus vector mediated treatment for X-
SCID (Cole, 2008). 
The latest moderately successful gene therapeutic treatment was reported while medicating 
patients suffering from an inherited blinding disease called Leber`s congenital amaurosis 
(LCA) (Bainbridge et al, 2008; Maguire et al., 2008). The patients’ blindness has onset during 
childhood caused by irreversible retina degeneration through a mutation in the retinal pigment 
epithelium (RPE65)-specific 65-kilo Dalton (kDa) protein gene, which is implicated in the 
production of vitamin A as a rhodopsin precursor. Rhodopsin is required for vision and 
photoreceptor function. In two trials each with three patients, the patients were subretinally 
injected with a recombinant adeno-associated virus (AAV) vector encoding the RPE65 gene. 
Modest improvement in visual function and acuity could be achieved in four out of six 
patients without adverse events. However, additional studies need to be carried out to support 
the potential for visual restoration using the current practise. 
 
1.2 Gene transfer systems  
 
Several different vectors and methods have been used, which are capable of transferring 
therapeutic nucleic acids into the cells. In principal two major groups exist: viral vectors and 
non-viral systems. The latter are also referred to as synthetic vector systems, which consist 
generally of a carrier, a compound that mimics the function of viral capsids, and one or more 
plasmids encoding the therapeutic gene and possibly different genes encoding integration-
supporting enzymes.  
Two-thirds of all gene therapy vectors used in clinical trials are viral vectors (Edelstein et al., 
2007). The vectors are mainly composed of retroviruses and adenoviruses (AdVs) which are 
able to mediate highly efficient gene transfer (Ragot et al., 1993; Annenkov et al., 2002). The 
AAV is the smallest among the viruses used for gene transfer (Dong et al., 1996) and is non-
inflammatory and non-pathogenic (Nakai et al., 1999). 
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Viral vectors differ in their vector genome forms. AdV and HSV genomes persist mainly in 
the nucleus, AAV genomes remain preferentially episomal (Nakai et al., 2001), although 
AAV integration in in vivo studies has also been documented as well (Nakai et al., 2003a; 
Miao et al., 1998). The group of retroviruses integrate their genomes into the host chromatin 
(Mitchell et al., 2004; Schroeder et al., 2002). 
For therapeutic applications, inactive replication-deficient viruses or viral capsids are used. 
Parts of the viral genome are deleted and replaced by an expression cassette including 
therapeutic genes of choice (Alba et al., 2005; Jaeger and Ehrhardt, 2007). The tropism of a 
few viral vectors as Lentiviruses, AAVs and AdVs is generally multi-faced. But inflammatory 
herpes simplex virus (HSV)-1 exhibits a strong preference for neurons (Palmer et al., 2000), 
whereas retroviruses transduce only dividing cells.  
While viral vectors are able to mediate highly efficient gene transfer, there are several 
drawbacks to using them. For example, most viral vectors mediate an inflammatory response 
triggering immunogenic complications, in particular AdV (Thomas et al., 2001; Simon et al., 
1993; Kafri et al., 1998) and HSV-1 (Epstein et al., 2005). Compared to synthetic vector 
systems, all viral vectors have a limiting cargo capacity. Additionally, the preparation of 
recombinant viral vectors in terms of production and purification is laborious and complex, 
especially for AdV-based vectors (Palmer and Ng, 2003). Moreover, viral vectors are 
frequently accompanied by various technical difficulties, e.g. availability for optimal 
therapeutic doses, biomedical safety or immunological properties of the individual patient 
(Lundstrom and Boulikas, 2003; Levine, 1987). 
In general, non-viral gene transfer systems represent an appropriate alternative to viral 
transduction with lower toxicity and lower immunogenicity than viral systems. These carriers, 
either synthetic or naturally based, are able to shield their cargo in form of plasmids or si 
(small interfering) RNA and are used to deliver therapeutic DNA into cells. The methods of 
non-viral gene delivery can be subdivided into physical (carrier-free) delivery and chemical 
approaches using synthetic vectors. The physical approaches involve needle injection, 
electroporation, gene gun and hydrodynamic delivery (Wolff et al., 1990; Heller et al., 2005; 
Yang and Sun, 1995). Transfection of hepatocytes, mediated by hydrodynamic intravascular 
injection of naked DNA via the tail vein of mice has become routine method for nucleic acid 
delivery into the liver (Gao et al., 2007; Zhang et al., 1999). The chemical approaches include 
polymer-based transfection or lipofection (Liu et al., 2003). The carriers consist of synthetic 
or native compounds as cationic lipids or polymers for transgene delivery (Gao et al., 2007). 
A successful gene transfer is strongly dependent on efficient delivery into the target cells 
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although the route of the genetic cargo is inhibited by several hurdles facing the gene delivery 
via extracellular and intracellular environments (Pouton and Seymour, 2001).  
 
1.3 Non-viral vectors 
 
There are several non-viral vector systems, e.g. viral Epstein-Barr virus (EBV)-based plasmid 
replicons and pEPI-based vectors. Several of these systems have been improved in the last 
decade. Non-viral vectors have shown increasing gene therapeutic potential and are of 
upcoming importance as a strong alternative to viral vectors. Low cost, simplicity of use, ease 
of large-scale production and lack of specific immune response are beneficial properties of 
non-viral vectors (Niidome and Huang, 2002). Like viral vectors, there are drawbacks with 
non-viral vectors as well. One of the major drawbacks is the low in vivo and in vitro 
transfection efficiency due to versatile cellular barriers, which prevent proper delivery of 
DNA into the target cells. In order to overcome this, viral properties are transferred into non-
viral systems in order to integrate or replicate the vectors and to achieve sustained and 
stabilised long-term transgene expression (Glover et al., 2005).  
Non-viral vectors for gene transfer are divided into non-integrating or episomally persisting 
elements and integrating vectors. Episomally persisting vectors comprise minicircles 
including a scaffold matrix attachment region (S/MAR) and pEPIs (Piechaczek et al., 1999; 
Chen et al., 2005; Darquet et al., 1997; Nehlsen et al., 2006). These plasmid-based vectors are 
still being optimised in respect to safety and efficient autonomous replication so as to 
improved stable long-term extrachromosomal persistence (Mairhofer and Grabherr, 2008). 
Non-viral vectors capable of somatic integration of entire plasmids or linear DNA sequences 
are plasmids that carry genes encoding various transposon systems derived from different 
eukaryotes and several bacteriophage-derived site-specific recombinases (SSR) such as 
integrases. 
1.3.1 Episomally persisting non-viral vectors 
Episomal vector systems with non-viral origins contain viral plasmid replicons, e.g. the origin 
of replication (oriP), Epstein-Barr virus nuclear antigen 1 (EBNA1), or chromosomal 
elements (Conese et al., 2004). In contrast to integrating vectors, episomal non-viral vectors 
do not cause insertional mutagenesis as a severe side effect of integration. Transfected 
plasmids only persist as extrachromosomal entities in rapidly dividing cells if they are able to 
replicate or if they are able to utilise the cellular mechanism for their nuclear retention. 
Another strategy to stabilise the plasmid’s presence in the nucleus is to modify the bacterial 
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backbone to render the plasmid replication-competent. EBV-derived episomal persisting, self-
replicating vectors, in which viral and non-viral elements are combined into one vector 
plasmid, overcome the rate-limiting step of non-viral gene transfer (Yates and Guan, 1991). 
Increased levels of transgene expression and improved transfection efficiency might be 
obtainable with EBV-based episomal vectors (Mazda et al., 1997). The first small episomal 
vectors which did not require any viral encoded trans-acting factors for replication were the 
pEPI vectors (Piechaczek et al., 1999). pEPI-1 replicates episomally at a copy number of 
about ten in Chinese hamster ovary (CHO) cells and is stable in the absence of selection for 
over one hundred generations ensuring long-term gene expression (Piechaczek et al., 1999). 
1.3.2 DNA recombination-mediated integration and excision by transposases 
and recombinases 
Being a safer alternative to recombinant integrating viral vectors, non-viral gene transfer 
systems have gained importance. The two major non-viral gene transfer vectors used for 
somatic integration are based on the Sleeping Beauty (SB) transposase and the bacteriophage 
PhiC31 integrase system.  
 
The SB transposase is a transposable element and belongs to the Tc1/mariner superfamily of 
transposons derived from fish (Ivics et al., 1997). Transposons are mobile DNA sequences 
that are able to move within a genome. The SB transposase system is utilised for insertion of 
an in trans delivered transposon with a cargo capacity of about 10 kb (Zayed et al., 2004), in 
which the transgene is flanked by 250-bp long terminal inverted repeats (IR). Both the 
transposase and the inverted repeats constitute the SB transposon system (Ivics et al., 1997). 
At the IRs, which represent the target sites, the precise cut-and-paste mechanism takes place 
resulting in transposon integration into the chromosome (Ivics et al., 1997; Izsvák et al., 
2002). In the SB transposon system, the quantity of transposase is limited by an effect termed 
overproduction inhibition. Transposition efficacy is negatively affected when the transposase 
dose reaches a certain threshold (Mikkelsen et al., 2003; Yant et al., 2000). A cellular 
mechanism described as postintegrative gene silencing has been documented in human cells. 
Transposon silencing was proposed to be associated with DNA methylation, histone 
deacetylation and promoter and cell line dependent (Garrison et al., 2007). Although the 
consensus sequence of SB target sites was found to be a short thymidine adenosine (TA) 
dinucleotide, the selection of the target insertion site is primarily determined by the level of 
DNA structure (Vigdal et al., 2002). Transcription units and their upstream regulatory 
sequences are strongly preferred by SB transposases (Yant et al., 2005). Several mutational 
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screens within the nucleotide sequence of the SB transposase increased the efficiency of SB 
between twofold and 100-fold in the last five years (Geurts et al., 2003; Yant et al., 2004; 
Zayed et al., 2004; Mátés et al., 2009).  
Since the sequence to be transposed consists of therapeutic genes, the SB transposase system 
has been frequently used as a versatile tool for efficient gene delivery in several preclinical 
gene therapy applications (Liu et al., 2006a) to achieve long-term therapeutic transgene 
expression in lung and liver cells of mice (Yant et al., 2000; Belur et al., 2003).  
The first clinical trial including a SB transposon vector has been approved, in which 
genetically altered T cells will be transferred into patients with CD19+ B lymphoid 
malignancies in an ex vivo approach (Williams, 2008). Besides applications in gene therapy or 
gene transfer, the SB transposase system is used extensively for cancer gene discovery in 
combination with insertional mutagenesis, as well as germline transgenesis, and functional 
genomics (Collier et al., 2005; Izsvák and Ivics, 2004; Luo et al., 1998). 
 
The PhiC31 integrase belongs to the serine-catalysed invertase/resolvase family of 
recombinases (Stark et al., 1992; reviewed by Groth and Calos, 2004). SSRs recognise 
sequence specific target sites in length of 30-40 base pairs (bp) and mediate recombination 
between these so-called attachment sites, attP and attB. This group of enzymes form two 
functionally and structurally diverse families (Smith and Thorpe, 2002). These families are 
based on their sequence homology, biochemical properties (Stark et al., 1992) and their 
mechanism of catalysis (Hatfull and Grindley, 1988). The main representatives of tyrosine- 
and serine-based integrase, all being recombination-efficient in mammalian cells, are listed in 
Table 1.2.  
The tyrosine recombinase or lambda integrase family makes use of a conserved tyrosine 
catalytic residue to mediate covalent bonds between the recombinase and the DNA target 
sequence (Sorrell and Kolb, 2005). Well known representatives of the tyrosine-mediated 
recombinases are cyclisation recombination (Cre) recombinase from phage P1 and Flippase 
(FLP) recombinase from Saccharomyces cerevisiae. Cre mediates a bidirectional 
recombination between identical locus of X-over in P1 (loxP) sites (Hoess et al., 1990). After 
its discovery, the Cre loxP system has been widely used to manipulate eukaryotic and 
prokaryotic genomes (Sternberg, 1979). The FLP recombinase mediates inversion between 
two 34-bp Flp recognition target (FRT) sites arranged in opposite directions. Since the target 
site sequences of the SSR before and after the recombination reaction are identical, Cre and 
Flp mediated reactions are reversible, leading to subsequent excisions in the presence of 
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recombinase. This renders the inserted DNA highly unstable. Contrary to the PhiC31 
integrase specific attachment (att) sites, the recognition sites of both the Cre and Flp 
recombination systems are missing in the mammalian genome. Therefore, to create an 
integrating recombination-based system in mammalian cells previous stable insertion of the 
specific loxP or FRT recognition sites into the genome is required.  
The second family of SSRs comprises the large, diverse and evolutionary unrelated 
invertase/resolvase or serine-based recombinase family. This family makes use of a 
conserved N-terminal serine residue to establish the covalent link between recombinase and 
DNA target sequence. Enzymes of this recombinase family utilise the hydroxyl group of the 
catalytic serine resulting in a strand exchange (Groth and Calos, 2004). The unidirectional 
site-specific recombination at the crossover point between two different DNA recognition 
sequences, the phage attachment site attP and the bacterial attachment site attB (Groth et al., 
2000), results in the generation of two non-identical hybrid att sites, attL and attR (Rausch 
and Lehmann, 1991). Safe integration and long-term expression of the therapeutic gene is in 
theory an excellent premise for curing inherited diseases since life-long treatment is usually 
required. The PhiC31 integrase as the most studied representative among the serine catalysed 
recombinases represents a convenient novel tool for gene therapeutic interventions, and may 
provide desired properties and approaches to fulfil these requirements. From at least thirty 
members of the serine-based recombinase family, several serine based integrases have been 
studied for the potential of chromosomal engineering (Chen and Woo, 2008).  
Among the serine recombinase family, the small gamma delta (γδ) resolvase, encoded by the 
transposon γδ, was the first to be solved in its crystal structure as a synaptic tetramer (Sauer, 
1994). Since that time, several synaptic models of γδ resolvase were analysed in great detail 
(Rice and Steitz, 1994; Yang and Steitz, 1995; Sarkis et al., 2001; Li et al., 2005). Therefore, 
it can be described as the model recombinase for structural analysis, catalysis and biochemical 
properties. Related enzymes such as R4 integrase (Olivares et al., 2001), TP901-1 (Stoll et al., 
2002), PhiFC1 (Yang et al., 2002) and PhiBT1 (Chen and Woo, 2005) were also investigated 
for recombination activity, yet with minor integration efficiency. 
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Table 1.2. Representative SSR family members grouped in two distinct families based on 
tyrosine and serine mediated catalysis are listed. 
 
 Phage 
name 
Host Amino acid 
length 
Overlap region Original 
reference 
Lambda (λ) E.coli 356 TTTATAC 
 
Enquist et al., 1979 
HK022 E.coli 357 AGGTGAA Yagil et al.,  
1989 
Cre (P1) E.coli 343 ATGTATGC Abremski and 
Hoess, 1984 
Tyrosine-
based 
integrases  
FLP S. cerevisiae 423 TCTAGAAA Andrews et al., 
1985 
PhiC31 
integrase 
Streptomyces 
lividans 
613 / 605 TTG Kuhstoss and Rao, 
1991 
R4 Streptomyces 
parvulus 
469 GAAGCAGTGGTA Groth et al., 2000 
TP901-1 Lactococcus 
lactis 
485 TCAAT Christiansen et al., 
1996 
Serine-
based 
integrases 
γδ E.coli 183 TATTTATAAAT Reed et al., 1982 
 
The enzymatic understanding of the site-specific recombination mechanism of recombinase 
family members has been investigated for about two decades (Stark et al., 1989; Stark et al., 
1992; Grindley, 1997; Li et al., 2005; reviewed by Grindley et al., 2006). The recombinase-
mediated strand exchange requires supercoiled structures of both chromosomal and of 
plasmid DNA substrates. It also requires a recombinase dimer for a DNA strand or a tetramer 
for two strands while being recombinase-type dependent. This process involves binding of the 
resolvase dimer to the target DNA, their synapsis, double strand cleavage at the crossover 
points and subsequent exchange and rejoining of the DNA strands (Murley and Grindley, 
1998). During catalysis, a synaptic complex of two DNA crossover sites and four 
recombinase subunits is formed (Grindley et al., 2006). Designed mutants, such as the serine 
recombinase Tn3, requires only short recombination sites and is a result of improved 
molecular understanding of synaptic and strand exchange processes (Burke et al., 2004; 
Arnold et al., 1999). Two different mechanistic models, the domain-swapping model and the 
subunit rotation model, for serine recombinase mediated strand exchange were proposed in 
which resolvase dimer structures composed of catalytic domains flexibly connected to DNA-
binding domains exist (Rice, 2005). The domain-swapping model has not become accepted 
(Yang and Steitz, 1995; Craig et al., 2002). The majority of analysed serine-recombinase 
mediated recombination events supported the subunit rotation model (Figure 1.1) as the 
mechanism of choice for strand exchange (Li et al., 2005) for TP901-1, PhiC31 integrase and 
other related enzymes (Yuan et al., 2008).   
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Figure 1.1. The putative mechanism of recombination by a serine recombinase. 
The subunit rotation model for recombinase-mediated strand exchange is illustrated above. 
For simplicity only with the catalytic domains of the recombinase dimers (oval circles) 
synapsed to the DNA strand is shown. Both recombinase dimers and DNA strands are 
represented in red and blue, respectively. First, the synaptosome is formed by attaching the 
target DNA cleavage site to the catalytic subdomains (either as monomers or dimers). The 
hydroxyl group of the conserved catalytic serine residue nucleophilically attacks the DNA 
backbone, leaving free 3´OH groups (Stark et al., 1992). The strand exchange is accomplished 
by a 180° rotation of two half sites of the tetramer relative to each other. DNA strands 
subsequently rejoin and opposite strands are ligated. The figure is modified and derived from 
Grindley et al., 2006.  
 
SSRs represent not only integration tools for plasmid-derived therapeutic genes delivered in 
trans but also are utilised for site-specific gene insertion into the genome of the target tissue. 
A second extensively used application of SSRs is based on intramolecular excision activity of 
a DNA sequence, which is flanked by both recognition sites. SSR mediated excision activity 
is utilised in applications such as gene activation, gene inactivation, and transgenesis e.g. with 
recombinase-mediated cassette exchange (RMCE). SSRs as an excision tool have become 
increasing relevant in the field of reverse genetics (Bischof and Basler, 2008).  
In transgenesis the FLP/FRT system has been explored two decades ago in Drosophila 
genetics to perform in vivo manipulations (Golic and Lindquist, 1989). The technique of gene 
activation has been utilised to generate constitutive expression of transgenes in cells (Struhl 
and Basler, 1993). Transgene expression is turned on by the excision of an “FLP out” 
cassette. This sequence containing a marker gene flanked by recognition sequences (FRT 
sites) in the same orientation separates the transgene from its promoter and contains a 
transcriptional termination site (polyA signal) (Bischof and Basler, 2008). The removal 
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consequently leads to the expression of the transgene. Gene inactivation by mitotic 
recombination between FRT sites involves the loss of a marker gene within a particular clone 
or a generated daughter cell and has been applied in Drosophila (Chou and Perrimon, 1992; 
Xu and Rubin, 1993). Transgenesis using the RCME strategy in combination with PhiC31 
integrase has also been carried out in the fruit fly (Groth et al., 2004; Bateman et al., 2006). 
The genetic manipulations during cassette exchange were proved by the loss of the marker 
gene. Transgenesis with PhiC31 integrase has been optimised by the generation of cell lines 
with precisely mapped attP sites and by raising transformation efficiency (Bischof et al., 
2007).  
 
1.4 PhiC31 integrase  
1.4.1 Recombination and integration efficiency  
The temperate sensitive bacteriophage PhiC31 has a genome size of about 41.5 kbp (Harris et 
al., 1983) and infects a large number of streptomycetes, including Streptomyces lividans 
(Kuhstoss and Rao, 1991; Chater, 1986). The natural recombination process consists of a 
stable unidirectional and site-specific integration of the phage genome into the bacterial host 
genome (Figure 1.2.A). This property makes PhiC31 integrase an ideal tool for gene 
therapeutic applications (Calos, 2006). PhiC31 integrase was first shown to mediate efficient 
integration in a mammalian cell environment using extrachromosomal vectors in bimolecular 
integration assays (Groth et al., 2000). The mechanism of recombination (Figure 1.2.B) is 
carried out by covalent attachment of the transient DNA to the two integrase monomers. As 
observed in related integrase families, the serine-based integrase utilises the hydroxyl group 
of the catalytic serine residue to nucleophilically attack the DNA backbone (Stark et al., 
1992). Serine integrases make a 2-bp staggered cut on both attachment sites, consequently 
breaking all four nucleotide strands at once. Double-stranded breaks made by protein dimers 
bound in cis follow a 180° rotation and subsequent DNA ligation (Groth and Calos, 2004). 
All four attachment sites involved in the recombination process, native attP and attB sites and 
the hybrid sites, attL and attR, contain a 3-bp long consensus sequence in the core region (5´-
TTG-3´) flanked by imperfect repeats (Rausch and Lehmann, 1991; Kuhstoss and Rao, 1991), 
depicted in Figure 1.3. 
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Figure 1.2. Integration mediated by PhiC31 integrase.  
(A) Natural integration of the phage genome into the bacterial genome. The phage genome 
with the attachment site attP is shown in blue. The red line represents the bacterial genome, 
with the bacterial attachment site attB (red square). In the presence of PhiC31 integrase the 
integration reaction proceeds resulting in the linearised phage genome (blue), flanked by two 
hybrid att sites, attL and attR (red and blue, respectively). Each hybrid site consists of half 
attB and half attP sites. (B) Integration of plasmid DNA into the mammalian genome. The 
plasmid containing the transgene (green) and the attB site is recombined by active PhiC31 
integrase into the pseudo attP site (magenta) of the mammalian genome. After integration into 
the mammalian genome hybrid attR and attL sites flanking the integrated transgene (green) 
are generated. The figure is derived from Calos, 2006. 
 
Attachment site Sequence 5´- 3´ Length 
consensus 
sequence of 
pseudo attP 
 
          CCTTGGTTAACCTTTAGGTTATCCATGG 
          A AG TAATTGTCAAG CC CAT CG 
 
attB GGTGCGGGTGCCAGGGCGTGCCCTTGGGCTCCCCGGGCGCGTACTCC 34 bp  
attP TAGTGCCCCAACTGGGGTAACCTTTGAGTTCTCTCAGTTGGGGGCGT 39 bp 
attL GGTGCGGGTGCCAGGGCGTGCCCTTGAGTTCTCTCAGTTGGGGGCGT 37 bp 
attR TAGTGCCCCAACTGGGGTAACCTTTGGGCTCCCCGGGCGCGTACTCC 36 bp 
 
Figure 1.3. PhiC31 integrase-specific attachment sequences.  
The multilevel consensus sequence of pseudo attP sites within mammalian genomes 
(Chalberg et al., 2006), the native attB and attP sequences and the hybrid sites, attL and attR 
are shown. The minimal recognition sequences are highlighted in red for attB (34 bp) with 
44 % homology to attP and in blue for attP (39 bp). The crossover site or overlap region TTG 
of each attachment site is underlined in black. The arrows indicate the positions of inverted 
repeats in attB and attP. Underlined bases in the attB sequence are identical with bases in the 
wt attP site. The hybrid sites attL and attR are formed by crossover of the sequences mediated 
by recombination of PhiC31 integrase. Sequences are derived from Thorpe et al., 2000. 
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With the discovery that SSRs as Cre are able to perform recombination in human cells 
transient assays have demonstrated that preinserted pseudo-loxP target sites support Cre-
mediated integration and excision in human cell environment (Thyagarajan et al., 2000). 
PhiC31 integrase-mediated recombination efficiency was also successfully tested in 
intramolecular recombination assays in the presence of attB and attP recognition sites. The 
PhiC31 integrase mediated recombination between the full-length attB and attP sites in the 
pBCPB+ plasmid vector was determined at a frequency of 52.4 % in human embryonic 
kidney (HEK)-293 cells, (or only 293 cells), whereas recombination frequency in E.coli was 
100 %. The minimal sequence length of the integrase specific attachment sites attB and attP 
with 34 bp and 39 bp were determined in this assay as well (Groth et al., 2000).   
The integration frequency of attB site containing plasmid into genomic pseudo attP sites of 
293 cells was found to be approximately tenfold higher than the frequency of random 
integration (Thyagarajan et al., 2001). Upon PhiC31 integrase mediated integration of a 
reporter plasmid encoding a luciferase gene and the attB site, stable long-term expression of 
the reporter gene was shown until four weeks post transfection (Thyagarajan et al., 2001). The 
integration activity of PhiC31 integrase in liver cells could also be verified in an in vivo 
approach with human blood coagulation Factor IX (hFIX) as reporter. High-pressure tail vein 
injection of integrase encoding plasmid and hFIX encoding plasmid could show an increase of 
hFIX levels more than tenfold compared to the control group (inactive integrase) (Olivares et 
al., 2002). In another study, transgene hFIX expression levels of the active PhiC31 integrase 
were detected fivefold higher compared to the control group at day 122 post injections even 
after three times cell cycle inductions (Ehrhardt et al., 2007). 
1.4.2 Integration specificity and aberrant integration events  
PhiC31 integrase performs unidirectional site-specific integration of a donor plasmid bearing 
the attB site into endogenous randomly scattered attachment sites termed pseudo attP sites 
within the genome. Imperfect pseudo attP sites are present in many eukaryotic genomes and 
have been targeted as insertion sites for transgenes in a site-specific manner in a variety of 
species. This site-specificity is possible due to a certain degree of homology between the 
native attB site within the donor plasmid and the pseudo attP sites present within the human 
genome. Site-specific recombination into pseudo attP sites within human cell lines has been 
primarily observed in human 293 cells and mouse 3T3 cells (Thyagarajan et al., 2001). 
Previously inserted attP sites present within plasmids, being stable inserted into the cells are 
competing with pseudo attP sites to perform recombination. The analysis of 96 integration 
events revealed an integration specificity of 15 % (14 out of 96) at which the plasmid was 
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integrated into the previously inserted attP site. The characterisation of pseudo attP sequences 
resulted in a sequence homology to the native attP site between 20 and 60 %. This implies 
that PhiC31 integrase does not need perfect sequence fidelity for recognition and 
recombination between these pseudo att sites (Thyagarajan et al., 2001).  
With a limited number of rescued integration sites (about 370 pseudo attP sites) and a non-
random integration profile due to a relatively large and complex recognition sequence of 
about 39 bp, the PhiC31 integrase system possesses significant advantages over competing 
integrating systems and has a lower risk of insertional mutagenesis (Chalberg et al., 2006) 
The same group could show in PhiC31 integration studies that the total number of rescued 
sites is lower than integration studies with viral vectors derived from retroviruses and AAVs 
(Mitchell et al., 2004; Schroeder et al., 2002; Nakai et al., 2003b). More than 500 HIV-1 
integration sites were mapped in SupT1 cells revealing a strong target preference for 
integration in transcription units (70 %) (Schroeder et al., 2002). Although retroviral based 
integration is not sequence-specific, different retrovirus-derived vectors show various 
preferences for integration sites in the human chromosomes (Mitchell et al., 2004; Bushman, 
2003). PhiC31 integration is also more site-specific compared to SB transposase since 
integration events upon SB transposition are widely distributed (Yant et al., 2005). A 
suggested number of more than 107 potential integration sites in the genome were assumed as 
target sites for SB mediated integration (Chalberg et al., 2006). 
A detailed study analysing integration specificity in three different eukaryotic cell lines (293 
embryonic kidney-derived, HepG2 liver-derived, and D407 retinal pigment epithelium-
derived) revealed almost 200 independent integration events in total (Chalberg et al., 2006). 
The analysis for site-specificity resulted in 56 % integration events. These pseudo attP sites 
are suggested to be recurrent integration sites distributed among 19 “hot spot” pseudo attP 
sequences. The most favoured pseudo attP recognition site at location 19q13.31 was targeted 
with a frequency of 7.5 %. The overall estimation of possibly 370 pseudo attP sites confirms 
the range of wild type (wt) PhiC31 integrase-mediated integration sites between 100 and 1000 
as predicted (Chalberg et al., 2006; Thyagarajan et al., 2001). Additional findings highlighted 
that integrase-specific pseudo attP sites are preferentially located in genes or gene dense 
regions, rather than in promoter regions, likely due to chromatin context effects (Ehrhardt et 
al., 2006; Chalberg et al., 2006). Integration specificity of PhiC31 integrase was presumably 
found to be cell line dependent (Chalberg et al., 2006; Ehrhardt et al., 2006; Aneja et al., 
2007). It was speculated that the chromosomal context had some influence on specificity 
(Calos, 2006).  
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Undesired side effects upon PhiC31 integrase-mediated recombination were first discussed 
due to chromosomal translocations in primary human fibroblasts being stably transfected with 
a PhiC31 integrase encoding plasmid (Liu et al., 2006). Recent studies have confirmed 
integrase-mediated chromosomal abnormalities in primary human embryonic and adult 
fibroblasts and in mammalian cell lines (Liu et al., 2009). Microdeletions upon recombination 
(Thyagarajan et al., 2001) and larger deletions of up to 160 bp were already found in mouse 
liver (Ehrhardt et al., 2005). A large study analysing chromosomal rearrangements in 
mammalian cells after PhiC31 integrase-mediated integration confirmed aberrations in human 
cells. Translocations were found linking two different chromosomes upon recombination at 
approximately 15 % probability besides rarely obtained larger deletions (Ehrhardt et al., 
2006). These rearrangements have only been shown in immortalised and rapidly dividing cells 
in vitro, but not yet in vivo. 
1.4.3 Domain organisation and putative protein structure of the PhiC31 integrase  
The coding sequence of PhiC31 integrase encompasses 605 amino acids (AA) corresponding 
to an open reading frame (ORF) of 1815 nucleotides (Kuhstoss and Rao, 1991; Rausch and 
Lehmann, 1991). The respective protein has a size of about 67 kDa (Thorpe and Smith, 1998). 
A second, longer version of 613 AA including an N-terminal addition of an upstream start 
codon and consists of eight additional AA to ensure full function of the protein (Keravala et 
al., 2009). This extended version of the integrase is used in the present study.  
PhiC31 integrase consists of two large domains, the N-terminal catalytic domain and the      
C-terminal DNA binding domain, which are connected by a conserved helix (Figure 1.4.B). 
The large serine recombinases share a highly conserved catalytic serine residue close to the 
N-terminal end of the enzyme and a similar N-terminal domain with the resolvase/invertase 
enzymes (Figure 1.4), providing protein-protein interaction and catalysis (Smith and Thorpe, 
2002). The function of the relatively large C-terminal domain of large serine integrases within 
recombination is not yet investigated in detail; however the C-terminal domain plays an 
important role in recognition of the attachment sites (Smith and Thorpe, 2002).  The same 
group could recently show a coiled-coil motif with typical heptad repeats comprising two 
α helices controlling the formation of the synaptic interface in integration and excision. This 
sequence has been claimed a hyperactive region due to hyperactive mutants found within this 
motif (McEwan et al., 2009; Rowley et al., 2008). Within this region, the tetramer RFGK 
comprising amino acid position 451-454 was identified to be crucial for the catalytic activity 
and responsible for the interaction with the ubiquitary protein DAXX (Chen et al., 2006). The 
presence of a helix-turn-helix motif within the small C-terminal DNA binding domain (Yuan 
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et al., 2008) suggests putative motifs conferring similar functions within the C-terminal 
domain of the large recombinase family as well, which serve as DNA-binding elements, such 
as zinc finger motifs or helix structures.  
The domain organisations of the well characterised γδ resolvase as the paradigm for the 
resolvase/invertase family and PhiC31 integrase are illustrated (Figure 1.4). Both NTDs show 
20 % homology (Rowley and Smith, 2008).  
 
Figure 1.4. Domain organisation of gamma delta resolvase and PhiC31 integrase. 
(A) The domain organisation of the γδ resolvase is shown. A larger N-terminal domain (NTD) 
(blue) is linked via a conserved alpha (α) E helix (black) with the C-terminal domain (CTD) 
(green) comprising a helix-turn-helix (HTH) motif. (B) The putative domain organisation of 
the PhiC31 integrase is illustrated. The NTD provides catalytic activity. The CTD contains 
DNA-binding motifs and is therefore termed DNA binding domain. A coiled-coil region (light 
blue) as a structural motif within the secondary structure was recently published (Rowley et 
al., 2008) according to the Jpred secondary structure prediction server (Cuff and Barton, 
2000). The conserved serine residue, which nucleophilically attacks the DNA at the crossover 
site, is shown in red at position 10 or 12 for γδ resolvase or PhiC31 integrase, respectively. 
 
The solved crystal structure of the γδ resolvase (Yang and Steitz, 1995) supports the domain 
distribution and serves as a putative model for the related enzyme PhiC31 integrase. The 
crystal structure of the PhiC31 integrase has not been solved to date. The Jpred secondary 
structure prediction server (Cole et al., 2008; Cuff and Barton, 2000) including COILS 
prediction (Lupas, 1997) has been used for analysis of the PhiC31 integrase to identify helical 
regions, extended types of secondary structure and coiled-coil regions (Figure 1.5). 
Identification of present secondary structure motifs within the protein context might shed 
some light on the function and the domain structure of the unknown C-terminal DNA binding 
domain. This might gain a better understanding of particular regions and the effect of 
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mutagenesis at critical residues, which are examined in this thesis. The output of the 
secondary structure prediction using Jpred 3 2 is shown in Figure 1.5 below. 
 
 
 
Figure 1.5. Secondary structure prediction of the PhiC31 integrase protein. 
The output from Jpred prediction (jnetpred: final secondary structure prediction, Lupas: coil 
prediction) is shown below the PhiC31 integrase sequence (Cole et al., 2008; Lupas, 1997), 
illustrated by Jalview a multiple alignment editor (Clamp et al., 2004). The green arrows 
represent extended types of secondary structure as β-sheets. The red bars represent helical 
types as α helices of secondary structure. The coiled-coil helical bundles are a structural motif 
only found within the large helical structures between amino acid position 450 and 516 using 
3 different algorithms (Lupas 21, 14, and 28) according to amino acid length of the particular 
heptads. Since the coiled-coil motif is only present at the given AA sequence, the Lupas 
coiled-coil predictions are only shown in the lines where they are present. The putative DNA 
binding domain encompasses amino acid position 360- 480 and is framed in black. 
 
The crystal structure of the model enzyme within the serine integrase family has first been 
solved for the catalytic domain only (Rice and Steitz, 1994) revealing that a formed dimer 
binds to one DNA strand. The complexed structure of a single resolvase dimer to uncleaved 
site I DNA and synaptic γδ resolvase tetramer structures bound to two cleaved site I DNA 
target sequences have also been solved (Yang and Steitz, 1995; Li et al., 2005). These 
structures were among the available models obtained from the Phyre server (Kelley and 
Sternberg, 2009) when searching for PhiC31 integrase related similar proteins3 showing 15 % 
and 18 % AA identity, respectively. Certain sequence divergence between the PhiC31 
integrase and the gamma delta resolvase (Thorpe and Smith, 1998; Yang and Steitz, 1995; Li 
                                                 
2
 http://www.compbio.dundee.ac.uk/www-jpred/advanced.html 
3
 http://www.sbg.bio.ic.ac.uk/phyre/qphyre_output/aa7792bd757b71d0/summary.html 
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et al., 2005) exist. However, primary structures are more conserved than corresponding 
primary sequences (Chothia and Lesk, 1986). This assumes similar function within the 
domains. Different images of the γδ resolvase protein structure are shown in Figure 1.6. 
 
Figure 1.6. Protein structures of the gamma delta (γδ) resolvase. 
Two different crystal structures of the γδ resolvase are illustrated. The upper images show the 
enzyme in its active form complexed with DNA. The lower images show the uncomplexed 
monomers. The colour of the protein changes with the position along the amino acid chain. 
Dark blue represents the N-terminal or 5´ end. Red represents the C-terminal or 3´ end. (A) 
The structure of a synaptic γδ tetramer covalently linked to two cleaved DNAs is shown (Li et 
al., 2005). The dimers are light blue and in light green. Two DNA double helices are shown, 
which are cleaved in the middle. The C-terminal end (indicated in red in Figure B) is shown 
on the outside relative to the DNA. The protein consists of 183 amino acids. The PDB 
(Protein data bank) ID is 1ZR2. (B) The gamma delta monomer without DNA from 1ZR2 is 
shown. (C) The crystal structure of the γδ resolvase complexed with a cleavage site is shown 
(Yang and Steitz, 1995). The dimer composed of 2 chains is shown in purple and complexed 
to the DNA in light green and red (lower strand) and blue and light blue (upper strand). The 
protein consists of 140 amino acids. The PDB ID is 1GDTA and 1GDTB. (D) The monomer 
without DNA from 1GDTA is shown. Protein figures are illustrated at the RCSB PDB 
website4 using Jmol version 11.6. 
                                                 
4
 http://www.rcsb.org/pdb/home/home.do 
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1.4.4 Applications for PhiC31 integrase 
One of the first studies using PhiC31 integrase-mediated gene integration in mice 
demonstrated delivery in vivo by the newly developed hydrodynamic tail vein injection 
technique of naked DNA to mouse hepatocytes. Therapeutic levels of hFIX were still 
detectable 250 days after injection due to stable integration and long-term expression even 
after two-third partial hepatectomy at day 100 post injection (Olivares et al., 2002). In another 
study, PhiC31 integrase was shown to stably introduce genes in an ex vivo approach in 
primary human keratinocytes grafted onto mice (Ortiz-Urda et al., 2002). A comparative liver 
study matched the in vivo and in vitro efficiency and the persistence of PhiC31 integrase with 
the SB transposon in mouse liver using the hFIX gene as a marker for gene delivery and 
expression (Ehrhardt et al., 2005). Both systems were capable of producing prolonged levels 
of hFIX. A novel two-vector system described a hybrid vector that combines stable 
transduction of the gene-deleted AdV vector and a specific integration potential of the PhiC31 
integrase (Ehrhardt et al., 2007). 
Since PhiC31 integrase-mediated recombination has been developed to function in 
mammalian cells, several disease-related studies have been performed to evaluate and 
improve PhiC31 integrase-mediated gene transfer in vitro and in vivo (reviewed by Calos, 
2006). The PhiC31 integrase has been successfully applied in numerous preclinical gene 
therapy trials (Olivares et al., 2002; Ortiz-Urda et al., 2002; Hollis et al., 2003; Ehrhardt et al., 
2005; Ehrhardt et al., 2007). 
Moreover, the PhiC31 integrase system represents a platform technology with additional 
applications (reviewed by Calos, 2006): genetic engineering of eukaryotic genomes, 
production of recombinant proteins and transgenesis have been performed with some success 
(Allen and Weeks, 2009; Thyagarajan et al., 2008; Sharma et al., 2008; Blaas et al., 2007; 
Raymond and Soriano, 2007; Thyagarajan and Calos, 2005; Belteki et al., 2003; Hollis et al., 
2003; Kolb, 2002). Besides the recombinase-mediated integration, the excision has been 
extensively investigated within the present study. Both recombination techniques are used for 
different approaches. 
1.4.5 Attempts to improve PhiC31 integrase integration efficacy  
Shortly after the PhiC31 integrase has been developed for integration into mammalian 
genomes, experiments involving mutagenesis by directed evolution via DNA shuffling 
resulted in enhanced mutant derivatives. Improvements in integration frequency and sequence 
specificity at a formerly found and preferentially targeted pseudo attP site on chromosome 8 
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were obtained after mutagenesis-selection by DNA shuffling and bacterial screening 
(Sclimenti et al., 2001). Further attempts to improve the integration efficiency of the PhiC31 
integrase were performed using alanine-scanning mutagenesis of the catalytic domain, error-
prone PCR or bacterial mutator strains. The chromosomal integration efficiency in cultured 
human cells could be increased about twofold at both a preintegrated attP site and at 
endogenous pseudo attP sites compared to wt PhiC31 integrase (Keravala et al., 2009). In a 
novel deletion assay a 1.74-fold enhancement of the relative beta-galactosidase activity was 
found upon C-terminal addition of a nuclear localization sequence (NLS) to the PhiC31 
integrase sequence compared to the wt integrase (Andreas et al., 2002). 
The generation of fusion proteins by linking the PhiC31 integrase with the hormone binding 
domain hRP891 gained new techniques for tightly steroid-inducible non-viral integration 
systems. Sharma et al. (2008) could demonstrate that the drug-regulated PhiC31 fusion 
proteins increased site-directed gene insertion in the presence of the hormone fourteenfold 
(Sharma et al., 2008). Recombination activity of a de novo synthesised codon-optimised 
derivative of the native PhiC31 integrase gene was assessed with beta-galactosidase as a 
reporter gene in embryonic stem cells. Codon-optimisation avoids gene silencing by reducing 
the number of CpG dinucleotides. This codon-optimised version tagged with the C-terminal 
NLS of the SV40 large T antigen showed with a twentyfold improvement compared to the wt 
integrase a similar recombination activity as Cre at inserted minimal target recognition sites 
flanking the reporter gene in the ROSA 26 based reporter cell lines (Raymond and Soriano, 
2007). 
Recent attempts beyond improving the enzymatic and the recombination reaction involve 
improvements of the overall PhiC31 integrase system targeting the expression plasmid and 
the donor plasmid in order to attenuate and prevent postintegrative gene silencing. This 
cellular mechanism has been addressed for the first time with the PhiC31 integrase system. 
Aimed at reducing steady decline in expression, modifications to cellular promoters, plasmid 
backbone, polyA signals and the addition of an NLS were carefully examined in pulmonary 
type II cells (Aneja et al., 2009). 
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1.5 Aims of this study 
 
PhiC31 integrase-mediated recombination of plasmid DNA has frequently been applied 
within the context of therapeutic gene transfer and transgenesis. Improving integration 
efficiency of recombinases is of critical importance, since the native, preferentially non-viral 
vector delivery represents the most crucial bottleneck. Specific integration is of general 
interest since chromosomal aberrations and the risk of insertional mutagenesis demonstrate 
major drawbacks of the PhiC31 integrase system. The final goal was to improve the 
recombination activity of PhiC31 integrase within the context of mammalian cells. Site-
directed mutagenesis within the integrase DNA-binding domain was performed with the 
objective of identifying integrase mutants with improved recombination activity. The 
following was implemented in this study: 
1. Screening of integrase mutants showing improved integration efficiency in selection 
based integration assays in various mammalian cell lines including double mutants and 
dose dependent studies of the integrase encoding plasmid 
2. Screening of integrase mutants revealing enhanced intramolecular excision activity 
within chromosomal context and within plasmid DNA by means of reporter assays 
(GFP/luciferase) being valuable in chromosomal engineering as transgenesis and gene 
activation 
3. Evaluation of integrase specificity of selected integrase mutants by detailed analysis of 
chromosomal insertion sites (pseudo attP sites) 
4. In vivo evaluation of PhiC31 integrase mediated integration efficiency of a substrate 
plasmid encoding human coagulation factor IX (hFIX) relative to hFIX long-term 
expression  
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2. Material  
2.1 Laboratory equipment  
 
Bench top centrifuge      Biofuge fresco, Heraeus 
Centrifuges (for bacterial cultures)   Sorvall and Eppendorf 
Cell-culture centrifuge    Rotanta 460, Hettich 
Electroporator      Gene Pulser II, Bio-rad 
Heating block      Eppendorf 
Incubator for cell culture    Thermo Electron  
Light Cycler      Light Cycler 2.0, Roche 
Luminometer, Microlumat Plus LB 96V  Berthold Technology 
Microwave      Samsung 
PCR machine      T professional basic, Biometra 
Spectrophotometer     Ultrospec 3000, Pharmacia 
FACS Canto      BD 
Counting cell chamber    Neubauer 
Shaker       Bachofer 
Spectrophotometer Ultrospec 2000   Pharmacia Biotech 
 
2.2 Chemicals 
 
Chemicals were purchased from the companies listed below. Supplies in form of sterile 
plastic ware were either delivered from Peske or Falcon.  
 
Chemicals used and their suppliers  
Agar-agar      Roth  
Ampicillin      Roth 
Amphotericin B     PAA Laboratories 
Bacto tryptone     BD Bioscience  
Bacto yeast extract     BD Bioscience    
BSA (Bovine serum albumine)   Roth 
Calcium chloride (CaCl2)    Merck 
Carbon tetrachloride (CCl4)    Riedel-de Haën 
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Dimethylsulfoxide (DMSO)    Roth 
EDTA (N,N,N,N-Ethylenediaminetetraacetic acid) Merck 
Ethanol (100 %)     Roth 
Ethidium bromide     Merck 
Formaldehyde      Merck 
Glacial acetic acid     Roth 
G418 sulphate      PAA Laboratories 
Glycerin      Invitrogen 
Isopropanol      Invitrogen 
Kanamycin      Roth 
L-Glutamine      PAA Laboratories 
Magnesiumchloride     Merck 
Methylene blue     Sigma-Aldrich 
Mineral oil      Sigma 
Phenol: Chloroform: Isoamyl Alcohol (25: 25: 1) Invitrogen 
(PCI) 
RNase inhibitor     New England Biolabs (NEB) 
SIGMAFAST OPD     SIGMA 
(o-Phenylenediamine dihydrochloride) 
Sodium bicarbonate (7.5 % solution)  Gibco 
Sodium chloride     Roth 
Tris       Roth 
Tris/ HCl      Merck 
Trypan blue 0.5 % (w/v)    Biochrom AG 
Trypsin      Gibco 
Tween 20      SIGMA 
 
2.3 Enzymes 
2.3.1 Restriction endonucleases 
All restriction endonucleases were ordered from NEB. 
2.3.2 Other enzymes 
Calf Intestinal Alkaline Phosphatase (CIP)  NEB 
KOD polymerase     Novagen 
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Pfx polymerase     Invitrogen 
Polynucleotide kinase (PNK)   NEB 
Proteinase K       Merck 
Ribonuclease A (RNaseA)    Qiagen 
T4 DNA ligase     NEB 
Taq polymerase     NEB or Invitrogen 
 
2.4 Solutions, media and buffers 
 
For plasmid isolation  
Bacterial resuspension buffer (buffer P1)  50 mM Tris-HCl (pH 7.5) 
10 mM EDTA (pH 8.0) 
100 µg/ml RNase A 
 
Lysis buffer (buffer P2)    0.2 M NaOH  
       1 % SDS 
 
Neutralization buffer (buffer P3)   4.09 M guanidine hydrochloride (pH 4.8) 
       759 mM potassium acetate 
       2.12 M glacial acetic acid 
 
Lysis buffer for eukaryotic DNA   10 mM Tris 
10 mM EDTA 
0.5 % SDS 
 
For gel electrophoresis 
Solution for agarose gels    1 % agarose in 1 ×  TAE 
       100 ml 1 ×  TAE buffer 
 
Ethidium bromide staining solution    (10 µg/ml) Ethidiumbromide in 100 ml 
       1 × TAE and agarose heated to 56 °C 
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50 ×  TAE-buffer     2 M Tris/HCl, pH 8.2  
1 M glacial acetic acid 
0.1 M EDTA, pH 7.6 
 
10 ×  loading buffer     125 mg (0.25 % w/v Bromphenol blue) 
25 ml Glycerol, 10 % (v/v) 
5 ml EDTA (0.5 M, pH 8.0) 
2.5 ml Tris (1 M, pH 7.5) 
 
1 kb DNA marker     10 µl 1 kb DNA marker (Peqlab) 
       20 µl loading buffer (Peqlab) 
       70 µl H2O 
 
For methylene blue staining 
Fixing solution      12 ml 37 % formaldehyde  
188 ml D-PBS  
 
Methylene blue solution     2 % methylene blue (Sigma-Aldrich) 
200 ml 50 % ethanol 
 
For incubation of bacteria 
LB medium      1 % (w/v) peptone 
       0.5 % (w/v) yeast extract 
       0.5 % (w/v) NaCl; autoclave 
 
LB Agar  1.5 % agar-agar suspended in LB medium 
 
SOC medium      2 % (w/v) bacto-tryptone 
       0.5 % (w/v) bacto-yeast extract 
       10 mM NaCl 
       2.5 mM KCl  
10 mM MgCl2  
20 mM glucose  
pH to 7.0 and autoclave 
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For preparation of competent cells 
MgCl2 solution     100 mM in H2O 
CaCl2 solution      100 mM in H2O 
       85 mM in 15 % glycerol 
 
For selection of bacteria with antibiotics  
Ampicillin solution     50 µg/ml in H2O 
 
Kanamycin solution     20 µg/ml in H2O 
 
For ELISA 
Coating buffer     0.1 M NaHCO3, pH 9.4 
 
Tris buffered saline (TBS)    10 mM Tris-HCl  
150 mM NaCl, in H2O 
 
TBS-Tween 20 (T)     10 mM Tris-HCl  
150 mM NaCl, in H2O 
0.05 % Tween 20 
 
Dilution buffer     10 mM Tris-HCl 
150 mM NaCl, in H2O 
5 % BSA 
0.05 % Tween 20  
2.4.1 Media, supplements and reagents for eukaryotic cell lines 
HEK 293 and HeLa cell lines   Dulbecco´s modified Eagle Medium 
       (DMEM) (Gibco/PAA) 
FBS (foetal bovine serum) 10 % (v/v) 
(Gibco) 
Penicillin/Streptomycin 1 % (v/v) (Gibco) 
Amphotericin B (250 µg/ml) 0.1 % (v/v) 
      (PAA laboratories) 
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Huh7 and Hep1A cell lines     DMEM 
FBS (foetal bovine serum) 10 % (v/v) 
Penicillin/Streptomycin 1 % (v/v)  
Amphotericin B (250µg/ml) 0.1 % (v/v) 
non essential amino acids (100 × ) (PAA) 
 
HCT cell line      McCoy’s 5A medium (GIBCO) 
FBS 10 % (v/v) 
Penicillin/ Streptomycin 1 % (v/v) 
Amphotericin B (250 µg/ml) 
sodium bicarbonate 7.5 % (v/v) (GIBCO) 
 
OptiMEM® (for serum-free transfection)  Invitrogen 
Dulbecco’s phosphate buffered saline   PAA 
(D-PBS) (for washing cells)     
 
Freezing media for eukaryotic cells   DMEM 80 % (v/v) 
FBS 10 % (v/v) 
       DMSO 10 % (v/v) (Roth) 
 
G418 solution      50 mg G418 sulphate in 1 ml H2O 
Trypan blue (for cell counting)   0.5 % (w/v) (Biochrom AG) 
 
Transfection reagents for transfection of cell lines 
FuGENE6 Transfection Reagent (Roche) 
FuGENE® HD Transfection Reagent (Roche) 
Lipofectamine 2000 (Invitrogen) 
 
2.5 Kits 
 
ALT Kit (Randox) 
Dual Luciferase reporter assay (Promega) 
High Pure PCR Product Purification Kit (Roche) 
LightCycler FastStart DNA MasterPlus SYBR Green I  
Nucleobond AX Anion exchange column for quick purification of nucleic acids in large-scale 
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(MACHEREY-NAGEL) 
PCR Cloning Kit (Qiagen) 
ProtoScript® First Strand cDNA Synthesis kit (NEB) 
Pure Yield™ Plasmid Midiprep System (Promega) 
Qiagen PCR Cloning kit 
QIAquick gel extraction kit (QIAGEN) 
QIA midi kit (QIAGEN) 
Zero Blunt® TOPO® PCR Cloning Kit (Invitrogen) 
 
2.6 Organisms 
2.6.1 Bacteria 
For cloning of recombinant DNA and amplification of plasmids the E.coli strains DH5α and 
DH10B were used. For subcloning of PCR products, chemical competent TOP10 bacterial 
cells (included in pTOPO Cloning Kit) were purchased from Invitrogen. All strains used in 
this study are summarised in Table 2.1. 
 
Table 2.1. Bacterial strains. 
Strain Designation Genotype 
E.coli DH5α supE44, ∆(lacZYargF)U169(φ80dlacZ∆M15), hsdR17, recA1, endA1, 
gyrA, thi-1, relA1; Invitrogen 
E.coli DH10B F- araD139, ∆(ara, leu)7697, ∆lacX74, galU, galK, mcrA, ∆(mrr-, hsdR, 
mcrBC), rspL, deoR, (φ80dlacZ∆M15), endA1, nup5, recA1; Invitrogen 
E.coli Stabl-2 F- endA1, glnV44, thi-1, gyrA96, relA1, ∆(lac-proAB), mcrA, ∆(mcrBC-
hsdR-mrr)λ- recA1; Invitrogen 
TOP 10  F- mcrA, ∆(mrr-hsdRMS-mcrBC), Φ80lacZ∆M15, ∆lacX74 recA1 
araD139, ∆(araleu), 7697 galU, galK, rpsL (StrR), endA1, nupG; 
Invitrogen 
 
2.6.2 Eukaryotic cells 
The following cell lines which were used or constructed in this study are depicted in Table 2.2 
 
Table 2.2. Eukaryotic cell lines. 
Cell line Tissue source Reference 
293 (HEK-293) human embryonic kidney  DSZM, Germany 
293+attP-BGHpolyA-attB-eGFP human embryonic kidney  This study 
HeLa epithelial tissue from 
human cervical carcinoma 
Mark Kay’s Laboratory, 
Stanford University, USA 
HCT human colon carcinoma Mark Kay’s Laboratory, 
Stanford University, USA 
Huh7 human hepatoma cell line Mark Kay’s Laboratory, 
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Cell line Tissue source Reference 
Stanford University, USA 
Hep1A Mouse hepatoma cell line Mark Kay’s Laboratory, 
Stanford University, USA 
HCT+ p7 (neoR cell lines upon 
integrase mediated integration) 
human colon carcinoma This study 
 
 
2.7 Oligonucleotides 
 
All oligonucleotides used in this study are listed below. Oligonucleotides were obtained from 
Operon and stored as 10 µM stock solutions. Restriction recognition sites are underlined and 
respective endonucleases are listed in the right column. Oligonucleotides listed below in 
Table 2.3 were used to design site-directed mutations in the integrase DNA sequence. 
 
Table 2.3. Oligonucleotides used for site-directed mutagenesis of the PhiC31 integrase. 
Name of oligonucleotide 
and description 
Sequence from 5´- to -3´ Restriction 
recognition 
BamHIforwouterNEW CGGGGATCCGGGTGTCTCGCTACG BamHI 
BstEIIrcouterNEW TAGGGTTACCGCATTCAGCGCGAC BstEII 
sdM-K367Aforward GCCATGGACGCGCTGTACTGC  
sdM-K367Areverse GCAGTACAGCGCGTCCATGGC  
sdM-E371Aforward CTGTACTGCGCGTGTGGCGCC  
sdM-E371Areverse GGCGCCACACGCGCAGTACAG  
sdM-R380Aforward ACTTCGAAGGCCGGGGAAGAA  
sdM-R380Areverse TTCTTCCCCGGCCTTCGAAGT  
sdM-K386Aforward GAATCGATCGCGGACTCTTAC  
sdM-K386Areverse GTAAGAGTCCGCGATCGATTC  
sdM-R394Aforward TGCCGTCGGCGAAGGTCGTC  
sdM-R394Areverse GACCACCTTCGCGCGACGGCA  
sdM-D398Aforward AAGGTGGTCGCCCCGTCCGCA  
sdM-D398Areverse TGCGGACGGGGCGACCACCTT  
sdM-D417Aforward GCGGCACTCGCCAAGTTCGTT  
sdM-D417Areverse AACGAACTTGGCGAGTGCCGC  
sdM-R423Aforward GTTGCGGAAGCCATCTTCAAC  
sdM-R423Areverse GTTGAAGATGGCTTCCGCAAC  
sdM-E435Aforward GAAGGCGACGCAGAGACGTTG  
sdM-E435Areverse CAACGTCTCTGCGTCGCCTTC  
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Name of oligonucleotide 
and description 
Sequence from 5´- to -3´ Restriction 
recognition 
sdM-R446Aforward GAAGCCGCCGCACGCTTCGGC  
sdM-R446Areverse GCCGAAGCGTGCGGCGGCTTC  
sdM-K457Aforward GCGCCTGAGGCGAGCGGCGAA  
sdM-K457Areverse TTCGCCGCTCGCCTCAGGCGC  
sdM-D470Aforward GAGCGCGCCCCGCCCTGAAC  
sdM-D470Areverse GTTCAGGGCGGCGGCGCGCTC  
sdM-D366Aforward TGTCCGCCATGGCCAAGTGTACTG  
sdM-D366Areverse CAGTACAGCTTGGCCATGGCGGACA  
sdM-E382Aforward CGAAGCGCGGGGCAGAATCGATCAAG  
sdM-E382Areverse CTTGATCGATTCTGCCCCGCGCTTCG  
sdM-E383Aforward GCGCGGGGAAGCATCGATCAAGGAC  
sdM-E383Areverse GTCCTTGATCGATGCTTCCCCGCGC  
sdM-R390Aforward GGACTCTTACGCCTGCCGTCGCCGG  
sdM-R390Areverse CCGGCGACGGCAGGCGTAAGAGTCC  
sdM-R393Aforward CCGCTGCCGTGCCCGGAAGGTGG  
sdM-R393Areverse CCACCTTCCGGGCACGGCAGCGG  
sdM-E406Aforward GGGCAGCACGCAGGCACGTGCAAC  
sdM-E406Areverse GTTGCACGTGCCTGCGTGCGCCC  
sdM-R429Aforward CAACAAGATCGCGCACGCCGAAGG  
sdM-R429Areverse CCTTCGGCGTGCGCGATCTTGTTG  
sdM-E4329Aforward CAGGCACGCCGCAGGCGAC GAAG  
sdM-E4329Areverse CTTCGTCGCCTGCGGCGTGCCTG  
sdM-K450Aforward GACGCTTCGGCGCGCTCACTGAGGC  
sdM-K450Areverse GCCTCAGTGAGCGCGCCGAAGCGTC  
sdM-R461Aforward GAGCGGCGAAGCGGCGAACCTTGTTG  
sdM-R461Areverse CAACAAGGTTCGCCGCTTCGCCGCTC  
 
Oligonucleotides listed below were used for cloning and sequencing (Table 2.4). 
 
Table 2.4. Oligonucleotides used for cloning and sequencing. 
Name of oligonucleotide 
and description 
Sequence from 5´- to 3´ Restriction 
recognition 
BamHINotIBstEIIfor GATCCGCGGCCGCG NotI 
BstEIINotIBamHIrev GTTACCGCGGCCGCG NotI 
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Name of oligonucleotide 
and description 
Sequence from 5´- to 3´ Restriction 
recognition 
PmeINcoIchr.2 GTTTAAACCCATGGGGCAGGTGGCGC
AGTCAA 
PmeI, NcoI 
Chr.2NcoIPmeI GTTTAAACCCATGGCCTGGGGCTGAA
GTTTGAT 
NcoI, PmeI 
SpeIXhoIHindIIIchr12 GGACTAGTCCCTCGAGGCCCAAGCTT
GGGTGGCTCTAGCGTCTACGATG 
SpeI,XhoI, 
HindIII 
Chr12HindIIISpeI XbaI TGCTCTAGAGCAGACTAGTCCCAAGC
TTGGGTGAGATATGCGGCAAAAACA 
HindIII, SpeI, 
XbaI 
SpeIEcoRVHindIII chr19 GGACTAGTCCGATATCCCCAAGCTTG
GGTTGTTTGGCTCAGACCTTCC 
SpeI, EcoRV, 
HindIII 
Chr19HindIIIEcoRI SpeI GGACTAGTCCGATATCCCCAAGCTTG
GGTGTTGGTAATTTGCGGTTCA 
HindIII, EcoRV, 
SpeI 
Luciferaserev.5 CCATCTTCCAGCGGATAGAATGGC  
Int-Pst5`- CGCCTGCAGGTACCGGTCCGGAAT PstI 
Int-BstEII3`- TGCGGTAACCCTCAATCTTCGTGG BstEII 
forwAgeIhs2 ACCGGTAGTGAGCTCCTGTTGCT AgeI 
revStuIhs2 AGGCCTTCCTGGGGCTGAAGTTTGAT StuI 
forwAgeIhs12 ACCGGTTGTCTCTCAAGAGGGAAGTG AgeI 
revStuIhs12 AGGCCTAAGCTTGGGTGAGATATGC StuI 
forwAgeIhs19 ACCGGTGTTGTTTGGCTCAGACCTT AgeI 
revStuIhs19 AGGCCTTGTTGGTAATTTGCGGTTCA StuI 
attB-F for sequencing TACCGTCGACGATGTAGGTCACGGTC  
attB-R for sequencing CGTGACCACCGCGCCCAGCGGTTT  
forw.DAXXqRT AGGAGTTGGATCTCTCAGAA  
rev.DAXXqRT TGATGAGCCGCTCAATG  
 
Duplex RNA listed in Table 2.5 below was used for quantitative real-time PCR in stocks of 
100 pmoles/µl and 30 pmoles/µl for DAXX siRNA and GL-siRNA. 
 
Table 2.5. Duplex RNAused for quantitative real-time PCR. 
Name of siRNA and description Sequence from 5´- to 3´ 
DAXX-siRNA  GGAGUUGGAUCUCUCAGAATT 
GL-siRNA (GAPDH specific) as control CUUACGCUGAGUACUUCGATT 
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2.8 Plasmids 
 
Plasmids constructed in the context of this study are shown in Table 2.6 and are described in 
the results section. 
 
Table 2.6. Plasmids used for cloning and transfection. 
Plasmid name Plasmid Description Reference 
pCS Int 
wild type 
 
Backbone plasmid contains wild type PhiC31 
integrase as template plasmid for point mutants, 
AmpR,  
Olivares et al., 2002, 
Ehrhardt et al., 2005 
mInt 
 
Integration deficient negative control plasmid 
of pCS Int, contains point mutation at S20F in 
catalytic centre, AmpR 
Olivares et al., 2002, 
Ehrhardt et al., 2005 
p7 
derivative of p11 
 
Substrate plasmid for PhiC31 integrase, 
contains attB site, high copy origin of 
replication from Tn5, KanR 
Ehrhardt et al., 2005 
 
pBSattBhFIX  
 
Substrate plasmid for PhiC31 integrase with 
attB site, hFIX minigene, liver- specific  
promoters and enhancer, AmpR 
Ehrhardt et al., 2005 
 
pCS Int + D366A Integrase gene contains D366A mutation This study 
pCS Int + K367A Integrase gene contains K367A mutation This study 
pCS Int + E371A Integrase gene contains E371A mutation This study 
pCS Int + R380A Integrase gene contains R380A mutation This study 
pCS Int + E382A Integrase gene contains E382A mutation This study 
pCS Int + E383A Integrase gene contains E383A mutation This study 
pCS Int + K386A Integrase gene contains K386A mutation This study 
pCS Int + R390A Integrase gene contains R390A mutation This study 
pCS Int + R393A Integrase gene contains R393A mutation This study 
pCS Int + R394A Integrase gene contains R394A mutation This study 
pCS Int + D398A Integrase gene contains D398A mutation This study 
pCS Int + E406A Integrase gene contains E406A mutation This study 
pCS Int + D417A Integrase gene contains D417A mutation This study 
pCS Int + R423A Integrase gene contains R423A mutation This study 
pCS Int + R429A Integrase gene contains R429A mutation This study 
pCS Int + E432A Integrase gene contains E432A mutation This study 
pCS Int + E435A Integrase gene contains E435A mutation This study 
pCS Int + R446A Integrase gene contains R446A mutation This study 
pCS Int + K450A Integrase gene contains K450A mutation This study 
pCS Int + K457A Integrase gene contains K457A mutation This study 
pCS Int + R461A Integrase gene contains R461A mutation This study 
pCS Int + D470A Integrase gene contains D470A mutation This study 
pLucCR wt Substrate plasmid for integrase with wt attP 
and attB site and firefly luciferase, AmpR 
Aneja et al., 2007, 
Carsten Rudolph’s 
laboratory, Munich 
pLuc+hs2 Substrate plasmid for integrase with pseudo 
attP from chr. 2q11.2, AmpR 
This study 
pLuc+hs12 Substrate plasmid for integrase with pseudo This study 
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Plasmid name Plasmid Description Reference 
attP from chr. 12q22, AmpR 
pLuc+hs19 Substrate plasmid for integrase with pseudo 
attP  from chr. 19q.13.31, AmpR 
This study 
phRL-0 Human codon-optimised Renilla luciferase 
containing vector, AmpR 
Invitrogen 
pRL-TK Renilla luciferase vector with TK promoter, 
AmpR 
Invitrogen 
pGL3  contains firefly luciferase gene, SV40 
promoter, AmpR 
Invitrogen 
pCRBluntIITOPO Cloning vector for inserts: PCR fragments or 
restricted fragments, KanR 
Invitrogen 
pHM5 Cloning vector, KanR Marc Kay’s 
laboratory, Stanford 
University, USA 
pEGFP pattP-BGHpolyA-attB-EGFP  
with CMV, eGFP, SV40, KanR 
Chen et al., 2006  
pCRmOrange Compensation plasmid to evaluate transfection 
efficiency detected by FACS, AmpR, KanR 
Invitrogen 
pQCXIX-GFP-I-
MDR 
eGFP expressing plasmid as control for FACS 
experiments, AmpR 
Wolfgang Pfützner’s 
laboratory, Munich 
pDrive+DAXX DAXX expressing plasmid as internal control 
for real-time PCR 
This study 
pBS Cloning vector used as stuffer plasmid DNA, 
AmpR 
Marc Kay’s 
laboratory, Stanford 
University, USA 
pUC19 High copy cloning vector used as stuffer 
plasmid DNA, AmpR 
Marc Kay’s 
laboratory, Stanford 
University, USA 
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3. Methods 
3.1 General methods with eukaryotic cell culture 
3.1.1 Cultivation of eukaryotic cells 
In this work only adherent cell lines were cultured and transfected. Cell lines were grown in 
10-cm tissue culture dishes in appropriate medium at 37 °C and 5 % CO2 with supplements as 
described in section 2.4.1 until confluent at approximately 90 %. Cells were passaged twice a 
week. For splitting, cells were washed with 3 ml D-PBS, and 3 ml trypsin (PAA) was added 
to detach cells from the plastic surface. Cells were centrifuged at 1.500 rotations per minute 
(rpm) for 3 minutes (min) in a Rotana 460 cell culture centrifuge. The supernatant was 
discarded, and cells were resuspended in medium and cells were diluted into differently sized 
culture plates (24-wells plate, 6-wells plate, 6-cm dish or 10-cm dish). 
3.1.2 Storage of eukaryotic cells 
For long-term storage in liquid nitrogen, cultured cells were treated with trypsin as described 
above and resuspended in 2 ml freezing medium containing 10 % DMSO as a cryoprotectant. 
Resuspended cells were aliquotted into two cryo tubes, slowly frozen down at -80 °C and 
stored in liquid nitrogen until use. 
3.1.3 Cell counting of cultured eukaryotic cells  
The number of cells was determined with a Neubauer counting cell chamber. Trypsinised 
cells were diluted with trypan blue at a ratio of 1:1. Blue dye is only taken up by dead cells. 
Therefore, dead blue stained cells could be distinguished from colourless, living cells. Twelve 
microlitres of this mix were transferred onto the counting chamber and living cells present 
within the grid were counted. The total cell number within four large squares was averaged 
and the dilution factor was taken into consideration in order to determine the exact number of 
cells. Multiplication of counted cells with factor 104 represented the entire cell number per 
millilitre (ml). 
3.1.4 Transfection of eukaryotic cells with plasmid DNA 
Mammalian cells were transfected with either FuGENE6, FuGENE® HD (Roche) or 
Lipofectamine 2000 (Invitrogen). Lipofection or liposome transfection alters the cellular 
plasma membrane allowing any kind of nucleic acid complexed with liposomes to cross into 
the cytoplasmic space. Short transfection protocols using either FuGENE® HD and 
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FuGENE6 (a) or Lipofectamine 2000 (b) are described below. Additional information is given 
in respective manuals. 
(a) A defined number of cells, depending on growth, size and origin, were seeded in the 
appropriate well size of the culture dishes the day before transfection to reach a confluency of 
60-90 %. According to well size and number of replicates the transfection reagent (here 
FuGENE) was diluted with serum-free Opti-MEM. After five minutes of incubation, the 
appropriate number and concentration of plasmid DNA (pDNA) was added to the medium. 
Total DNA (in ng) and appropriate transfection reagent (in µl) were used at a ratio of 3:1 
unless stated otherwise (Table 3.1). The transfection mix was incubated for at least 15 min at 
room temperature before it was added dropwise to the cells and incubated for two days. For 
the FuGENE6 system, cells were transfected at low cell densities 50-80 % confluent. For the 
FuGENE HD system, cells were transfected at high densities ranging between 80 and 90 %. 
(b) One day before transfection, cells were plated so that cells would be 90-95 % confluent at 
the time of transfection. DNA was diluted in appropriate volume of Opti-MEM medium and 
gently mixed. Lipofectamine 2000 was diluted in the same amount of Opti-MEM medium and 
incubated for 5 min at room temperature. Upon incubation, diluted DNA and diluted 
Lipofectamine were combined, gently mixed and incubated at room temperature for 20 
minutes. The complex was subsequently added to each well or dish containing cells and 
medium. Cells were gently mixed by rocking the plates and incubated at 37 °C and 5 % CO2. 
Cells were harvested and assayed two days post transfection for transgene expression in 
respective assays. 
 
Table 3.1. Guidelines for transfection reagents in different well size using FuGENE6 
transfection reagent: DNA ratio of 3:1. 
 
Well size 
format 
Seeding 
density* 
Volume of 
FuGENE6 reagent 
Mass of 
DNA 
Total volume 
of complex 
Growth 
medium 
24 well- 1 well 0.05 ×106 1.2 µl 0.4 µg 20 µl 1 ml 
6 well- 1 well 0.3 ×106 6.0 µl 2.0 µg 100 µl 3 ml 
6-cm dish 0.8 × 106 10 µl 5.0 µg 250 µl 5 ml 
*The number of cells in a confluent well varies depending on the cell type. This table shows 
the approximate number of HeLa cells being used for transfection. For 293 cells, 
approximately twice as many cells are required since 293 cells are smaller in size. 
 
3.1.5 Transfection with siRNA and plasmid DNA and further applications 
HEK 293 cells were seeded into 6-well plates to reach confluency of about 30 % the next day. 
Transfections were carried out according to the protocol (Invitrogen). One hundred picomoles 
(pmol) siRNA were transfected with 5 µl Lipofectamine 2000 and 250 µl Opti MEM. The 
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cells were incubated at 37 °C and 5 % CO2. One day later 2000 ng plasmid DNA were 
additionally transfected with 6 µl Lipofectamine 2000 and 100 µl Opti MEM. Two days post-
transfection, the cells were either harvested and prepared for real-time PCR (RT PCR) or were 
splitted and cultivated under selection for quantification of integration events (Figure 3.1). 
Transfection setups using siRNA and plasmid DNA for each group are described in Table 3.2. 
 
Co-transfection of 293 cells with siRNA and plasmid DNA  
 
Isolation of total RNA (tRNA)  
48 hours post transfection 
Splitting of cells 48 hours post transfection 
 
Reverse transcription into complementary 
DNA (cDNA) 
 
Cultivation of cells under selection pressure 
(500 ng/µl) for approximately 14 days 
 
 
Quantitative real-time PCR (qRT PCR) 
 
Quantification of integration events by 
colony-forming assay 
Methylene blue staining and  
counting of clones 
Determination of relative 
knock down efficiency 
 
 
Figure 3.1. Overview of process after with siRNA and plasmid DNA 
 
Table 3.2. Transfection setup and applications. 
Transfected HEK 293 cells were divided into different groups based on the amount of plasmid 
DNA and siRNA used in the transfection. All groups were determined for integration 
efficiency by a colony-forming assay (CFA). Groups II and III were used in RT PCR. 
 
Group Transfected  
Plasmids 
Transfected siRNA  
in pmoles  
Further 
applications 
I 1000 ng pCS Int +  
1000 ng p7  
1000 ng stuffer plasmid  
as control   
CFA 
II 1000 ng pCS Int + 
1000 ng p7  
100 pmol DAXX  
specific siRNA 
CFA, 
real-time PCR 
III 1000 ng pCS Int + 
1000 ng p7  
100 pmol unspecific  
siRNA (GAPDH) 
CFA, 
real-time PCR 
IV 1000 ng mInt + 
1000 ng p7  
100 pmol DAXX specific  
siRNA 
CFA 
V 1000 ng mInt + 
1000 ng p7  
100 pmol unspecific  
siRNA (GAPDH) 
CFA 
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3.2 Process to select stable cell lines with integrated plasmid 
 
Colony-forming assays were based on co-transfection of substrate plasmid p7 and integrase 
encoding plasmid into cell lines. The substrate plasmid p7 carrying a neomycin resistance 
gene and a recognition attB site was recombined with in trans delivered PhiC31 integrase at 
pseudo attP sites (attP`) within the genome resulting in the formation of hybrid attL/attR 
sites. Stable substrate plasmid integration into the genome was achieved under selection 
pressure in cell culture medium supplemented with 500 ng/ml neomycin. The substrate 
plasmid p7 and the PhiC31 integrase encoding plasmid were used for co-transfection into cell 
lines and the plasmid maps are illustrated in Figure 3.2. The co-transfection of the substrate 
plasmid and integrase encoding plasmid is outlined in Figure 3.3 below. Recombination of the 
attB/attP´ sites leading to integration of substrate plasmid p7 into the genome and the 
selection of stable single cell clones is shown. 
 
 
Figure 3.2. The plasmids used for co-transfection into cell lines are shown.  
(A) The substrate plasmid p7 contains the simian virus SV40 promoter, the Tn5 promoter, the 
neomycin-resistance gene (neo), the integrase PhiC31 attachment site attB and the origin of 
replication (oriP). (B) The integrase plasmid pCS Int encodes a cytomegalovirus virus 
promoter (CMV-p) and an integrase encoding gene, which should represent all types of 
integrase (wt Int, mInt or designed mutants). The expressed integrase mediates recombination 
of the substrate plasmid p7 at attB × attP´ within the genome. 
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Co-transfection of cells with integrase expressing plasmid (pCS Int) 
and substrate plasmid p7 containing attB site (in 6-well plate format) 
 
 
Splitting of cells 48 hours post transfection into 10-cm dishes 
 
 
Cultivation of cells under selection pressure (500 µg/ml G418) for approximately 14 days 
 
 
Quantification of 
integration events (3.2.1) 
(Colony-forming assay) 
Methylene blue staining and  
counting of clones 
 
Establishment of stably transfected  
cell lines (3.2.2) 
Isolation of single cell clones and amplification  
 
 
Isolation of genomic DNA (3.2.3) 
 
 
Analysis of integration events  
 by plasmid rescue (3.2.4) 
• Triple digestion (SpeI, NheI, and XbaI) 
• Re-ligation of genomic fragments 
• Selection by transformation 
• Plasmid purification 
• Control digestion (PstI) 
• Sequencing from hybrid attL/attR sites 
into chromosomal DNA 
 
Figure 3.3. Outline of plasmid transfection, cultivation and subsequent applications. 
The assays and methods are in bold. The respective section number for each activity is shown 
in brackets. 
 
3.2.1 Quantification of integration events 
PhiC31 integrase mediated integration efficiencies were quantified by a colony-forming assay 
(CFA). As control groups, cells were transfected with the wild type integrase (wt Int) as 
positive control or with the mutated integrase (mInt) as negative control. Cells were 
transfected in triplicate with 2000 ng pDNA/ well and plated on either 6-cm dishes or 6-well 
plates. Forty-eight hours post-transfection, the cells were counted and split in triplicate into 
10-cm dishes at a seeding density of 4×  104 or 4×  105 cells/10-cm dish. Twenty-four hours 
later, the medium was supplemented with 500 µg/ml G418. Stable genomic integration of the 
substrate plasmid conferred resistance to the transfected cells for G418 by the neomycin 
resistance gene neoR encoding an aminoglycoside 3‘- phosphotransferase. Medium 
supplemented with 500 µg/ml G418 was changed every three to four days for approximately 
two weeks keeping the selection pressure maintained until individual cells grew into clearly 
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separated colonies. For the subsequent quantification of integration events, the cultures were 
stained with methylene blue. Medium was removed and the clones were washed once by 
adding 3 ml D-PBS onto each 10 cm dish. Cell clones were fixed by addition of 3 ml of 3 % 
formaldehyde solution and incubation for 10 min. After washing with 3 ml D-PBS, 3 ml 
methylene blue solution were added to the dishes and the cells were stained at room 
temperature for 5 min. Methylene blue was removed and plates were rinsed with water and 
dried. Clones in size of about 2 millimetres and larger were counted and evaluated as 
integration events. 
3.2.2 Establishment of stably transfected cell lines  
Twenty-four hours post-transfection, 500 µg/ml G418 were added to the cells cultivated in a 
6-well format. Selective medium supplemented with G418 was changed every three to four 
days for about two to three weeks until colonies were observed as individual cell clones. 
Single clones were picked and individually isolated (monoclonal) from the original dish either 
by tips or by means of cloning rings filled with 40 µl trypsin. Trypsinized cells were 
transferred into one well of a 24-well plate. Cell-clones were then established as new cell 
lines by amplifying them in selective medium. 
3.2.3 Isolation of genomic DNA from eukaryotic cells 
Confluent cells grown in a 10-cm dish were treated with 3 ml trypsin. Detached cells were 
transferred into 1.5 ml Eppendorf tubes and harvested by centrifugation for 2 min at 2000 
rpm. The supernatants were discarded, and the cells were washed once with D-PBS. The cells 
were harvested by centrifugation. Eukaryotic cell pellets were resuspended in 200 µl D-PBS. 
Two hundred micro litres of lysis buffer were added, and the content was mixed in tubes. 
Thirty micro litres of 10 % SDS were added followed by 20 µl (20 µl/ml) Proteinase K. The 
solution was mixed thoroughly and incubated overnight at 55 °C with agitation. The next day 
2 µl RNaseA were added. After incubation for 30 min at 37 °C 350 µl phenol-chloroform-
isoamylalcohol (PCI) were added to remove proteins. After vortexing briefly, the cells were 
centrifuged for 2 min at maximum speed in a table top centrifuge. The supernatants were 
transferred to new Eppendorf tubes and extracted with PCI again. The supernatants were 
transferred to new Eppendorf tubes. Fifty microlitres NaAc (pH 5.0, 3 M) and 1 ml 100 % 
ethanol were added to precipitate the DNA. The solution was vortexed until the genomic 
DNA was visible. The genomic DNA was pelleted by centrifugation at maximum speed for 
10 min. The supernatants were discarded and 500 µl of 70 % ethanol were added. Another 
centrifugation step at maximum speed was performed for 2 min and the genomic DNA 
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samples were washed with 500 µl 70 % ethanol at room temperature with agitation for at least 
30 min. The centrifugation step was repeated and genomic DNA pellets were air dried and 
resuspended in 120 µl TE buffer at 37 °C with agitation until DNA became viscous. Genomic 
DNA concentrations were estimated with Ultrospec 3000 and stored at -20 °C until needed 
further.  
3.2.4 Analysis of integration events by plasmid rescue 
Up to 10 µg of genomic DNA from clones were digested with the restriction enzymes SpeI, 
XbaI, and NheI purified, and eluted in 20 µl H2O. Digested DNA was religated using 20 µl 
purified restricted genomic DNA, 5 µl 10 × ligation buffer, 1 µl ligase, and H2O up to 50 µl. 
The ligation mixture was precipitated with ethanol and resuspended in 20 µl sterile H2O, 1 µl 
transformed into DH10B cells by electroporation. Single colonies were cultured and plasmid-
isolated. Rescued plasmids were analysed by restriction enzyme digestion with PstI. Plasmids 
with a characteristic fragment size of 1.6 kb and additional fragments were sequenced with 
specific sequencing primers. The plasmid rescue described in Figure 3.3 is schematically 
illustrated in Figure 3.4 below with the analytical PstI digestion and the sequencing of 
flanking chromosomal DNA. 
Methods 
 42 
 
 
Figure 3.4. The plasmid rescue. 
After genomic DNA was isolated from cell lines containing the substrate plasmid p7, a triple 
digest was performed with SpeI, NheI and XbaI. Genomic fragments were further re-ligated 
and transformed into E.coli. Isolated plasmids were analysed for integration events by 
analytical digestion with PstI resulting in a specific fragment size of 1.6 kb. Sequencing with 
attR/attL specific sequencing primers could determine the target location, at which the 
plasmid was recombined into genomic DNA.  
 
3.2.5 Estimation of the quantity of colonies dependent on the integrase plasmid 
concentration 
Several integrase mutants were screened for dose dependency. In these experiments, integrase 
plasmid amounts were either increased up to twentyfold or decreased down to twentyfold 
compared to the amount of plasmid p7 transfected. The prerequisite for comparative studies 
with different amounts of integrase plasmids was that the amount of substrate plasmid p7 was 
kept constant in all experiments. To ensure that equal amounts of total pDNA were 
transfected per dish the appropriate amount of stuffer DNA, pBS or pUC19, was added. The 
plasmid ratios used in the initial assay and in dose dependent studies are listed in Table 3.3. 
Transfections were carried out as described in Section 3.1.4 (Table 3.1) in 6-well plates. 
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Table 3.3. Overview over transfection setups with increasing and decreasing integrase 
plasmid amounts. 
Different transfection conditions based on weight ratio and molar ratio used for CFA to 
analyse integration efficiencies are listed. The initial CFA experiments were performed at a 
weight ratio of 1:1, which corresponds to a molar ratio of 0.48:1, taking the size of the 
transfected plasmids into consideration; (pCS Int = 6230 bp, substrate plasmid p7 = 2966 bp). 
The dose dependent studies with increasing and decreasing amounts of Integrase plasmid 
were based on molar transfection ratios of substrate plasmid and integrase plasmid. 
 
 Molar ratio for 
transfections  
p7: integrase 
plasmid 
Amount of 
p7 substrate 
plasmid  
in ng 
Amount of 
integrase 
plasmid  
in ng 
Amount of 
pUC19 stuffer 
plasmid in ng  
initial screening ratio  
in HeLa cells 
1 : 0.48 1000 1000 / 
1 : 0.025 50 2.6 1947.4 
1 : 0.1 50 10.3 1939.7 
decreasing amounts 
of integrase plasmid 
1 : 0.5 50 52 1898 
1 : 1 50 102 1848 
1 : 5 50 513 1437 
1: 10 50 950 / 
increasing amounts 
of integrase plasmid 
 
1 : 20 50 1950 / 
 
3.3 Molecular biology techniques 
3.3.1 Strain cultivation and storage of bacteria 
E.coli strains were cultured in autoclaved sterile LB medium. For solid agar 1.5 % agar was 
added. Media were supplemented with 50 µg/ml respective antibiotic ampicillin (Amp) or 20 
µg/ml kanamycin (Kan). Bacteria on LB agar were cultivated overnight at 37 °C. Bacteria in 
liquid culture were cultivated overnight at 37 °C on a shaking platform at 200 rotations per 
minute (rpm). For long-term storage, bacteria were resuspended in LB medium supplemented 
with 10 % glycerol and frozen at -80 °C.  
3.3.2 Transformation of bacteria 
 
a) Preparation of electro-competent cells and electro-shock transformation of bacteria 
Bacteria from DH10B stock solution were incubated on LB only plates overnight at 37 °C. 
One single colony was used to inoculate 5 ml low salt LB medium at 37 °C overnight with 
agitation. The culture was used to inoculate 1 litre (l) LB medium at 37 °C until OD600 had 
reached 0.6- 0.7. After cells were chilled on ice for 40 min, centrifugation was performed at 
4000 rpm for 10 min at 4 °C. Bacterial pellet was resuspended in 1 l H2O. Centrifugation 
steps were repeated twice while cells were resuspended in 500 ml 10 % glycerol. Bacterial 
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pellet was resuspended in 20 ml 10 % glycerol, centrifuged and resuspended in two to three 
ml ice-cold 10 % glycerol, aliquoted in volumes of 50 µl, frozen in liquid nitrogen and stored 
at -80 °C.  
 
b) Electroporation 
Fifty microlitres of competent cells were thawed on ice. One microlitre purified plasmid DNA 
or up to 2 µl newly ligated DNA was added. The mixture was transferred into a prechilled 
electroporation cuvette on ice. Cells and DNA were electroporated with a Bio-rad 
GenePulser II electroporator under the following characteristics: 2.5 kV (kilovolt), 200 Ω 
(Ohm), 25 µF (microfarad). Immediately after electroporation 600 µl Super Optimal Broth 
(SOC) medium were added to the cells. The suspension was transferred into a 1.5 ml 
Eppendorf tube shaken at 37 °C for 1 hour. The appropriate amount of cell suspension was 
plated onto appropriate solid agar and incubated at 37 °C overnight. 
 
c) Preparation of heat-shock competent cells and heat-shock transformation of bacteria 
Chemical competent E.coli cells were made using strain DH5α. Cells were streaked for 
isolation on LB, incubated at 37 °C overnight. One single colony was used to inoculate 3 ml 
LB medium which was shaken overnight at 37 °C. Three millilitres culture was used to 
inoculate 1 l LB medium until OD600 reached 0.3-0.4. All centrifugation steps were performed 
at 5000 rpm for 10 min at 4 °C. After the initial centrifugation, the pellet was resuspended in 
100 mM 250 ml MgCl2 (magnesium chloride), the cells were centrifuged, and the pellet was 
resuspended in 100 mM 50 ml CaCl2. 450 ml 100 mM CaCl2 were added and the mixture was 
chilled on ice for 20 min. The centrifugation was repeated, and the cells were resuspended in 
85 mM 20 ml CaCl2 (diluted in glycerol). Aliquots in one hundred microlitres were 
immediately frozen down in liquid nitrogen and stored at -80 °C. 
 
d) Heat-shock transformation 
One vial of chemically competent cells were thawed on ice. One µl plasmid DNA (pDNA) or 
two µl newly ligated DNA were added to the cells and chilled on ice for 10 min. The 
suspension was then incubated at 42 °C for 45 seconds and subsequently transferred on ice for 
2 min. After 600 µl of SOC medium were added to the transformed cells, the mix was shaken 
1 hour at 37 °C. Cells were then plated onto selective agar and incubated at 37 °C overnight. 
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3.3.3 Preparation of plasmid DNA 
For plasmid DNA isolation, E.coli culture volumes were chosen based to the need for purified 
plasmid DNA.  
 
a) Plasmid mini preparation 
The plasmid mini preparations were prepared from 3 ml liquid bacterial culture. Overnight 
cultures were transferred into 1.5 ml Eppendorf tubes and centrifuged for 2 min at maximum 
speed (13000-14000 rpm). Supernatants were discarded and bacterial pellets were 
resuspended in 100 µl resuspension buffer P1. One hundred µl lysis buffer P2 were added and 
Eppendorf tubes were turned upside down several times and incubated for three minutes. 
After adding 100 µl neutralization buffer P3, tubes were subsequently shaken and centrifuged 
in a table top centrifuge at 13000 rpm for 5 min. Supernatants were then transferred into new 
Eppendorf tubes. Thirty microlitres NaAc (3M, pH 5) and 600 µl ice-cold 100 % ethanol were 
added for precipitation. The tubes were vortexed for three seconds and centrifuged at 
maximum speed for 10 min. Supernatants were discarded, and 70 % ethanol was added. 
Another centrifugation step at maximum speed for 10 min was performed. The tubes 
containing the DNA pellets were inverted and briefly dried upside down. The pellets were 
resuspended in 30-40 µl H2O or TE buffer.  
 
b) Plasmid preparations in large-scale: Midi and Giga preparations 
The Pure Yield™ Plasmid Midiprep System from Promega was used for bacterial culture 
volumes between 50-100 ml. For pDNA purification in Gigaprep scale (bacterial cultures of 
1-2 l) the Nucleobond® AX anion exchange columns for quick purification of nucleic acids 
from MACHEREY-NAGEL were used. Bacterial cultures (100 ml up to 2 l) supplemented 
with antibiotic were grown at 37 °C with agitation overnight. The cultures were centrifuged at 
8000 rpm for 10 min at room temperature. The pellets were either stored at -20 °C or used 
immediately for DNA purification according to the manufacturer´s instructions. High 
quantities of pDNA were isolated from bacterial cultures using different kits.  
3.3.4 Polymerase chain reaction (PCR) 
PCR is a simple technique to exponentially amplify defined DNA sequences in vitro (Saiki et 
al., 1988) by means of specific primers. PCR was used for generation and cloning of DNA 
fragments or for mutagenesis approaches. PCR was carried out in a volume of 50 µl and 
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cycled in a thermocycler (Gen AmpTM PCR System from Applied Biosystems or from Bio-
Rad) with the reaction components in the PCR setup listed below. 
10 ×  Taq buffer   5 µl 
Oligonucleotide 1 (10 µM)  1.5 µl 
Oligonucleotide 2 (10 µM)  1.5 µl 
dNTPs (2 mM)   2- 5 µl 
Template DNA   0.1- 5 µg 
Polymerase (5 U/ µl)   0.5- 1 µl 
H2O     up to 50 µl 
 
95 °C for 2 min 
 
30 - 35 cycles of 
95 °C for 30 seconds 
annealing temperature 5 for 30 seconds 
68 °C or 72 °C for variable time6 
 
Followed by one cycle of  
68 °C or 72 °C for 3 to 5 min 
Hold at 4 - 15 °C 
 
Final elongation was done to fill up 3´- ends of uncompleted PCR products. Five microlitres 
of PCR setup were analysed by agarose gel electrophoresis for fragment size and approximate 
DNA quantification. 
 
Site-directed mutagenesis PCR of PhiC31 integrase binding domain 
For overlapping PCR reactions, the proofread polymerases KOD or Pfx were used. Reaction 
conditions were similar to those described above with slight changes. The elongation step was 
performed at 68 °C and 1- 2 µl MgSO4 was added to the reaction mix.  
Up to 5 µl Enhancer solution were added to the PCR setup to enhance the amplification and 
output of PCR. One hundred ng PCR templates (small and large fragments) were used for 
overlapping PCR. Optimised PCR temperature profiles for first and second PCR to generate 
small and large products are presented in Table 3.4 and Table 3.5 below. 
                                                 
5
 The temperature for primer hybridisation was calculated with the following formula: Tm = no of base pairs (bp) 
(A+T) ×  2 + no of bp (C+G) ×  3. The annealing temperature of each primer for optimal hybridization was set 
as Tm plus 5°C and should be similar among both primers. 
6
 Elongation time (polymerisation) depends on the size of the PCR product. Polymerisation of 1 kb product 
requires 1 min using Taq polymerase. 
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Table 3.4. Temperature profiles of the first PCR.  
Conditions were optimised for different PCR products according to TM and PCR product size. 
PCR products were obtained in different sizes according to the mutated amino acid position. 
 
 PCR conditions for different fragment sizes 
PCR steps 762- 640 bp 572- 425 bp 370- 173 bp 
initial denaturation 95 °C for 1.50 min 95 °C for 1.50 min 95 °C for 1:50 min 
denaturation 95 °C for 0.5 min 95 °C for 0.5 min 95 °C for 0.5 min 
annealing 52 °C for 0.50 min 52 °C for 0.75 min 52 °C for 0.67 min 
elongation 71 °C for 1.00 min 71 °C for 0:.75 min 71 °C for 0.5 min 
final elongation 71 °C for 3.00 min 71 °C for 3.00 min 71 °C for 3.00 min 
 
A second overlapping PCR was performed to anneal the products from PCR 1 and PCR 2, 
respectively using the outer oligonucleotides to obtain full size construct. 
 
Table 3.5. Temperature profiles for overlapping PCR using proofreading Pfx and KOD 
polymerases. The PCR program was run for 35 cycles. 
 
PCR steps PCR conditions for Pfx 
polymerase 
PCR conditions for KOD 
polymerase 
initial denaturation 95 °C for 2.00 min 94 °C for 2.00 min 
denaturation 95 °C for 0.33 min 94 °C for 0.33 min 
annealing 55 °C for 1.00 min 60 °C for 0.5 min 
elongation 68 °C for 1.00 min 72 °C for 0.67 min 
final elongation 68 °C for 3.00 min 72 °C for 3.00 min 
 
The PCR product was loaded on an agarose gel and purified upon separation.Purified PCR 
products were adenylated by Taq polymerase using five µl 10 mM dATP (as the nucleotide 
donor) and 1 µl T4 PNK in a volume of 50 µl at 37 °C for 30 min. This was done to add 
adenine overhangs rendering the PCR products compatible to subcloning vectors. After PCI 
purification adenylated PCR products were immediately subcloned into the pTOPO 
intermediate vector. Alternatively, the PCR product was separated by gel electrophoresis, 
extracted, digested by restriction endonucleases BamHI and BstEII and phosphorylated for 
subsequent ligation into the final expression vector pCS Int.  
The DNA binding domain of PhiC31 integrase (Int) was used as a template for site-directed 
mutagenesis, which was performed by overlapping PCR. Two PCR products containing the 
desired point mutation were generated in a first round of PCR (Figure 3.5). Gel-purified PCR 
products serve as templates in a second round of overlapping PCR with flanking primers. The 
product of the second PCR comprised the full size binding domain construct, which was 
digested and inserted into the vector pCS-NotI. 
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Figure 3.5. Overview of two-step overlapping PCR to generate point mutations.  
(A) Fragments were generated in the first PCR using one outer primer and a primer containing 
a mismatch depicted in red. (B) The small and large PCR products include the nucleotide 
mismatch with the designed point mutation. They were used as templates in an overlapping 
PCR to generate the full length gene construct. 
 
3.3.5 Design of a linker sequence and construction of a cloning vector pCS+NotI  
Two oligonucleotides with BamHI and BstEII recognition sites at their 5´- ends flanking a 
NotI restriction endonuclease cutting site were annealed by dilution of ten µl 100 mM 
oligonucleotides with H2O in a total volume of 100 µl. Oligonucleotides were rapidly boiled 
and cooled to room temperature. Thirty microlitres of annealed oligonucleotides were 
phosphorylated in 10 ×  ligase buffer with 1 µl dATP and 3 µl PNK (phosphate nucleotide 
kinase) in a 50 µl reaction at 37 °C for 1 hour, PCI-purified, and eluted in 40 µl elution buffer. 
Linearised dephosphorylated original vector and annealed phosphorylated oligonucleotides 
were ligated and transformed by electroporation. Positive clones of the backbone vector 
pCS+NotI without the binding domain were verified by restriction digestion using NotI and 
PstI, as documented in Section 4.1.1. 
3.3.6 Restriction digestion of pDNA and gel electrophoresis  
Purified pDNA or purified DNA fragments were digested with restriction endonucleases. 
Diagnostic restriction enzyme digests were performed in a total volume of 20 µl with 5- 8 µl 
digested plasmid DNA, 2 µl of the 10 ×  buffer, 2 µl of 10 ×  BSA if recommended, 0.5 µl 
restriction endonucleases and the appropriate volume of sterile H2O. Restriction digests were 
performed for 2 hours - overnight at the optimal reaction temperature of the endonuclease. 
When pDNA digestion required two restriction endonucleases at the same time, whose 
restriction buffers and recommended cleaving temperatures were different, double digests 
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were first subject to endonuclease cleavage by one enzyme. The digestion mix was purified 
with the High-pure purification Kit from Roche. Subsequently purified pDNA was digested 
with the second enzyme.  
3.3.7 Isolation of DNA fragments from agarose gels 
DNA fragments were separated by gel electrophoresis on a 1 % agarose gel with EtBr 
(0.5 µg/ml) in 1 ×  TAE buffer. The electrophoresis was performed at constant voltage of 
120 V for 20- 30 min until the migrating DNA samples were sufficiently separated. DNA was 
visualised by UV light exposure on a transilluminator. The appropriate DNA fragments were 
excised from the agarose gel and extracted using a Qiagen gel extraction kit according to the 
manufacturer´s instructions. DNA was eluted in 20 µl elution buffer or sterile H2O. 
3.3.8 Dephosphorylation of DNA fragments 
Dephosphorylation at 5´- ends of the digested pDNA was performed to avoid self-ligation. 
Plasmid DNA was dephosphorylated using 0.5 U calf intestinal phosphatase (CIP) at 37 °C 
for 1 hour. CIP treated vectors were purified from buffers and enzymes with QIAquick Gel 
extraction Kit (Qiagen) or with the High Pure PCR purification Kit (Roche) according to the 
manufacturer´s instructions.  
3.3.9 Ligation of DNA fragments and vectors 
DNA ligations were performed with T4 DNA ligase in a total reaction volume of 10-20 µl. 
Depending on the length of the vector and the insert, the molar ratio of plasmids to insert ratio 
varied between 1:4 and 1:16. Ligation reactions consisted of 10 ×  ligase buffer, 1 µl T4 DNA 
ligase, DNA insert and vector backbone. Reactions were brought to the final volume with 
sterile H2O. Ligations were incubated at 16 °C overnight. One to 2 µl of the ligation reaction 
mix were used to transform E.coli by electroporation. 
3.3.10 Determination of DNA concentration 
The concentration of DNA was determined using Ultrospec 3000 spectrophotometer 
(Pharmacia Biotech). To determine the concentration of pDNA or genomic DNA, fiftyfold 
dilution with sterile H2O was done. The concentration of DNA was determined by the 
following equation: 
501000260 ××= ODionconcentratDNA  [ng /ml] 
The number 50 is the dilution factor, and 1000 is the conversion factor. The ratio extinction of 
260 nm to 280 nm (A260/A280) was also measured to determine the purity of DNA. Pure DNA 
results in extinction ratios of greater than or equal to 1.8.  
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3.3.11 DNA sequencing and DNA alignments 
To verify DNA sequences 15 µl of DNA at a concentration of 100 ng/µl were sent for DNA 
sequence analysis to Eurofins MWG Operon Company. Nucleic acid sequence alignments 
were performed using Clustal W2 software provided by EMBL NBI7. Individual sequences 
were analysed and compared against the database by using the basic local alignment search 
tool (BLAST), which was provided by National Centre for Biotechnology Information 
(NCBI).8 
3.3.12 Analysis of RNA, isolation and reverse transcription into cDNA 
For isolation of total RNA from eukaryotic (293-derived) cells, the RNeasy kit (Qiagen) was 
used according to the manufacturer’s instructions. The concentration of isolated RNA was 
determined by a spectrophotometer. All steps were carried out on ice and in a cooled 
centrifuge to avoid RNA degradation. RNA was stored at -80 °C. Transcription of RNA into 
complementaty DNA (cDNA) was done according to the first strand synthesis protocol from 
the Protoscript® First Strand cDNA Synthesis kit (NEB) with two µg of purified total RNA. 
3.3.13 Quantitative real-time PCR to determine relative DAXX knock down  
Gene expression of individual genes can be influenced by RNA interference, which 
consequently leads to gene-specific down regulation. In principle, specifically designed 
siRNA binds to a particular ORF in question and consequently inhibits gene expression. The 
relative down regulation of the target gene can be determined by real-time PCR using reverse 
transcribed cDNA as a template and appropriate controls. For determination of the standard 
curve in real-time PCR, a dilution series including five dilutions in duplicates was used. 
Furthermore, known copy numbers of a control plasmid pDrive+DAXX as an internal 
standard were used. The construction of the internal control plasmid is described below. The 
slope of the standard curve was used to calculate the PCR efficiency (1) using either DAXX 
specific siRNA (target) or GAPDH specific siRNA (reference). The PCR efficiency E was 
calculated by the ratio R between target and reference (2). The relative down regulation (3) in 
percentage was derived from the ratios R calculated in (2). 
 
(1) )/1(10 slopeEefficiencyRPC −=  
(2) )()arg( )()arg()/arg( referencecpettcp referenceEettEreferenceettrarioR ×= −  
E represents the calculated PCR efficiency in (1) and cp represents the averaged 
crossing point values in triplicate obtained by RT PCR 
                                                 
7
 whttp://www.ebi.ac.uk/Tools/clustalw2/ 
8
 http://blast.ncbi.nlm.nih.gov/Blast.cgi 
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(3) 100)(/)arg( ×= referenceRettRregulationdownrelative  
Target represents the samples treated with DAXX specific siRNA and reference 
represents the samples treated with unspecific siRNA (GAPDH specific) 
 
The fluorescence marker Light Cycler Fast Start DNA MasterPLUS SYBR Green I (Roche) 
functions as a DNA-binding dye and can be detected upon intercalation with the amplified 
DNA (PCR products). The following PCR program for the light cycler was used: pre-
incubation at 95 °C for 10 minutes, amplification in 45 cycles at 95 °C for 10 sec, 52 °C for 
5 sec and 72 °C for 8 sec.  
 
Construction of control plasmid pDrive+DAXX as an internal standard for qRT-PCR 
The genomic sequence from DAXX was derived from the NCBI database. PCR was carried 
out with Taq polymerase using 200 ng/µl purified genomic DNA derived from 293 cells as 
template and DAXX specific forward (forw.DAXXqRT) and reverse (rev.DAXXqRT) 
primers. PCR products in size of 204 bp were inserted into the pDrive Cloning Vector as 
described in the Qiagen® PCR Cloning Handbook. Insert size was verified by restriction 
digestion. 
 
3.4 Fluorescence activated cell sorting (FACS)  
 
Flow cytometry describes the emission of optical signals sent by the cells, when passing a 
laser stream, which is detected by several photomultiplier. The forward scatter detector (FSC) 
is in line with the light beam and the side scatter detector (SSC) lies perpendicular to it. FSC 
correlates with the size and SSC depends on the cell’s complexity (granularity). The 
fluorescent detector distinguishes between green fluorescent protein (GFP) expressing cells, 
cells expressing other fluorescence markers (e.g. mOrange) and non-fluorescent cells. The 
fluorescence labels (FL), depending on the laser excising the fluorochromes, were FITC for 
green colour (FL1) and PE for orange colour (FL2). FACS was used to sort cells according to 
their fluorescent properties upon transfection of plasmids carrying genes expressing 
fluorescent proteins. 
Two different transfection setups using different plasmids were carried out with subsequent 
FACS analysis: 
Methods 
 52 
a) Establishment and evaluation of stable GFP-containing reporter cell lines 
293 cells were stably transfected with the plasmid pattP-polyA-attB-EGFP (Figure 4.16) in a 
6-cm dish with a ratio FuGENE [µl]: DNA [µg] = 2:1. Two weeks after selection in cell 
culture D-MEM medium supplemented with 500 ng/ml neomycin, clones were transferred 
into plates with fresh medium and expanded to an appropriate amount of cells to establish 
293-based GFP containing reporter cell lines. Established GFP-containing reporter cell lines 
were transfected with five µg pDNA encoding either an active (wt Int) or inactive (mInt) 
version of integrase to analyse fluorescence activity of GFP. GFP is activated upon integrase-
mediated out-recombination of the terminating polyA signal. 
b) Evaluation of integrase mutants for recombination activity in a GFP-containing reporter 
cell line obtained from transfection setup a  
The GFP-containing cell line (established as described above) was co-transfected with 
integrase-encoding plasmids and mOrange expressing plasmid in one well of a 6-well plate 
using a weight ratio of 2:1, which corresponds to 1333 ng integrase plasmid and 666 ng 
mOrange plasmid.  
 
Forty-eight hours post-transfection cells were harvested by washing once with D-PBS, 
centrifuged at 2000 rpm for 5 min at 4 °C and subsequently resuspended in appropriate 
amount of FACS buffer (D-PBS with 1 % FBS), transferred into an Eppendorf tube and 
stored on ice. Up to 10000 cell counts (equals to 100 %) per sample were analysed by flow 
cytometry using a FACS Canto. The fractions of each sample containing non-fluorescent 
cells, eGFP expressing cells, or eGFP and mOrange expressing cells were quantified. 
Transfection efficiencies were only corrected in the second transfection setup by co-
transfection with mOrange, assuming an equal plasmid uptake per cell. The relative GFP 
expression level was recorded as a measure for excision activity within a genomic context. 
 
3.5 Dual luciferase assay  
 
The dual luciferase assay (Promega) was performed to measure the excision activity of wt Int 
and its mutants. HEK 293 cells were grown on 24-well plates and were at the same time co-
transfected with three different plasmids 48 hours before luciferase measurement. The 
transfection setups are described in detail in Table 3.6. The first plasmid pCS Int encodes the 
integrase enzyme or its mutant derivative. The second plasmid pLucCR contains the CMV 
promoter-driven firefly luciferase reporter gene downstream of the Int-specific excision 
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construct, in which a termination site (polyA sequence) is flanked by the attB and attP 
recognition sites. The third plasmid pRL-TK encoding a tymidine kinase promoter driven 
Renilla luciferase gene is co-transfected as an internal control for transfection efficiency. 
Alternatively, a plasmid was co-transfected encoding human codon-optimised Renilla 
luciferase (phRL-O). 
 
Table 3.6. Experimental outline of transfection conditions of luciferase assays performed. 
The initial experiment was performed with the conditions stated in Setup 1 to analyse the 
effect of the integrase plasmid concentration on DNA excision. 
 
Parameters Setup 1 Setup 2 Setup 3 
plasmid ratio pLucCR : Int 1 : 0.9 1: 1 1: 5 
total DNA transfected in ng  
per triplicate in 24-well scale 
1200  2040 2040 
integrase plasmid (pCS Int) 600 400 1600 
pLucCR (+hs) in ng 540 400 400 
pRL-TK in ng 60 - - 
phRL-O in ng - 40 40 
stuffer plasmid pUC19 in ng - 1200 - 
amount of transfection reagent : 
DNA complex per well in µl 
20 33 33 
amount of transfected cells used  
for luciferase assay in µl 
5 10 10 
with injector, ∆t = constant no yes yes 
manually  yes no no 
 
One hundred microlitres of freshly prepared 1 times passive lysis buffer were added to each 
well of a 24-well plate. The cells were incubated at room temperature for 10 min. Ten 
microlitres of each cell lysate were directly pipetted into a 96-well plate (Nunc). The 
remaining cell lysates were transferred into Eppendorf tubes and rapidly frozen in liquid 
nitrogen.  
Thirty-five microlitres LAR II were injected automatically per well to initiate the firefly 
luciferase reaction. After 10 seconds, 35 µl Stop&Glo reagent were added automatically by 
injectors. Simultaneously, with quenching firefly luciferase activity, Renilla luciferase was 
activated. Luciferase activities were measured in a plate-reading Microlumat Plus LB 96V 
Luminometer.  
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3.6 Animal studies 
3.6.1 Hydrodynamic tail vein injection  
Female C57BL/6 mice derived from a common inbred strain of lab mice were housed in the 
animal facility and treated according to the regulations of the Government of Upper Bavaria. 
Mice were injected by hydrodynamic plasmid delivery via the tail vein over 6 seconds using a 
3-ml syringe with a 28-G needle. Twenty micrograms of Int encoding plasmids and 20 µg 
substrate plasmids containing the attB site and the expression cassette for human blood 
coagulation Factor IX (hFIX) were injected. Total volume was 1.8 ml of 0.9 % NaCl. Cell 
cycles of murine liver were induced by intraperitoneal administration of 50 µl carbon 
tetrachloride (CCl4) diluted in mineral oil at a ratio of 1:1.  
3.6.2 Measurement of alanine aminotransferase (ALT) 
ALT is normally present in high concentrations in the liver. Elevated ALT levels in the blood 
usually indicate a liver disease or a hepatic injury, which should be observed after tail vein 
injection of foreign DNA. For quantitative determination of ALT in murine serum as a signal 
for liver toxicity, the ALT kit from Randox was used according to the manufacturer´s 
instructions. Blood samples were taken retro-orbitally from mice, collected in Eppendorf 
tubes and centrifuged for 2 min at 10000 rpm between 5 °C and 10 °C. Supernatant 
containing mouse serum was collected and stored at 4 °C until ALT assay was carried out by 
applying 15 µl serum per mouse with 90 µl substrate buffer/enzyme mix. ALT activity 
corresponds to absorbance change over time detected at 340 nm in a photo spectrometer. 
3.6.3 Enzyme Linked Immunoabsorbent Assay (ELISA) 
Detection of hFIX concentration in murine serum was performed using a sandwich ELISA. 
For the generation of the standard curve, purified hFIX (ProSpec-Tany Technogene) was used 
in final concentrations between 3200 ng/ml and 3 ng/ml. 96-well plates (Nunc Maxi Scorp) 
were coated with an anti-hFIX antibody (Sigma). The anti-hFIX antibody was used in a 
dilution of 1:10000 in coating buffer (0.1 M NaHCO3, pH 9.4) and plates were incubated with 
50 µl per well at 4 °C overnight. Plates were washed twice with 200 µl dilution buffer TBS-T 
per well. After removing TBS-T, 200 µl dilution buffer (TBS-T+ 5 % BSA) were used to 
block the wells for one hour at room temperature. Plates were washed twice with TBS-T. 
Murine serum samples were diluted in appropriate relations with dilution buffer. After 
blocking, plates were loaded with 50 µl per well and incubated at 37 °C for two hours. Plates 
were washed twice with TBS-T. For detection, an anti-HRPO (horseradish peroxidase) 
antibody (Biozol) was used. Fifty microlitres of an HRPO conjugated secondary antibody 
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were added to each well as a 1:1000 dilution. Plates were incubated for one hour at 37 °C. 
Plates were washed three times with TBS-T. Fifty microlitres substrate solution (OPD Sigma 
Fast) were added for final development incubating at room temperature for about 10 min. The 
reaction was stopped and enhanced by adding 50 µl 1 M H2SO4. Samples were read at 492 nm 
in a plate reader (Tecan, Magellan3 software). 
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4. Results 
4.1 Construction of integrase mutants by site-directed mutagenesis  
 
The aim of this work was to increase the integration efficiency of PhiC31 integrase by site-
directed mutagenesis of the PhiC31 integrase binding domain (BD). Mutations were 
introduced by replacing charged amino acids with alanine, an approach named alanine 
scanning. The PhiC31 BD has not yet been screened in a large-scale mutagenesis study using 
alanine scanning. Since beneficial mutations were found within the same domain of the 
Sleeping Beauty transposase (Yant et al., 2004), alanine scanning was chosen for the BD of 
PhiC31. The integrase BD was analysed for charged amino acids, such as aspartic acid (D), 
glutamic acid (E), lysine (K) and arginine (R). From the 41 charged amino acids identified, 22 
amino acid positions (53 %) were mutated to alanine (A). The schematic outline of the 
cloning strategy for the generation of plasmids containing individual point mutations in the 
nucleotide sequence of the PhiC31 integrase DNA-binding domain is presented in Figure 4.1. 
 
Preparation of truncated cloning vector 
pCS+NotI without binding domain (4.1.1) 
 Generation of mutated PCR product 
(insert) by overlapping PCR method (4.1.2) 
   
Digestion of pCS-Int with BamHI and 
BstEII to remove binding domain 
 
 First round of PCR to construct small and 
large mutated fragments 
 
Design of a short linker sequence 
containing NotI and compatible flanking 
restriction sites 
 
 Second round of PCR using overlapping 
PCR of small and large mutated fragments 
to create binding domain with desired point 
mutation 
 
Insertion of linker sequence into linearised 
backbone vector pCS by ligation 
 
 Subcloning of full length mutated 
binding domain into pTOPO vector 
Linearisation of truncated vector 
pCS+NotI with BamHI and BstEII 
 Isolation of mutated binding domain 
from intermediate vector pTOPO 
with BamHI and BstEII 
 
Generation of plasmids encoding the mutated integrase gene (4.1.3) 
Ligation of open pCS vector and insert containing mutated binding domain and  
transformation, plasmid isolation and verification of mutation by sequencing 
 
Figure 4.1. Cloning strategy for the construction of integrase point mutants. 
The outline describes the preparation and construction of the vector (Section 4.1.1) and the 
insert (4.1.2) with single point mutations within the PhiC31 integrase binding domain and the 
subsequent generation of plasmids encoding the mutated integrase gene (4.1.3). 
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4.1.1 Preparation of truncated cloning vector pCS+NotI 
The original expression vector pCS Int encoding the full-length wt integrase gene was 
digested with restriction endonucleases BamHI and BstEII to remove the DNA binding 
domain. With insertion of a short linker sequence into the linearised vector at the respective 
cutting sites the truncated vector pCS+NotI was constructed for simplified cloning to avoid 
false positive clones encoding wt integrase. The design of the linker sequence and the 
construction of the cloning vector pCS+NotI were described in Section 3.3.5. Agarose gel 
electrophoresis documented the restriction digestion of the truncated vector pCS+NotI (Figure 
4.2.A). Vector maps of pCS Int and pCS+NotI supporting the cloning strategy are illustrated 
in Figure 4.2.B and 4.2.C, respectively. 
 
 
 
Figure 4.2. Agarose gel electrophoresis of the vector backbone pCS+NotI uncut, BamHI 
digested, and NotI+PstI digested and respective vector maps. 
The original expression vector pCS Int was modified by replacing the sequence encoding the 
native binding domain (BD) between BamHI and BstEII with a short oligonucleotide 
sequence containing a NotI site to construct the pCS+NotI backbone vector for simplified 
cloning. (A) Agarose gel showing restriction digest of respective plasmids. The restriction 
pattern in line 1 and 2 show the pCS Int vector uncut and BamHI restricted in size of 6230 
base pairs (bp), the restriction pattern in line 3 shows the digest of the backbone vector in size 
of 5341 bp with NotI and PstI resulting in two fragments in size of 4329 bp and 1012 bp, 
respectively. M = 1 kb DNA marker. (B) Vector map of pCS Int. BamHI and BstEII are 
flanking the BD, BamHI and SpeI flank the entire integrase coding sequence. (C) Vector map 
of pCS+NotI. The NotI site is inserted instead of the BD. 
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4.1.2 Generation of mutated integrase binding domain by overlapping PCR 
In the first round of PCR, oligonucleotides containing either a BamHI or BstEII site together 
with one mismatch oligonucleotide were used to yield mutated PCR products by overlapping 
PCR (Figure 3.2.A). The restriction endonucleases BstEII and BamHI are unique cutters in the 
pCS Int vector flanking the DNA binding domain within a region of 910 bp. PCR products 
containing 6 point mutations of PCR 1 and PCR 2 are presented in Figure 4.3.  
 
 
Figure 4.3. PCR products obtained after the first round of PCR with mutagenic primers were 
analysed by agarose gel electrophoresis. 
PCR products were loaded on a gel together with the 1 kb DNA marker (M). Three 
highlighted bands in size of 1000, 500, and 250 bp within the marker help to identify the 
fragment size of the samples. The PCR products contain individual point mutations as 
indicated in the figure. The small and the large fragments were used as template in 
overlapping PCR. 
 
The PCR products (Figure 4.3) were used for overlapping PCR resulting in full-length PCR 
products with the mutated DNA binding domain sequence (Figure 4.4).  
 
 
Figure 4.4. Analysis of second round PCR products by agarose gel electrophoresis. 
PCR products including the mutated binding domain (BD) are shown for four mutants. 
Controls were included: C- contains no template, C+ represents amplification of pCS Int with 
outer primers resulting in a band of 910 bp. M = 1 kb DNA marker, M* = 100 bp DNA 
marker. Two highlighted bands in size of 1000 and 900 bp within the marker help to identify 
the size of the samples. PCR products comprising the full size construct in size of 910 bp 
were subcloned into intermediate pTOPO vector. 
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4.1.3 Generation of plasmids encoding the mutated integrase gene 
The insert containing the mutated integrase binding domain was isolated from the pTOPO 
vector and inserted into BamHI and BstEII linearised pCS+NotI vector as described in Figure 
4.1. The final set of 22 plasmids contained point mutations within the integrase binding 
domain and were named based on the mutation positions (Table 4.1). 
Nucleotide and amino acid sequences with the native integrase BD are shown in Figure 4.5. 
The amino acid positions which were changed to alanine are represented in bold and 
underlined text. Integrase BD mutant vectors were confirmed by DNA sequence analysis.  
   
atggacaagctgtactgcgagtgtggcgccgtcatgacttcgaagcgcggggaagaatcg 
M  D  K  L  Y  C  E  C  G  A  V  M  T  S  K  R  G  E  E  S 
atcaaggactcttaccgctgccgtcgccggaaggtggtcgacccgtccgcacctgggcag 
I  K  D  S  Y  R  C  R  R  R  K  V  V  D  P  S  A  P  G  Q 
cacgaaggcacgtgcaacgtcagcatggcggcactcgacaagttcgttgcggaacgcatc 
H  E  G  T  C  N  V  S  M  A  A  L  D  K  F  V  A  E  R  I 
ttcaacaagatcaggcacgccgaaggcgacgaagagacgttggcgcttctgtgggaagcc 
F  N  K  I  R  H  A  E  G  D  E  E  T  L  A  L  L  W  E  A 
gcccgacgcttcggcaagctcactgaggcgcctgagaagagcggcgaacgggcgaacctt 
A  R  R  F  G  K  L  T  E  A  P  E  K  S  G  E  R  A  N  L 
    gttgcggagcgcgccgacgccctgaacgcccttgaagagctgtacgaag 
     V  A  E  R  A  D  A  L  N  A  L  E  E  L  Y  E 
 
Figure 4.5. Nucleotide sequence and amino acid sequence of the integrase binding domain. 
Underlined and bold letters represent the 22 residues changed to alanine to construct the 
respective mutants. The first letter M represents amino acid position 365. The last letter E 
represents the amino acid position 480 within the amino acid sequence of the integrase. The 
nucleotide sequence was translated using the translate tool at www.expasy.ch/tools/dna.html. 
 
Exclusively charged amino acids were selected to be mutated towards the uncharged and 
small amino acid alanine to generate alanine substitution mutants. The alanine scanning 
approach represents a convenient method in enzyme mutagenesis. The domain to be 
mutagenised within the integrase ORF was the DNA binding domain since this domain has 
not yet been screened for efficiency mutations in a large-scale mutagenesis using alanine 
scanning and beneficial mutations were found within the same domain of the Sleeping Beauty 
transposase (Yant et al., 2004). The peptide sequence of the integrase BD was screened for 
charged amino acids, such as aspartic acid (D), glutamic acid (E), lysine (K) and arginine (R). 
From the 41 charged amino acids, 22 amino acid positions (53 %) were mutated towards 
alanine (A) by altering the genetic code. Mutations of the integrase BD were confirmed by 
DNA sequence analysis. All constructed integrase single mutants presented in Table 4.1 were 
screened for altered recombination proficiency. At first, integration efficiency of Int mutants 
was investigated in HeLa cells. 
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Table 4.1 Constructed PhiC31 integrase mutants.  
The first letter indicates the amino acid changed to alanine (A). Aspartic acid represents the 
letter D, glutamic acid E, lysine K and arginine R. The number within the ORF indicates the 
amino acid position which was changed.  
 
PhiC31 integrase point mutants* 
D366A E406A 
K367A D417A 
E371A R423A 
R380A R429A 
E382A E432A 
E383A E435A 
K386A R446A 
R390A K450A 
R393A K457A 
R394A R461A 
D398A D470A 
 
*General comment: the 22 designed mutants within this thesis represent a different amino 
acid position (4 amino acid shift) than the PhiC31 integrase mutants within my publication 
(Liesner et al., Human Gene Ther., 2010). The mutant D366A is referred to D470A, K367A is 
referred to K371A and so on.   
 
4.2 Integration efficiency in HeLa cells of PhiC31 integrase mutant derivatives  
 
The rationale of this experiment was to determine the integration efficiency of the 22 PhiC31 
integrase mutants in mammalian cells. The integration efficiency is directly correlated with 
the number of clones surviving selection after transfection. Experiments were carried out by 
co-transfecting HeLa cells with plasmids coding either for the wt Int, non-functional Int 
(mInt) or for each of the newly constructed Int mutants and the donor plasmid p7. The number 
of colonies, being used as a measure for integration, was determined by a method termed 
colony-forming assay (CFA), schematically illustrated in Figure 4.6. The used molar ratio of 
Int:p7 was 0.5:1 using 2000 ng pDNA. No additional stuffer DNA was included.  
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Figure 4.6. Schematic overview over a colony-forming assay (CFA).  
The text to the right describes the procedure of the assay. mInt designates the cells transfected 
with non-functional Int (negative control). wt Int designates the cells transfected with wt Int 
encoding plasmids. 
 
Colony numbers obtained after wt Int mediated integration were compared to colony numbers 
obtained by individual Int mutants as a measure of the relative integration efficiency. The 
integration efficiency was calculated from the absolute number of integration events by 
setting the colony number obtained after wt Int-mediated integration to 100 %. The 
integration efficiencies of the 22 different single amino acid substitution mutants are 
presented in Figure 4.7.  
Five integrase mutants, D366A, E382A, E383A, K457A and D470A, showed an integration 
efficiency between 1.2 and 1.7-fold higher than wt Int. Seven mutants (K367A, R380A, 
R393A, R394A, D417A, E432A, and K450A) lost their recombination activity into pseudo 
attP (attP`) sites. The integration efficiencies of these mutants were as low as the negative 
control mInt, which was about seven times lower than wt Int mediated integration. Ten Int 
mutants, E371A, K386A, R390A, D398A, E406A, R423A, R429A, E435A, R446A, and 
R461A, showed integration efficiencies comparable to wt Int-mediated integration.  
 
 
 
 
 
 
 
Co-transfection of cells with  
integrase encoding plasmid and  
substrate plasmid p7 in 6-well plates 
 
 
Splitting cells 48 hours post 
transfection in triplicate (4x 104 cells 
from 1 well of a 6-well plate into one 
10-cm dish and neomycin selection 
pressure (500 ng/µl) for about 14 days  
 
 
 
 
Quantification of integration events  
by methylene blue staining
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Figure 4.7. Integration efficiency of all constructed integrase mutants obtained by colony-
forming assay (CFA) in HeLa cells. 
The molar ratio of p7: Int = 1:0.48, which equals to a plasmid amount of 1000 ng p7 and 
1000 ng integrase encoding plasmid was used (Table 3.2). Effect of amino acid substitutions 
in the integrase binding domain on the integration efficiency is shown. HeLa cells were co-
transfected with plasmids encoding the wt integrase (wt Int), the non-functional version 
(mInt) or with integrase missense mutant together with a substrate plasmid p7 encoding 
neomycin and the attB site. Mean values are shown with error bars indicating deviation within 
a triplicate of one mutants. 
 
In the first recombination screening in HeLa cells, only mutant D470A had an increase in 
integration efficiency of 1.7. In the next step towards improving integration efficiency, the 
plasmid ratio of integrase encoding plasmids was addressed in dose dependent studies. 
 
4.3 Dose dependent studies with different amounts of PhiC31 integrase plasmids 
 
The following studies were performed to evaluate to what extent the ratio between the Int 
expressing plasmids and the substrate plasmid p7 would influence the formation of colonies. 
Therefore, we wanted to analyse, whether and how the overall integration efficiency is 
influenced by the dose of Int within a cell. This was done by varying the plasmid ratios as 
described in Table 3.2.  
Four mutants, D366A, E383A, K457A and D470A, showing improved integration efficiency 
within the first assay at a molar ratio of p7:Int = 1:0.48 were used for dose-dependent studies 
in HeLa cells (Figure 4.8.A) to evaluate the effect on colony formation at different plasmid 
ratios. HeLa cells were co-transfected with only 50 ng substrate plasmid p7 and 102 ng Int 
plasmid (molar ratio 1:1) or with 513 ng Int plasmid (molar ratio 1:5) and with additional 
amount of stuffer plasmid pBS, respectively (Table 3.2). The cells transfected with high Int 
Results 
 63 
plasmid dose p7:Int = 1:5 resulted in 1.3-fold increase in integration events compared to low 
amounts of Int transfected (1:1 ratio). 
The initial integration efficiency of mutant D366A in the overall CFA was 122 % at a 1:1 
ratio without stuffer plasmid. With the new conditions, the mutant had a 68 % integration 
efficiency at a 1: 1 ratio and decreased slightly to 61 % at a 1:5 ratio.  
The mutant E383A was slightly better with 107 % integration efficiency and 111 % 
integration efficiency at 1: 1 and 1: 5 ratios, respectively; the original result was a 1.28-fold 
increase (Figure 4.1).  
The mutant K457A had an initial efficiency of 120 % (Figure 4.8.A), but was 65 % at a 
1:1 ratio and increased more than twice to 135 % at a 1:5 ratio. 
The mutant D470A, which showed the most promising integration efficiency (1.7-fold) at the 
initial ratio (Figure 4.5) but had an integration efficiency of 121 % (1:1) and 104 % (1:5) 
compared to wt. 
The evaluation of the CFA showed very few differences in integration efficiency between the 
plasmid ratios in mutants D366A, E383A and D470A.  
In another experiment, the plasmid ratios were changed to p7:Int = 1:1 and 1:20 (=1950 ng Int 
plasmid) (Figure 4.8.B). Wild type integrase mediated integration efficiency was increased 
1.3-fold when increasing the Int plasmid 20 times. The mutants K457A and D470A showed 
about 1.5-fold improvements at equimolar ratios (Figure 4.8.B). At high Int dose (1: 20 ratio) 
the fold increase of K457A and D470A was only slightly higher compared to wt Int, with an 
integration efficiency of 1.4 times and 1.5 times, respectively, compared to 1.2-fold 
improvement with the wt Int. In the CFA experiments (Figure 4.8.B) two independent 
experiments with almost identical outcome were combined to verify the improved integration 
efficiency. 
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Figure 4.8. Dose dependent studies with increasing plasmid transfection ratios of selected 
integrase mutants. 
Colony-forming assay of the integrase mutants D366A, E383A, K457A, and D470A in 
comparison to wt integrase and mInt in HeLa cells is shown. For each transfection 50 ng 
substrate plasmid p7 were used. For the different plasmid ratios, respective plasmid amounts 
in ng are listed in Table 3.2. (A) For plasmid transfection the molar ratios of p7 to integrase 
plasmid were 1:1 and 1:5, respectively. (B) The molar ratios of p7: Int plasmid were 1:1 and 
1:20, respectively. In the second experiment, transfections were performed twice in triplicate.  
 
Next, the effect of lowering the integrase dose on integration efficiency was analysed. Dose 
dependent studies were performed in which the substrate plasmid p7 was transfected in 
surplus compared to the Int plasmid. The plasmid amounts in favour of p7 were twofold, 
tenfold and fortyfold higher compared to the integrase plasmid (Figure 4.9). Substrate plasmid 
p7 was transfected in constant amounts (50 ng) and stuffer plasmid was used for 
compensation for missing plasmid volume. The molar ratios of transfected plasmids with 
respective amounts in ng are described in Table 3.2. 
The integration assay clearly showed that with decreasing amounts of Int plasmid transfected, 
the number of G418 resistant colonies also decreased. Integration events with a transfection 
ratio of p7:Int = 1:0.5 were higher for each Int mutant than integration events at ratios 
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p7: Int = 1:0.1 and 1:0.025, respectively. Comparing the absolute number of colonies with the 
previous assays confirmed the result (data not shown).  
Mutant E383A showed a more than twofold increase in colony formation compared to wt 
integrase at a ratio p7:Int = 1:0.5. The fold decrease from the initial plasmid ratio (1: 0.5) to 
the lowest transfection ratio (1:0.025) was 20 % for wt Int, about 140 % for mutant E383A, 
100 % for mutant K457A and 40 % for mutant D470A. However, the overall number of 
resistant colonies was very low and ranged between 5-16 colonies per 10-cm dish.  
 
Figure 4.9. Dose dependent studies with decreasing amounts of integrase plasmid compared 
to substrate plasmid p7. 
The integrase mutants E383A, K457A and D470A were compared with wild type integrase. 
The plasmids were transfected in three different transfection ratios (p7: Int) = 1:0.5, 1:0.1 and 
1:0.01 into HeLa cells and integration efficiency was evaluated by CFA. The experiment was 
carried out in triplicate. 
 
The integration efficiency of single mutants in HeLa cells could not be significantly improved 
compared to the wt integrase. Therefore, additional strategies to further improve integration 
efficiency involved the construction and testing of double mutants based on the integration 
efficiencies obtained so far. 
4.4 The effect of double mutants on integration efficiency  
 
After the first analysis using single mutants, additional attempts to increase the integration 
efficiency further were performed. Therefore, single Int mutants showing increased efficiency 
in HeLa cells were used to generate double mutants. The strategy was to select the mutant 
D470A showing the most improved integration efficiency in the first screen in HeLa cells and 
use it in combination with other single mutants, showing slightly higher integration 
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efficiencies than wt integrase. The double mutants E382A+ D470A and K457A+ D470A 
were constructed and tested. 
Selected mutants and two selected double mutants were tested for integration efficiency in 
HeLa cells by CFA using low amounts of Int and substrate plasmids. The integration 
efficiency is presented in Figure 4.10. All tested mutants showed enhanced integration 
efficiency compared to wt Int. The single mutants D470A and E382A obtained about 1.4 
times better integration efficiency compared to wt Int. The double mutant E382A+ D470A 
showed synergistic effects with a fold improvement of 1.7 times compared to wt Int. 
Combining the mutation K457A with mutant D470A had a negative effect on integration. The 
double mutant K457A+ D470A showed only a slight improvement. The negative control 
group mInt dropped about 6 times compared to the wt integrase.  
 
 
Figure 4.10. Integration efficiencies of single and double mutants in HeLa cells. 
The plasmid ratio for transfection was p7: Int = 1: 0.5. The remaining amount of DNA was 
transfected with stuffer plasmid pBS. Plasmid ratios for transfection are listed in table 3.4. 
Experiments were carried out in triplicate. 
 
Next, the effect of enhanced Int plasmid concentrations of the two double mutants shown in 
Figure 4.10 was investigated. Plasmid transfections with two different plasmid ratios were 
carried out (Figure 4.11) in triplicate. 
The first experiment (#1) shows relative integration events after transfection of two different 
Int plasmid doses, p7:Int = 1:0.5 and 1:20. The mutant K457A+ D470A obtained almost the 
same integration efficiency as wt Int. The mutant E382A+ D470A obtained 1.7 times higher 
integration efficiency than wt Int at a low Int plasmid dose with a plasmid ratio p7:Int = 1:0.5 
(light blue bars). Increasing the Int plasmid dose twentyfold leads to a drop to 85 % of wt Int. 
The double mutants K457A+ D470A (110 % at a 1:1 ratio and 265 % at a 1:20 ratio) and 
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E382A+ D470A (170 % at a 1:1 ratio and 235 % at a 1:20 ratio) however, showed improved 
integration efficiency at a high Int plasmid dose.  
These results were confirmed by repeating the integration efficiency twice in experiments #2 
and #3. This resulted in an averaged fold-increase of 3 times and 3.3 times of the mutant 
K457A+ D470A and E382A+ D470A (magenta and dashed magenta bars), respectively, 
compared to the wt integrase. The integration efficiencies for mutant K457A+ D470A were 
within 30 % deviation for all three independent experiments (#1, #2, and #3). The integration 
efficiency of integrase mutant E382A+ D470A shown in experiment #2 was almost twofold 
higher than obtained from experiment #1 and #3, which is inconsistent. The integration 
efficiency of the negative control mInt, representing random integration events, included only 
in experiments #2 and #3 was approximately 5 times lower than wt Int. 
 
 
Figure 4.11. Integration efficiencies of double mutants in HeLa cells at two different plasmid 
ratios p7:Int = 1:0.5 and 1:20. 
The CFA was performed to compare double mutants K457A+ D470A and E382A+ D470A 
against wt integrase at a low and a high dose of transfected integrase plasmid. Experiment #1 
shows integration efficiency after high and low integrase dose, experiment #2 and #3 were 
independently performed to confirm the tendency of increased integration mediated by the 
double mutants. The three independent experiments were performed in triplicate.  
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4.5 Integration efficiencies of integrase mutants in cell lines of different origin 
 
Since the single and double mutants demonstrated improved integration efficiencies in HeLa 
cells, we wanted to evaluate the mutants within the context of other human cell lines. 
Therefore, the human cell lines HCT, Huh7, 293 and the mouse cell line Hep1A were 
transfected with mutant plasmid DNA. In the context of these cell lines, individual integrase 
mutants were evaluated for their integration efficiencies and compared to wt integrase. The 
efficacy of a mutant in different cell lines was not expected to be comparable, due to cellular 
cofactors and chromosomal context effects influenced by transcription patterns.  
4.5.1 Integration efficiencies in HCT cells 
Human colon-derived HCT cells were transfected with selected integrase mutants at high and 
low plasmid ratios to analyse the effect and influence of integrase mutants and plasmid dose 
on the integration efficiency (Figure 4.12). The mutants K457 and D470A showed a 1.5-fold 
improvement of integration efficiency at a high plasmid ratio compared to wt Int at 1:1 ratio. 
At the equimolar plasmid ratio (1:1) however, the mutant K457A had almost twofold 
integration efficiency and the mutant D470A dropped to 42 % of the wt Int. The two double 
mutants had different effects upon increasing the plasmid ratio twentyfold with integrase 
encoding plasmid. The double mutant K457A+ D470A showed a decline from 143 % (at a 1:1 
ratio) to 115 % (at a 1:20 ratio), while the second double mutant E382A+ D470A showed a 
slight increase from 127 % (at a 1:1 ratio) to 144 % (at a 1:20 ratio) in integration efficiency. 
A second CFA was performed to confirm these results shown in Figure 4.12 (data not shown). 
This assay showed between 2.5-fold and fourfold higher integration efficiencies of the 
mutants compared to the wt integrase. The number of colonies, transfected with wt integrase 
encoding plasmid (control group) was with an average of 33 very low, compared to 144 
obtained from the raw data in Figure 4.12.  
Due to this large inconsistency between the control groups of both integration assays the 
second assay could not be properly evaluated, although the number of colonies obtained with 
several mutant integrases were evaluable and within the expected range of colonies. An 
additional confirming experiment should be performed. 
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Figure 4.12. Integration efficiencies of selected integrase mutants in HCT cells. 
Two integrase single mutants K457A and D470A and two double mutants K457A+ D470A 
and E382A+ D470A were screened. Co-transfection was performed at a ratio of p7:Int = 1:1 
and 1:20. Experiments were carried out in triplicate. 
 
4.5.2 Integration efficiencies in Huh7 cells 
Integration assays at high integrase plasmid doses p7: Int = 1:20 in liver-derived Huh7 cells 
were carried out (Figure 4.13). The mutant K457A analysed twice, showed 70 % integration 
efficiency compared to wt Int. The mutant D470A had no improvement compared to wt 
integrase although the results had a high standard deviation. The double mutants 
K457A+ D470A and E382A+ D470A displayed 1.5- and 2.3-fold improvements, 
respectively, compared to the wt integrase. The negative control showed about 20-fold lower 
integration efficiency. 
 
Figure 4.13. Integration efficiencies of selected integrase mutants in Huh7 cells.  
For co-transfection a plasmid ratio of p7:Int = 1:20 was used. The mutants K457A, D470A 
and the double mutants K457A+ D470A and D470A+ E382A were tested. Two independent 
experiments were performed with wt integrase and the mutants  K457A and K457A+ D470A 
in triplicate. The values were averaged.  
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4.5.3 Integration efficiencies in HEK 293 cells 
Integration efficiencies of several integrase mutants and a mouse codon-optimised derivative 
of the wt PhiC31 integrase were evaluated in 293 cells using both low and high amounts of Int 
plasmids at ratios p7:Int = 1:1 and 1:20, respectively (Figure 4.14). The synthesised codon-
optimised version of the PhiC31 integrase with a reduced number of CpG dinucleotides to 
avoid gene silencing showed promising recombination activity in an embryonic stem cell-
derived mouse strain (Raymond and Soriano, 2007). The codon-optimised version was only 
used in 293 cells and was tested in luciferase assays also, performed in 293 cells (data not 
shown).  
To test whether the codon-optimised integrase also shows positive effect on integration 
efficiency within the context of human-derived 293 cells, this derivative was included in the 
recent experiment. The integration efficiencies of the mutants K457A, D470A and K457A+ 
D470A were with 1.17, 1.09 and 1.19-fold rather similar to the wt Int. The double mutant 
E382A+ D470A showed about 1.5-fold improvement, and the included codon-optimised 
integrase (Int c.o.) showed only the same integration efficiency as wt integrase. The mutant 
D470A with high efficiency in HeLa cells showed a very low improvement at an equimolar 
plasmid ratio (1:1) comparable to wt levels. At a high plasmid dose, 1.5-fold higher 
integration was observed in D470A compared to wt Int with 1.2-fold (magenta bars). The 
improvement in integration efficiency in both wt Int and D470A was 1.24-fold when shifting 
the plasmid ratio from p7:Int = 1:1 to 1:20. The mInt was about 5 times lower than wt Int 
(Figure 4.14).  
 
Figure 4.14. Integration efficiencies of selected integrase mutants in 293 cells. 
Co-transfection of plasmids was carried out using plasmid ratios p7: Int = 1: 1 for all mutants 
tested. The plasmid ratio p7:Int = 1:20 was used for wt Int and mutant D470A within the same 
experiment. At equimolar ratios (1: 1) 85 % stuffer plasmid pBS was used for transfection. 
The codon-optimised version of integrase (Int c.o.) was included. Two triplicate of each group 
were used in the experiment. 
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4.5.4 Integration efficiencies in Hep1A cells 
Three mutants have been tested in the mouse derived Hep1A cell line (Figure 4.15). The 
plasmid ratio used for transfection was p7:Int = 1:10 and 50 ng p7, and 1950 ng pCS Int 
plasmids were transfected twice in duplicate. No additional stuffer plasmid was used. The 
mutants K457A and E382A+ D470A showed a 1.3-fold increase in colony formation 
compared to the wt integrase. The double mutant K457A+ D470A (63 %) showed only a 
slight improvement compared to mInt (53 %), which is relatively high compared to the 
negative control groups in the previous assays. The mutant D470A was included in the assay 
but could not be evaluated properly and is therefore not shown.  
 
 
Figure 4.15. Integration efficiencies of selected integrase mutants in Hep1A cell line. 
Two double mutants and one single mutant were compared to the control groups at a plasmid 
ratio p7:Int = 1:10 using a high integrase plasmid amount without additional stuffer plasmid. 
Experiments were carried out twice in triplicate.  
 
In summary, improved integration efficiencies were seen for several integrase point mutations 
in different mammalian cell lines. Integration efficiencies of the same mutant were not always 
consistent among different experiments. Increasing the plasmid dose showed increased colony 
formation in HeLa cells and 293 cells but not in HCT cells. Three different tendencies of 
recombination activity could be observed in HeLa cells (Figure 4.7). Synergistic effects with 
double mutants were not observed for every double mutant. 
In the next step using a different setup addressing recombination efficiency, the integration 
efficiency of wt integrase should have been boosted by reducing its interaction with a 
recombination-decreasing protein. 
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4.5.5 Evaluation of integration specificity in DAXX siRNA transfected cells 
PhiC31 integrase mediated integration efficiency has been demonstrated to be influenced by 
strong interaction with a cellular protein, a death domain associated protein, called DAXX. 
DAXX is present as an ubiquitary protein in human cells. Specific DAXX knock down with a 
DAXX-specific duplex RNA or small interfering RNA (siRNA) has been shown to increase 
recombination efficiency (Chen et al., 2006). During cellular processes with RNA 
interference (RNAi), specific double stranded RNA inhibits the expression of a particular 
gene in a sequence-specific manner (Fire et al., 1998).  
Therefore, siRNA was used to reduce the production of DAXX protein. Cells transfected with 
DAXX specific siRNA were then used in a CFA to evaluate whether down regulation of 
DAXX has an effect on the integration efficiency of PhiC31 integrase. We expected an 
increase in integration efficiency due to a reduced interaction between inhibiting DAXX and 
the integrase. 
HEK 293 cells were co-transfected with siRNA (DAXX specific and nonspecific) and 
plasmid DNA (wt Int or mInt encoding plasmids and substrate plasmid p7) (Section 3.1.5) 
and evaluated by RT PCR. The PCR efficiency and the relative down regulation of DAXX-
specific siRNA compared to nonspecific siRNA were determined with the method 
“calculation by means of a standard curve” (Section 3.3.13) using obtained crossing points 
(cp). The cp value is frequently used as a measure to detect a certain PCR cycle, at which 
fluorescence significantly increases versus background fluorescence.  
Differences in crossing points (cp) could be observed between the group treated with DAXX 
specific siRNA and the group treated with nonspecific siRNA (GAPDH specific) (Figure 
4.16.A).The relative knock down of DAXX by DAXX-specific siRNA compared to 
nonspecific siRNA was determined to be 76 % (Figure 4.16.B). The down regulating effect of 
DAXX specific siRNA on DAXX expression was thereby confirmed. 
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Figure 4.16. The relative knock down of DAXX by DAXX-specific siRNA in relation to 
nonspecific siRNA. 
(A) Crossing point (cp) values after real-time PCR are shown for groups transfected with 
DAXX-specific siRNA, nonspecific siRNA and untransfected 293 cells. The left bar shows 
the cp values using the DAXX encoding plasmid as internal control, the right bar shows the 
cp values using the plasmid containing unspecific siRNA. (B) The rest activity of DAXX after 
specific and nonspecific siRNA-mediated knock down of DAXX is shown in siRNA 
transfected cells and untransfected control. Calculations are described in Section 3.3.13. 
DAXX siRNA samples are shown in blue, reference values are magenta for nonspecific 
siRNA and green for untransfected cells. 
 
Having tested and verified the down regulation of DAXX by DAXX-specific siRNA, 
integration efficiencies of active and inactive integrase versions were determined in context of 
siRNA transfected 293 cells. As a control for the siRNA transfected cells, nonspecific siRNA 
was used. The integration efficiencies of integrase in siRNA-transfected 293 cells are shown 
in Figure 4.17 below. No difference was observed between wt integrase mediated integration 
efficiency in cells without siRNA (black bar) and wt integrase mediated integration efficiency 
in cells transfected with DAXX specific siRNA (blue bar). Integration efficiency of wt 
integrase transfected with nonspecific siRNA showed a 10 % decline. Likely, siRNA 
transfection 24 hours prior to integrase encoding plasmid transfection has no differential 
effect on integration efficiency between wt integrase and mInt (blue and magenta bars). 
Considering the absolute number of colonies (between 80 and 100) in the recent assay (data 
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not shown), the integration efficiency in this recombination assay is relatively low. Hence, the 
siRNA-specific down regulation of the DAXX protein has no increasing effect on integration 
efficiency in 293 cells using the present transfection conditions (plasmid ratios, choice of 
transfection reagent, FuGENE:DNA ratio, temporal distance between the transfections). Since 
the effect of siRNA on DAXX expression is only transient and lasts up to about four days, the 
suppressive effect of DAXX-specific siRNA onto the DAXX protein can only be sustained 
within the beginning of the selection process. DAXX is not suppressed for the entire duration 
of selection pressure on the cells. Hence, DAXX specific siRNA did not continuously 
suppress DAXX. The siRNA transfection could have been repeated two to three times during 
the selection, but were not due to these results. No further siRNA knock down experiments 
were carried out.  
 
 
Figure 4.17. Integration efficiency of integrase in siRNA transfected 293 cells. 
Integration efficiencies of wt Int and mInt are shown in 293 cells being siRNA transfected 24 
hours prior to plasmid transfection. The DAXX specific siRNA was used as a reference, the 
GAPDH specific siRNA was used as control. HEK 293 cells were transfected with 100 
pmoles siRNA by means of Lipofectamine 2000. One day later 2000 ng plasmid DNA with a 
molar plasmid ratio Int:p7 = 0.48:1 were transfected and another two days later, cells were 
splitted in 4 ×104 cells/10-cm dish. Transfections were carried out in triplicate.  
 
The integration efficiency of PhiC31 integrase into mammalian cells has been evaluated in 
detail. As an additional approach, introduced in the next sections, the excision activity of 
PhiC31 integrase within intramolecular substrate DNA molecules was addressed using either 
chromosomal DNA or plasmid DNA. Both recombination events, integration and excision, 
have different applications in genome engineering but with discrepancies in efficiency. 
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4.6 Integrase mediated excision in context of chromosomal DNA 
 
An excision-based assay in chromosomal context of 293 cells was established using the 
reporter plasmid p-attP-polyA-attB-eGFP depicted in Figure 4.18. The reporter plasmid 
contains an expression cassette with a CMV promoter-driven eGFP gene. A transcriptional 
termination site (polyA signal), flanked on both sites by the native integrase recombination 
sites attP and attB, separates the transgene from its promoter. The removal of the polyA 
signal via integrase-mediated recombination leads to the fusion of the promoter to the GFP 
cDNA and consequently to expression. The expression of GFP as a measure for excision 
activity was assessed by flow cytometry using different transfection setups as described in 
Section 3.4. 
 
 
 
Figure 4.18. The p-attP-polyA-attB-eGFP reporter plasmid. 
The plasmid consists of a CMV promoter, followed by the integrase specific attP and attB 
sites, flanking a terminating polyA signal. The eGFP (enhanced green fluorescent protein) 
reporter gene (green) downstream the attB site is turned on upon excision of the termination 
signal polyA. A neomycin resistance marker (orange) allows for plasmid retention within the 
cell during G418 selection pressure. The plasmid was a great gift from Jia´s laboratory 
(Chen et al., 2006).  
 
First, the functionality of the GFP reporter plasmid was tested and confirmed upon transient 
transfection in a preliminary experiment. The GFP reporter plasmid was co-transfected with 
the wt Int encoding plasmid, with the mInt encoding plasmid or with the stuffer plasmid pBS 
in equal amounts (1000 ng per plasmid) in a 6-cm dish. Forty-eight hours post transfection the 
GFP expression from the transiently delivered plasmid was assessed by flow cytometry. Cells 
transfected with the wt Int encoding plasmid showed with a total fraction of 27 % fluorescent 
cells a 10 times higher GFP expression level than cells transfected with mInt encoding 
plasmid (2.7 %) or pBS (2.5 %). 
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4.6.1 Establishment and evaluation of GFP reporter cell lines 
HEK 293 cells were stably transfected with the GFP reporter plasmid (Figure 4.18) to 
establish reporter cell lines with conditional GFP gene activation in the presence of active 
integrase. These reporter cell lines conferring neomycin resistance cultured in D-MEM 
medium supplemented with G418 (500 µg/ml) were evaluated for GFP expression levels upon 
transfection of the Int plasmid.  
The activation of the GFP gene within a stable chromosomal context depends not only on the 
recombination activity of the integrase to excise the polyA signal, but also on the targeted 
insertion site of the reporter plasmid within the chromosomal context, at which the reporter 
plasmid was inserted. Chromosomal features such as gene density and chromatin effects 
flanking the insertion site also influence the recombination and the subsequent GFP 
expression.  
Therefore, each of the established reporter cell lines was individually transfected with the 
plasmid encoding the wt integrase to screen for a cell line which shows a rather high GFP 
expression potential in presence of active Int. Additionally, plasmid encoding mInt was solely 
transfected into each reporter cell line as a control to evaluate the function of the termination 
site blocking the reporter gene expression without active integrase. Cells were harvested 48 
hours post integrase plasmid transfection and were analysed by flow cytrometry to obtain the 
fraction of GFP expressing cells. This was done by gating the target cell population 
(10000 events), in which “living cells” were included, and among this cell fraction, the 
number of GFP expressing cells was determined. 
Eleven reporter cell lines were evaluated for GFP expression (fraction of cells expressing GFP 
among all cells) in presence of active and inactive integrase. The ratio of GFP expression 
between cells transfected with wt Int and mInt encoding plasmids was measured in each cell 
line (Figure 4.19.A). 
The GFP expression of wt Int transfected cells was about 2-4 times improved compared to 
cells transfected with mInt encoding plasmid. Active Int obtained between 6 % and 15 % GFP 
expression levels in 9 of the 11 analysed clones, except clone #20 and #45. The cell line based 
on clone #24 showed elevated GFP expression levels of 26.5 % and 13.6 % after transfection 
of plasmids encoding active or inactive versions of integrase. Taken the ratio between active 
and inactive integrase encoding plasmids into consideration, four reporter cell lines were 
selected for additional analysis (Figure 4.19.B). The selected reporter cell lines, termed 
according to the initially isolated numbered clone, were transfected with pBS as an additional 
negative control. GFP expression ratios between wt Int and mInt transfected cell lines resulted 
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in ratios of 5.12:1 (for cell lines originated from clone #28), 3.95:1 (clone #31), 3:1 (clone 
#39) and 6:1 (clone #41), respectively (Figure 4.19.B). Based on these ratios, the cell line, 
originated from clone #28, was selected to test all constructed integrase mutants. 
 
Figure 4.19. FACS analysis of various clones upon transfection of integrase plasmids. 
HEK 293 cells were transfected with the plasmid shown in Figure 4.18 and selected in 
medium containing 500 µg/ml G418 containing medium. Generated cell lines were transiently 
transfected either with plasmids containing wt Int or mInt or with pBS plasmid. GFP 
expression was measured by flow cytometry via FACS as a measure of integrase mediated 
polyA excision. (A) Transfected cells were applied to FACS and eGFP expression was 
comparably detected between active (wt Int) and inactive (mInt) integrase. (B) Four 
promising clones (#28, #31, #39, and #41) show a high difference between wt Int and mInt 
mediated excision. Cell lines based on these four clones were transfected with wt Int or mInt 
encoding plasmid or with non-relevant stuffer DNA, respectively. Experiments were carried 
out in one replicate. 
 
4.6.2 Evaluation of PhiC31 mutants in the eGFP reporter cell line #28 
According to the GFP expression levels (Figure 4.19), the cell line based on clone #28 was 
chosen for further analysis of Int mutants. This selected cell line was co-transfected with an 
integrase encoding plasmid (wt Int, mInt or designed mutant) together with the plasmid 
pCR3mOrange. This plasmid encoding an “orange-fluorescent protein” can be used for 
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compensation since eGFP and mOrange show different excitation maxima in their spectra. 
Co-transfections were carried out as described in Section 3.4.  
Plasmid-transfected cells were harvested and fluorescence-analysed by flow cytometry as 
described in Section 3.4. Cell properties were measured by FACS as described below. The 
first gating to target “living” cell populations reduced the size of the sample to at least 45 %, 
referred to 293 cells eGFP stable inactive (“eGFP inactive”, light blue bars), which contains 
the “living” cells considered for further analysis, in which GFP is only active or expressed, 
when the integrase mediates recombination.  
The gated population of “living” cells was analysed for orange-fluorescent cells (red bars). 
The cell population transfected with both mOrange and eGFP fluorescence was considered to 
be the target population. Relative ratios of these GFP expression levels between wt Int 
transfected cells and cells transfected with Int mutants are shown in Figure 4.20. The FACS 
analysis displayed as dot plots and histograms is shown for the two control groups, wt Int and 
mInt, in Figure 4.20.A and 4.20.B. The gating of different cell populations according to their 
fluorescence properties was adjusted and the sizes of different cell fractions are graphically 
illustrated in Figure 4.20.C. The events (fluorescent properties) of individual cells were sorted 
by gating the individual cell fractions. The first gating (fraction of cells termed “gated 293 
cells”; light blue bars) comprised 4833 and 5173 cell counts for the cells transfected with wt 
Int plasmid or mInt plasmids. These cell populations were considered as “healthy” or “living” 
and further analysed in terms of fluorescence properties. 2682 cells (or 55.5 %; red bar) 
transfected with wt Int and mOrange plasmids showed mOrange expression. Among 5173 
cells, 3019 cells (58.4 %; red bar) being transfected with mInt and mOrange plasmids showed 
mOrange fluorescence. Within this cell fraction the positive control (wt Int) showed 1216 
cells (green bar), which equals to 45.3 % of mOrange transfected cells, that express GFP. 
Hence, 1216 cells have taken up both plasmids. Cells transfected with mInt and mOrange 
obtained only 144 events (green bars), corresponding to 4.8 % of 3019 cells, which have 
taken up both plasmids. 
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Figure 4.20. FACS analysis in reporter cell line #28. 
The left panel shows raw data after analysis of the reporter cell line transfected with wt 
integrase. The right panel shows raw data after analysis of the reporter cell line transfected 
with mutated version (mInt). (A) Dot plots of the eGFP reporter cell line (#28) transfected 
show the distribution or sorting of single cells according to their fluorescence. Blue coloured 
cells represent the fraction being considered for fluorescence evaluation. Among the blue cell 
fraction, the cells presented in red show orange fluorescent protein expression. Green 
coloured dots represent cells showing GFP expression among the cells fluorescing orange. 
(B) Histograms showing the frequency scale of eGFP fluorescing cells (counts) versus the 
eGFP intensity (x-axis). (C) The cell counts of each cell fraction or events per population are 
presented and sorted according to their fluorescence properties. 
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The reporter cell line (#28) was transfected with plasmids containing Int mutants and 
pCR3mOrange. Forty-eight hours post transfection FACS analysis was performed and Int 
mutants were evaluated for their respective excision activity corresponding to corrected GFP 
expression (Figure 4.21). Data obtained by flow cytometry revealed eight mutants with 
similar excision activity compared to wt Int. The mutants E382A, D398A, E408A, R429A, 
E435A, R446A, K457A, and R461A resulted in excision activities comparable to wt Int. Two 
mutants R367A and D417A showed very low excision activity, even below that of mInt. Two 
other mutants, R380A and R393A, showed 40 % excision activity relative to wt Int. No 
integrase mutant with higher excision activity compared to wt Int was observed (Figure 4.21). 
Integrase-mediated excision within a chromosomal context could not be evaluated upon 
evaluation of the designed mutants using the present settings and conditions.  
 
 
Figure 4.21. Integrase mediated excision activity of integrase mutants. 
All 22 integrase mutants and two controls, wt Int and mInt, were evaluated for their excision 
activity in a genomic context. The reporter cell line (#28) was used. GFP expression values 
were normalised using the mOrange expressing cell population. GFP expression levels were 
detected by FACS analysis. wt Int was set to 100 %. 
 
4.7 Integrase mediated excision within episomal plasmid DNA  
4.7.1 An extrachromosomal assay to measure PhiC31 integrase mediated 
integration 
In this experiment, the PhiC31 integrase-mediated recombination activity was analysed with a 
reporter on the plasmid pLucCR. pLucCR served as a substrate plasmid for excision and is 
depicted in Figure 4.22. The luciferase gene (yellow) represents the reporter, which is driven 
by a CMV promoter (red). An expression blocking site (polyA signal), which terminates 
promoter activity, is inserted between the promoter sequence and the luciferase gene. This 
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termination sequence is flanked on both sites with the native PhiC31 integrase attachment 
sites. Plasmid construction was similar to the work introduced in Section 4.6 and Figure 4.18. 
Intramolecular recombination at the attachment sites is performed in the presence of PhiC31 
integrase, which excises the terminating polyA signal. Consequently, the promoter and the 
coding sequence of the reporter gene are fused by hybrid site formation leading to luciferase 
expression. The principle of the excision-based recombination event is schematically 
illustrated in Figure 4.22. The integrase-mediated excision activity correlates with the 
luciferase expression levels, which are detected by a luminometer. 
 
 
Figure 4.22. Schematic overview over luciferase expression after PhiC31 integrase-mediated 
polyA excision. 
In presence of integrase the sequence between the attB and attP, sites are recombined out of 
the substrate plasmid pLucCR. Upon hybrid site formation (attR or attL), the CMV-promoter 
activates luciferase expression. CMV-p = CMV promoter, attB and attP = sequence specific 
attachment sites for PhiC31 integrase, polyA = polyadenylation signal to terminate  
translation and gene expression, respectively. Luciferase = reporter gene, hybrid attR/L = 
attachment sites after recombination of attB and attP. 
 
The integrase-encoding plasmid, the substrate plasmid pLucCR, and an internal control 
plasmid encoding a Renilla luciferase, were transfected into 293 cells by transient triple 
transfections using different DNA ratios as described in Table 3.3. The two different types of 
luciferase enzymes, firefly luciferase and Renilla luciferase, present in different plasmids, 
could be activated under different conditions, and their activities, bioluminescent signals as 
relative light units (RLU), could be detected independently from each other. Bioluminescent 
signals by Renilla luciferase were used for normalisation of transfection. The corrected 
excision efficiency was calculated by forming the quotient between firefly luciferase light 
units and Renilla luciferase light units. 
The data for the experiment shown in Figure 4.23 were based on a weight ratio of plasmids 
pLucCR:Int = 1:0.9 co-transfected with 60 ng (5 %) Renilla luciferase plasmid. The 
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individual mutants were measured at least twice. When excision activities were highly 
different or values were not correctly detected, individual mutants were measured up to five 
times and final data were set in relation to the wt integrase excision activity and averaged. The 
overall luciferase assay showed diverse luciferase expression levels. Integrase mutants 
showed excision activities between 10 and 210 % compared to wt Int at 100 %. Five mutants, 
E371A, E383A, E406A, R423A, and K450A showed about twofold higher excision activity. 
Eleven mutants, D366A, E382A, K386A, R390A, R394A, D398A, R429A, E435A, R446A, 
K457A, and D470A obtained similar results as wt Int in range of 70-120 %. Six mutants, 
K367A, R380A, R393A, D417A, E432A, and R461A were inactive and showed between 5 % 
and 30 % excision activity (Figure 4.23).  
 
 
Figure 4.23. Excision activity of integrase mutants detected by a luciferase assay in 293 cells. 
Relative luciferase activity indicated as relative light units (RLU) corresponds to the excision 
activity of wt integrase (black bar) divided by the excision activity of integrase mutants (blue 
bars). The mass ratio of plasmids was pLucCR:Int = 0.9:1. The luciferase experiments were 
performed in triplicate, and the results were averaged. Experiments were carried out between 
two and five times. The substrate plasmid is shown in Figure 4.22.  
 
Moreover, to evaluate the influence of the integrase dose on the excision of the polyA signal, 
two different transfection ratios of pLucCR: Int = 1:1 and 1:5 were used. Forty-eight hours 
post transfection 293 cells were harvested and 10 µl lysed cells were measured for luciferase 
expression.  
At a high amount of Int plasmids (pLucCR:Int = 1:5) three mutants, E371A, E383A, and 
K386A showed improved excision activities between about 130 % and 160 % compared to wt 
integrase. Ten mutants, E382A, R390A, E406A, D417A, R423A, R429A, E432A, E435A, 
R446A, and K457A, showed similar excision relative to luciferase expression levels of wt 
integrase (Figure 4.24). Five mutants, D366A, K367A, R380A, K450A, and D470A, showed 
excision activities below 60 %. The differences in excision activities of integrase mutants are 
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due to different transfection setups (plasmid ratios) and conditions. The experiment shown in 
Figure 4.24 was performed in triplicate. Absolute RLU were higher using increased amounts 
of Int encoding plasmids (pLucCR:Int = 1:5), compared to the raw data from Figure 4.23.  
 
Figure 4.24. Excision activity of integrase mutants detected in a luciferase assay.  
Relative luciferase activity indicated as relative light units (RLU) corresponds to the excision 
activity of wt integrase (black bar) divided by the excision activity of integrase mutants (blue 
bars). A plasmid ratio of pLucCR:Int = 1:5 was used in a total of 2000 ng plasmid transfected 
per well. Luciferase expression levels of wt Int were set to 100 %. Mean values are shown. 
Transfections were carried out in triplicate.  
 
4.7.2 Construction of reporter plasmids containing favoured pseudo attP sites  
By replacing the wt attP site with favoured pseudo attP sites the integrase-mediated 
specificity towards the pseudo attP sites could be addressed in a simple and fast excision 
based intramolecular assay. These preferentially targeted pseudo attP sites found at 
chromosomal positions 19q13.31, 12q22, and 2q11.2 also termed hot spots (hs), were 
identified among the most frequent sites of PhiC31 integrase mediated integration in human 
cell lines with an overall integration frequency between 2.9 % and 14.5 % (Ehrhardt et al., 
2006). Insertion sites at chromosomal positions 2q11.2, 12q22, and 19q13.31 were found in 
293 cells, HCT 116 cells and Huh7 cells, respectively. These three hot spots were targeted 
two times (2q11.2), ten times (12q22) and six times (19q13.31) in a total of 69 integration 
sites analysed (Ehrhardt et al., 2006). Two of these targeted sites, 2q11.2 in 293 cells and 
19q13.31 in 293, D407 and HepG2 cells were also observed in an independent study 
(Chalberg et al., 2006). These three preferentially targeted insertion sites were selected to be 
used in intramolecular recombination assays in combination with the wt attB site since they 
were observed in two different studies, in different cell lines and on different chromosomes. 
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These selected attachment sites should give a representative example as hot spots for PhiC31 
integrase-mediated integration. 
The pseudo attP sites were obtained from the publications revealing PhiC31 integrase-
mediated integration studies (Chalberg et al., 2006; Ehrhardt et al., 2006). Those query 
sequences were inserted into the sequence database using “nucleotide blast” as the BLAST 
program and the “human genomic plus transcript” as the selected database. The genomic 
DNA was isolated from 293 cells in order to be used as a PCR template to amplify these 
selected pseudo attP sites. The genomic sequences flanked on both sites of the particular hot 
spot comprising a length of about 350 bp were amplified by PCR using specific primers 
(Figure 4.25). For amplification of these pseudo attP sites, 400 ng eukaryotic DNA was used 
as template. PCR products were subcloned in pTOPO vector. After an additional PCR with 
oligonucleotides that included the restriction sites AgeI and StuI, the constructs were cloned 
into pLucCR replacing the native attP site. Modified substrate plasmids and the sequence of 
pseudo attP sites, which were inserted instead of the wt attP site, are schematically illustrated 
in Figure 4.26.A and 4.26.B, respectively. 
 
 
 
Figure 4.25. Analysis of amplified genomic hot spot DNA sequences with preferred PhiC31 
integrase sites by agarose gel electrophoresis. 
PCR was carried out using 400 ng genomic DNA isolated from 293 cells as template. 
Fragments with pseudo attP sites named according to their chromosomal position were 
amplified. The fragment hs12 (~330 bp) contains the pseudo attP site located at chromosomal 
position 12q22. hs19 (~290 bp) contains the pseudo attP site 19q13.31, and hs2 (~350 bp) 
contains the pseudo attP site 2q11.2. The particular pseudo attP sites were 39 bp long and 
surrounded by genomic DNA, obtained by nucleotide BLAST. PCR products of each hot spot 
were loaded onto two lanes and specific bands were gel-purified and subcloned. The 
remaining bands are referred to as nonspecific amplification products and were not 
considered. Two highlighted bands within the marker helped to identify the appropriate 
fragments. M= 1 kb DNA marker. 
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A 
Genomic location of 
integration site 
Genomic sequence of integration site Homology to 
wt attP site 
native (wt) attP site  
 
ACTGGGGTAACCTTTGAGTTCTCTCAGT  
pseudo attP site on 
chromosome 2q11.2   
CCAGGGAAAAGCTTCAGTCTCTCCCTGG 15 / 28 
pseudo attP site on 
chromosome 12q22 
GTCCGGGGCGCCGCTCGGGTCTCCCAGG 14 / 28 
pseudo attP site on 
chromosome 19q13.31 
CCACGGAATACCATAGGGGTCACCAGGG 13 / 28 
 
B 
 
 
 
 
 
 
 
 
 
Figure 4.26. Plasmid constructs with wt attP site and three different pseudo attP sites. 
The different pseudo attP sites were selected as preferred PhiC31 integrase attachment sites 
within different human cell lines (Chalberg et al., 2006; Ehrhardt et al., 2006). These 
particular pseudo attP sites were selected because they were found in two independent studies 
as favoured integration sites and were present in different cell lines. (A) Sequence alignments 
of three selected, preferentially targeted PhiC31 integrase specific pseudo attP sites. The 
minimal core sequence of wt attP site consists of a specific 5´-TT sequence. Sequence 
homology to wt attP is shown. (B) Excision constructs with different pseudo attP sites as 
shown in Figure 4.22. These constructs were used for luciferase assays. The wt attP site (in 
grey) in the luciferase substrate plasmid was replaced either by the pseudo attP site from 
chromosome 2q11.2 (red), from chromosome 12q22 (blue) or from chromosome 19q13.31 
(green). CMV promoter activates luciferase gene (light blue) upon integrase-mediated 
excision of the polyA signal by binding to attB and wt or pseudo attP sites, respectively. 
 
4.7.3 Evaluation of integrase mediated site-specific excision at attB/pseudo attP 
In order to analyse pseudo attP site-specific excision by Int mutants, pseudo attP sites were 
derived from favoured genomic PhiC31 integrase target sites within the mammalian genome 
and inserted into the substrate plasmid. HEK 293 cells were co-transfected with integrase 
encoding plasmids and the substrate plasmid at a low Int dose pLuc:Int = 1:1 and at a high Int 
dose pLucCR:Int = 1:5. First, the pseudo attP site derived from chromosomal location 2q11.2 
was analysed and luciferase results were shown in Figure 4.27.  
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Comparing the results from the two experiments with different plasmid ratios showed that the 
relative fold change is higher in 9 of 21 mutants when a high amount of Int plasmid was 
transfected (magenta bars in Figure 4.27). Only mutants E382A, E383A, and K450A showed 
about 33 % higher excision activities at low dose of Int plasmid (pLucCR: Int = 1:1; blue 
bars) compared to a plasmid ratio pLucCR:Int = 1:5 (magenta bars).  
Twelve mutants, K367A, E371A, R380A, R386A, R390A, R394A, D398A, D417A, R432A, 
R429A, R448A and D470A, showed no significant difference in excision activity between a 
high and a low dose of Int plasmid. In both experiments, a few mutants showed improved 
excision compared to wt Int. At a plasmid ratio of 1:1 five Int mutants showed higher excision 
activity compared to wt Int (blue bars > 100 %). At a plasmid ratio of pLucCR:Int = 1:5, nine 
mutants showed higher excision activity compared to wt Int (magenta bars > 100 %). 
However, five of them showed only minor improvements up to 1.25-fold. The negative 
control mInt dropped only about 60 % compared to wt Int in both ratios. 
 
 
 
Figure 4.27. Excision activity of integrase mutants at pseudo attP site 2q.11.2 (abbreviated as 
hs2). Two assays were performed with a 1: 1 ratio (blue bars) and a 1: 5 ratio (magenta bars) 
of transfected plasmids pLucCR: Int plasmid. A total of 2000 ng plasmid DNA was 
transfected per well. Relative light units (RLU) of wt Int were set to 100 %. Experiments were 
carried out in triplicate. 
 
Next, the pseudo attP site derived from 12q.22 was analysed for recombination (Figure 4.28). 
When Int plasmid was transfected fivefold in excess compared to substrate plasmid pLucCR, 
improved excision activity in 14 of 21 Int mutants was observed. Several Int mutants showed 
lower excision activity than wt Int in the context of pseudo attP site 12q.22. Only mutant 
E382A showed up to 1.5-fold higher excision activity than wt Int at low and high Int plasmid 
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dose. The excision activity of mutant R429A increased 2.7-fold when increasing the integrase 
plasmid dose compared to substrate plasmid. Sixteen mutants showed lower excision activity 
between 20 % and 80 % compared to wt Int at both plasmid ratios. The excision activity of 
mInt dropped to 30 % and 45 %. 
 
 
 
Figure 4.28. Excision activity of integrase mutants at pseudo attP site 12q.22 (hs12). Two 
assays were performed with a 1:1 ratio (blue bars) and a 1:5 ratio (magenta bars) of 
transfected plasmids pLucCR:Int plasmid. A total of 2000 ng plasmid DNA was transfected 
per well. Relative light units (RLU) of wt Int were set to 100 %. Experiments were carried out 
in triplicate. 
  
Furthermore, the excision based assay was performed with substrate plasmid pLucCR 
containing pseudo attP site 19q.13.31 (Figure 4.29). The excision activity of integrase 
mutants at recombination target sites attB × attP´ (19q13.31) confirmed that slightly higher 
excision activities were obtained when more Int plasmid was transfected. Only two mutants, 
K367A and K450A, showed a decrease of 30-40 % after enhancing Int plasmid dose. The 
mutant E371A obtained the highest excision efficiency with almost twofold increase at both 
plasmid ratios. Twelve mutants showed excision activities lower than wt Int-mediated 
excision. At a 1:1 ratio, the mutants E371A and K450A showed twofold and 1.4-fold higher 
excision activity than wt integrase. At high integrase plasmid dose, the mutants E371A, 
E382A, and E406A obtained increased excision activities between about 1.5- and twofold, 
compared to wt Int. The decrease of mInt compared to wt Int to 30 % and below at both low 
and high integrase plasmid dose proved the functionality of the assay. 
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Figure 4.29. Excision activity of integrase mutants at pseudo attP site 19q13.31 (hs19). Two 
assays were performed with a 1:1 ratio (blue bars) and a 1:5 ratio (magenta bars) of 
transfected plasmids pLucCR: Int plasmid. A total of 2000 ng plasmid DNA was transfected 
per well. Relative light units (RLU) of wt Int were set to 100 %. Experiments were performed 
in triplicate. 
 
Taken together, analysing the site-specific excision activity of integrase mutants in the context 
of different pairs of recombination recognition sites, wt attB × wt attP, wt attB × attP´ (at 
chromosomal position 2q11.2), wt attB × attP´ (12q.22), and wt attB × attP´ (19q.13.31) in an 
intramolecular plasmid-based recombination assay showed high variations. Differences in 
recombination activity were not only observed among mutants recombining the same pair of 
recognition sites but also within single mutants at different pseudo attP sites. Individual 
mutants showed increased excision activity when the introduced pseudo attP sites were 
targeted. However, whether these mutants might integrate into the tested pseudo attP sites in 
context of genomic DNA as well, is highly influenced by variables like accessibility and 
potential preference for competing integration sites.  
A summary showing relative recombination activities of integration and excision assays 
obtained from colony-forming assays and the GFP and luciferase reporter systems is 
presented in Table 4.2 below. Improved activities compared to wt integrase are presented in 
bold. The double mutants and D470A showed 1.5-fold to threefold improved integration 
efficiency in HeLa and HCT cells, and the mutants E371A, E382A, E383A, E406 and K450A 
showed between 1.3 and 2.2-fold excision activities in luciferase assays at different 
recognition sites. 
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Table 4.2. Overview of PhiC31 integrase-mediated recombination activities in colony-forming assay, FACS and luciferase assay carried out in vitro. 
The recombination activity for each mutant is given in percentage compared to wt integrase (100 %). Plasmid ratios and plasmids are described. 
 
Assay Colony-forming assay FACS Luciferase assay 
cell line HeLa HCT Huh7 293 Hep1A #28 293 
figure 4.7 4.8 4.10 4.11 4.12 4.13 4.14 4.15 4.21 4.23 4.24 4.27 4.28 4.29 
plasmid names substrate plasmid p7: Integrase plasmid  substrate plasmid pLucCR : integrase plasmid 
plasmid ratio 1:0.5 1: 1 1:0.5 1:20 1:1 1:20 1:1 1:10  0.9:1 1:5 1:1 1:5 1:1 1:5 1:1 1:5 
attB/ attB sites all targeted attP´sites within particular cell lines attB × attP attB × attP´ attB × attP´ attB × attP´ 
position of attP          native (2q11.2) (12q.22) (19q13.31) 
wt integrase 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
D366A 1.22        0.63 0.97 0.58 0.94 1.37 0.82 0.87 1.00 1.06 
K367A 0.10        0.07 0.05 0.43 0.99 1.21 0.39 0.74 0.78 0.52 
E371A 0.90        0.62 1.94 1.63 1.44 1.58 1.06 0.93 2.04 1.89 
R380A 0.16        0.36 0.31 0.33 0.60 0.74 0.40 0.53 0.41 0.28 
E382A 1.36  1.36      1.01 0.70 1.02 1.80 1.23 1.34 1.49 0.77 1.44 
E383A 1.28        0.83 1.87 1.32 2.16 1.25 0.95 1.16 0.77 1.10 
K386A 0.61        0.72 1.34 1.50 0.56 0.76 0.35 0.45 0.48 0.63 
R390A 0.60        0.64 1.15 0.79 0.91 0.89 0.91 0.45 0.64 0.58 
R393A 0.05        0.35         
R394A 0.13        0.85 0.89 0.69 0.59 0.83 0.36 0.42 0.41 0.55 
D398A 0.76        1.07 1.02 0.65 0.73 0.83 0.46 0.61 0.67 0.76 
E406A 0.86        1.03 1.93 0.83 1.28 1.73 1.02 0.71 0.58 1.56 
D417A 0.03        0.04 0.04 1.08 0.35 0.47 0.20 0.34 0.16 0.22 
R423A 0.81        0.88 1.75 0.90 0.74 0.74 0.63 0.53 0.76 0.83 
R429A 0.60        1.11 0.77 0.85 1.03 1.06 0.62 1.69 0.53 0.91 
E432A 0.09        0.53 0.12 0.78 0.03 1.78 0.01 0.71 0.00 0.73 
E435A 0.77        1.05 1.19 0.85 0.81 1.23 0.60 0.82 0.57 1.05 
R446A 1.04        0.95 1.01 0.91 0.69 0.86 0.53 0.51 0.56 0.63 
K450A 0.04        0.68 2.20 0.40 1.57 0.98 0.72 0.74 1.40 1.04 
K457A 1.20 1.66   1.95 0.7 1.17 1.3 1.02 0.89 0.87 0.69 1.12 0.72 0.78 1.08 1.05 
R461A 1.14        0.94 0.20 0.73 0.15 1.01 0.16 0.92 0.09 1.02 
D470A 1.70 1.47 1.45  0.42 1.05 1.09  0.60 0.84 0.38 0.86 0.89 0.74 0.60 0.65 1.02 
E382A+D470A   1.70 3.3 1.27 2.33 1.44 1.3          
K457A+D470A   1.10 3.0 1.43 1.46 1.19 0.63          
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Based on these results, a few mutants were investigated for their detailed integration 
specificity in order to determine the specific location of integrase-mediated insertion within 
the genome of HCT cells. 
 
4.8 Integration specificity of PhiC31 integrase in the genome of HCT cells  
 
In order to characterise the integration profile of PhiC31 integrase within the human genome, 
the DNA sequences were analysed for integration sites, which were rescued from human cell 
lines. The human colon carcinoma-derived HCT cell line was used to determine 
PhiC31 integrase mediated integration specificity. HCT cells were co-transfected with the 
integrase expression plasmid pCS Int encoding either wt integrase or selected integrase 
mutants and with the substrate plasmid p7 carrying attB and a neomycin resistance gene. 
Single colonies, which were based on stable integrants due to G418 resistance, were selected 
for about two weeks and separately expanded to cell lines. From these cell lines, genomic 
DNA was isolated. Thereafter, integration sites were identified and analysed for chromosomal 
position by plasmid rescue (Section 3.2.4) (protocol adopted from Ehrhardt et al., 2006). The 
plasmid rescue, a convenient method to analyse genomic integration of extrachromosomal 
DNA, allows identification of both chromosomal sites flanking the hybrid attL and attR sites. 
Genomic integration is based on neomycin resistance over a period of more than two weeks. 
This technique however, might lead to artefacts resulting in only one rescued site.  
The initial goal towards analysis of PhiC31 integrase specificity was to compare the 
integration profile of different PhiC31 integrase mutants within the genomic context of HCT 
derived cell lines. Approximately one hundred single clones were isolated and expanded to 
individual cell lines. Prior to isolation and cultivation of single clones, cells were transfected 
with the various versions of integrase encoding plasmid. Different numbers of clones (n) were 
expanded to cell lines, which were initially transfected with wt Int (n=21), mInt (n=8), mutant 
K457A (n=22), mutant D470A (n=22), double mutant K457A+ D470A (n=8), and double 
mutant E382A+ D470A (n=23). Rescued plasmids including p7 were first analysed by 
restriction digestion with PstI (Figure 3.4). The analytical digestion showed a characteristic 
fragment size of 1.6 kb and served as a preselection to identify rescued plasmids containing 
substrate plasmid sequence. Among the control-digested rescued plasmids, 50 samples were 
sequenced with specific sequencing primers and 44 rescued plasmids obtained quantitative 
sequencing results. 
These DNA sequences were then analysed for PhiC31 integrase-mediated integration events. 
DNA sequences, which were identified as derived from the human genome, were further 
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analysed for the genetic content near the crossover site. The databases of bioinformatics 
websites were browsed for ORFs at or in the proximity of particular insertion sites. The 
human BLAST database or nucleotide BLAST at the NCBI website9 and the UCSC Genome 
browser, with the BLAT Search Genome and database from UCSC Genome Bioinformatics 
website10 were used (Cline and Ken, 2009; Kent, 2002; Kent et al,. 2002). Identified 
integration pseudo attP sites targeted by different versions of integrases, the respective 
sequencing primer, query versus genomic sequence size, the exact area and genomic location 
of each insertion event were presented. The genomic context near the integration site, which 
represented either a targeted gene or two flanking genes, if integration was intergenic, was 
also listed (Table 4.3). Each pseudo attP site was analysed for its chromosomal position and 
named according to the location, including the chromosome, the arm and band designation to 
differentiate between other pseudo attP sites. For example, the site 19q13.2 is located on 
chromosome 19 within the long arm “q”, whereas the short arm is termed “p”. Within the 
arm, the region “1”, the particular band “3”, and eventually a sub-band “2” describe the 
position in question, in this context an insertion site, in detail.  
Eight different integration events could be indicated in the context of a human genome at 
locations within seven different chromosomes. The position 19q13.31 within the ORF of 
ZNF223 encoding a zinc finger was targeted twice in two independent events, mediated by wt 
integrase (clones #1 and #13.1). Another wt integrase performed recombination in an 
interagency region at position 20p13. Two insertion sites were determined at interagency 
positions, 13q21.2 and 4q28, by the integrase mutant D470A. The double mutant 
K457A+ D470A (clone #2) hit the largest among the human chromosomes at position 1q44 
within ORF 71. The mutant D470A+ E382A (clone #23/1) hit two different chromosomal 
sites; more than two thirds of the queried sequences were found in chromosome X. Remaining 
sequences were identical to a small region (170-270 bp) in chromosome 6 within different 
arms. Three insertion sites at genomic location 19q13.2 and 20p13 and Xp11.22 could be 
identified by sequencing into both directions of the chromosome. Ideograms of all human 
chromosomes with the respective banding pattern and identified integration events (red 
arrows) are represented in Figure 4.30.  
Remaining sequences did not reveal human genomic DNA. Most of the sequences obtained 
large parts of the transfected substrate plasmid p7 (data not shown). Therefore, these 
sequences could not be assigned to PhiC31 integrase mediated chromosomal integration.  
                                                 
9
 Nucleotide BLAST / BLAST human sequences at http://blast.ncbi.nlm.nih.gov/Blast.cgi 
10
 Human BLAT search at http://genome.ucsc.edu/cgi-bin/hgBlat 
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Figure 4.30. Positions of clonally rescued PhiC31 integration sites in the human genome. Chromosome ideograms are shown with integration sites 
marked in red.  
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Table 4.3. Summary of rescued sites of PhiC31 integration in HCT cell line. 
Type of 
integrase clone 
name 
Sequencing 
primer 
Query size/ 
genomic 
sequence (bp) 
Sequence 
start- sequence 
stop (bp) 
Genomic 
location  
 
If intronic, 
gene name 
 
If intergenic, features flanking this part 
of subject sequence (intergenic sequence) 
attB-F 988/ 852  16832229-
16833079 
Chr. 19q13.31 ZNF223 mRNA  wt Int  
#1 
attB-R 991/ 851 16833079-
16832229 
Chr. 19q13.31 ZNF223 mRNA  
attB-F 949/ 929 3719234- 
3720163 
Chr. 20p13 
 
 CDC25B phosphatase (protooncogene) 
cell division cycle 25B isoform 1 and 3 
wt Int 
#3 
attB-R 908/ 457 3727808- 
3727352 
Chr. 20p13 
 
 CDC25B phosphatase (protooncogene) 
cell division cycle 25B isoform 1 and 3 
wt Int 
#13.1 
attB-F 929/ 849 16832228-
16833079 
Chr. 19q13.31 ZNF223 mRNA  
D470A 
#2 
attB-F 669/ 408 
(266-665) 
42769741-
42769342 
Chr. 13q21.2 
 
 647567 bp at 5' side: tudor domain 
containing 3 isoform 2;  
195635 bp at 3' side: protocadherin 20 
D470A  
#3/2 
attB-R 589/589 50782528-
50783119 
Chr. 4q.28 
 
 602715 bp at 5' side: ankyrin repeat domain 
50 2595 bp at 3' side: FAT tumor 
suppressor gene homolog 4  
K457A+D470A 
#2 
attB-F 943/ 893 246753004 
246753906 
 
Chr. 1q44, 
 
C1 ORF 71 23574 bp at 5' side: mitochondrial TF B2 
959 bp at 3' side: hypothetical protein 
LOC163882 isoform 2 
561/394 
(1-397) 
334782- 
334391 
Chr. Xp11.22  
 
shroom family 
member 4 
 D470A+E382A  
#23/1 
attB-F 
561/167 
(394-561) 
 Chr. 6q11.1  323645 bp at 3' side: KH domain-
containing, RNA-binding, signal 
transduction-associated protein 2  
948/ 601 
(76-674) 
334803- 
335403 
Chr.Xp11.22  
 
shroom family 
member 4 
 D470A+E382A  
#23/1 
attB-R 
948/277 
(671-948) 
 Chr. 6p11.2  325094 bp at 3' side: KH domain-
containing, RNA-binding, signal 
transduction-associated protein 2 
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Among these few analysed insertion sites, no statistical predictions could be drawn. The 
chromosomal site 19q13.31 has also been found several times in previous studies analysing 
integrase specificity (Ehrhardt et al., 2006; Chalberg et al., 2006) and can rightly be assumed 
as a preferred integration site. 
 
4.9 Human Factor IX (hFIX) expression upon plasmid delivery in murine liver 
 
To analyse in vivo efficiencies of the different PhiC31 integrase mutants, plasmid DNA was 
transfected via hydrodynamic plasmid injection into the tail veins of mice. Two selected 
integrase mutants, K457A and D470A, which showed promising results in vitro, were 
compared to the control groups wt Int and mInt for integration into the genome of murine 
liver cells. Substrate plasmid pBS-attB-hFIX including the integrase specific wt attB site and 
the human blood coagulation Factor IX minigene (hFIXmg) was co-injected with either 
plasmid encoding wt Int, mInt, or with mutant K457A, D470A or K457A+ D470A, 
respectively (Table 4.4). Injected plasmids are shown in Figure 4.31.  
At various time points, retro-orbital blood was collected. From the collected blood serum, 
liver toxicity was determined by detection of alanine aminotransferase (ALT) levels in both in 
vivo experiments (Figure 4.32). Additionally, hFIX levels in mouse serum were determined 
by enzyme-linked immunosorbent assay (ELISA).  
In order to analyse the progression and the persistence of hFIX in murine liver tissue mice 
were treated at day 49 and day 71 post plasmid injection via intraperitoneal injection with 
carbon tetrachloride (CCl4). CCl4 is known to function as a liver-toxic substance and affected 
hepatocytes undergo necrosis. Application of 50 µl diluted CCl4 leads to necrosis of at least 
70 % of hepatic cells (Das et al., 2007). The original size of the CCl4-damaged mouse liver 
was reconstituted by proliferating hepatocytes. Induction of the cell cycle leads to removal of 
episomal plasmids. Upon injection and DNA uptake in mouse liver hFIX plasmids persisted 
in the nucleus of hepatocytes either episomally or integrated into the genome. The hFIX 
concentration (in ng/ml) in individual mice of different groups (n = 3-5) were monitored at 
different time points in experiment #2 (Figure 4.33). 
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Figure 4.31. DNA sequences injected into female C57BL/6 mice.  
The depicted plasmids were injected in different ratios into the tail vein of mice. (A) The 
pBS-attB-hFIX plasmid has already been used for hFIX delivery via injection (Ehrhardt et al., 
2005). This plasmid contains the human blood coagulation Factor IX minigene (hFIXmg) as a 
reporter gene and the native attB site for PhiC31 integrase-mediated recombination. The 
expression cassette consists of different cis-acting regulatory sequences, the hFIXmg and the 
polyA sequence. The expression controlling sequences are the apolipoprotein E hepatic 
control region (ApoE/HCR), which further contains a matrix attachment region (MAR) and 
liver-specific enhancer elements, and the liver-specific human α1-antitrypsin promoter 
(hAAT-p). This promoter enhancer combination is introduced by Miao et al. (2000). (B) The 
plasmid pCS Int contains the CMV promoter (CMV-p) and the PhiC31 integrase gene (blue), 
which is exemplary shown for all versions of integrase (wt Int, mInt and different integrase 
mutants) being used for tail vein injection. 
 
Table 4.4. Experimental setup of two independent in vivo experiments.  
Different characteristics for experiments #1 and #2 are shown. For experiment #1, 20 µg 
plasmid DNA were diluted in 2 ml 0.9 % NaCl solution and for experiment #2, 40 µg plasmid 
DNA were diluted in 1.8 ml 0.9 % NaCl solution. The appropriate amounts of diluted 
plasmids were injected via hydrodynamic tail vein injection in 6 seconds into the tail veins of 
mice. Plasmid ratios, individual plasmid amounts and numbers of mice per group are listed 
for both experiments.  
 
In vivo 
experiment 
Plasmid ratio 
pBS-attB-hFIX: 
Int  
Amount of pBS-
attB-hFIX 
plasmid 
Amount of Int 
encoding plasmid and 
Int mutant 
Mice evaluated 
per group 
#1 1: 10 2 µg 18 µg wt Int n= 3 
#1 1: 10 2 µg 18 µg mInt n= 3 
#1 1: 10 2 µg 18 µg D470A n= 5 
#1 1: 10 2 µg 18 µg K457A+ D470A n= 4 
#1 Control mice uninjected n= 2 
#2 1: 1 20 µg 20 µg wt Int n= 4 
#2 1: 1 20 µg 20 µg mInt n= 4 
#2 1: 1 20 µg 20 µg K457A n= 5 
#2 1: 1 20 µg 20 µg D470A n= 4 
#2 Control mice uninjected n.d. 
 
The average ALT levels of the four treatment groups show expected progression over time. 
ALT levels were measured at day one post injection since ALT levels reach a peak shortly 
after plasmid injection. The toxicity profile relative to the ALT levels was monitored over 
time. ALT levels declined to normal range within eight days post injection and stayed normal 
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(Figure 4.32A and 4.32.B). The normal ALT levels are in range between 10 and 40. However, 
they may vary greatly (Kaplan, 2002). 
 
Figure 4.32. Surveillance of alanine transaminase (ALT) levels to evaluate liver damage.  
ALT levels were determined in murine serum. ALT levels are represented in U/l (Units per 
litre). High-pressure tail vein injection was carried out at day 0. Two individual experiments, 
#1 and #2 as indicated in Table 4.4 were performed. (A) ALT expression levels of experiment 
#1 were detected at day 1 and 8 post injection. (B) ALT expression levels of experiment #2 
were detected at day 1, day 8 and day 15 post injection. 
 
The progression of hFIX concentration in different groups was determined by ELISA 
(Figure 4.33). hFIX levels increased about twofold between day 14 and day 28 post injection 
for all groups. Highest hFIX values could be obtained at day 42 post injection for wt Int 
(about 3500 ng/ml) and D470A (about 3000 ng/ml), mice co-injected with mutant K457A 
showed a decline to 1800 ng/ml and mInt to 900 ng/ml at day 42 post injection. The serum 
hFIX concentrations of wt Int (940 ng/ml) and integrase mutants K457A (957 ng/ml) and 
D470A (1061 ng/ml) were about 6 times higher than hFIX levels generated after injection 
with plasmids encoding mInt (140 ng/ml) at day 63 post injection. 
After a second CCl4 injection at day 71 post plasmid injection, hFIX serum levels even 
increased 1.33 times in wt Int transfected mice, 1.65 times in mice injected with mutant 
K457A, and 1.76 times in mice injected with mutant D470A.  
At day 98 post injection, hFIX levels of the serum collected from wt Int or collected from the 
groups injected with integrase mutants dropped to a value of about 780 ng/ml, which is still 
about 25 times higher than the serum levels obtained from mice injected with mInt, 
approximately 30 ng/ml. 
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Figure 4.33. Human Factor IX (hFIX) expression levels in vivo. 
Integrase encoding plasmids and hFIX encoding plasmids were co-injected via hydrodynamic 
delivery into the tail veins of female C57BL/6 mice according to the amounts in experiment 
#1 (Table 4.4). Blood serum samples from 4 different groups of mice, being injected with wt 
Int encoding plasmid, mInt, K457A mutant or D470A mutant, were analysed by ELISA for 
hFIX expression in murine liver at different time points. hFIX levels were averaged from all 
mice per group (n = 3-5). Fifty microlitres of liver toxic diluted CCl4 (carbon tetrachlorid) 
were injected at day 49 and day 71 post injection to reduce the liver size and subsequently 
induce proliferation of hepatocytes and plasmid integration. hFIX progression is shown over a 
period of 14 weeks. 
 
In order to address hFIX expression the progression of serum hFIX levels were detected 
starting at day 48 post injection. CCl4 was injected at day 49 and day 71 post plasmid 
injection. The absolute (concentration in ng/ml) and the relative (in %) serum hFIX 
concentrations were presented for each mouse and group including percent values (Table 4.5). 
The serum hFIX concentrations from mice between the four groups but also in mice within 
the same group, at day 63 and 85 post injection had deviations higher than 100 %. Differences 
in serum concentrations of 100 % and higher were observed within all groups.  
At day 85 post injection, the averaged hFIX serum level in mice injected with mutant K457A 
was 50 % higher than in mice injected with wt integrase. The averaged hFIX expression 
levels in mouse serum taken at the last time point of the experiment (day 98 post injection), 
however, were very similar to each other showing hFIX concentrations between 770 and 
795 ng/ml in mouse serum collected from groups injected with wt Int and with the two Int 
mutants K457A and D470A.  
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Table 4.5. Serum hFIX concentrations from different groups of mice injected with PhiC31 
integrase plasmid and hFIXmg plasmid post initial CCl4 injection are shown. 
Supporting data to Figure 4.33 show the averaged hFIX concentration (in ng/ml) as absolute 
hFIX serum levels and the relative values in % from mice injected with wt Int, mInt, and 
mutants K457A and D470A in duplicates for each mouse per group. The values of hFIX 
concentrations are set to 100 % at day 48 post initial hydrodynamic plasmid delivery. From 
each mouse of the four different groups, blood samples were taken at day 48, 63, 85, and 98 
post injections. The serum hFIX concentrations were determined by ELISA in ng/ml and the 
relative serum level was calculated for single mice within the same group and for the average 
in each group, based on the values at day 48 post injection. CCl4 was injected at day 49 and 
71 post initial injection to induce hepatic cell cycles. The number of mice in each group was 
n = 3-5. n.d. means not detected or below detection minimum for serum from mice injected 
with mInt. 
 
 Serum hFIX levels of individual mice per group and average in ng/ml and % 
wt Int mInt K457A D470A days post 
injection 
no. of 
mouse ng/ml % ng/ml % ng/ml % ng/ml % 
day 48 #1 /  476 100 % 1918 100 % 1903 100 % 
 #2 2029 100 % 1400 100 % 1983 100 % 1853 100 % 
 #3 2230 100 % 963 100 % 2078 100 % 1482 100 % 
 #4 2028 100 % 49 100 % /  1910 100 % 
 #5 1964 100 % /  2299 100 % /  
 #6 /  /  2016 100 % /  
 average 2062,75 100 % 722 100 % 2058,8 100 % 1787 100 % 
day 49 CCl4 injection 
day 63 #1 /  105 22,1% 723 37,7% 1228 64,5% 
 #2 620 30,6% n.d.  543 27,4% 1075 58,0% 
 #3 1213 54,4% 124 12,9% 971 46,7% 1265 85,4% 
 #4 dead  n.d.  /  1085 56,8% 
 #5 985 50,2% /  1197 52,1% /  
 #6 /  /  1349 66,9% /  
 average 939,33 45,5% 114,5 15,9% 956,6 46,5% 1163,25 65,1% 
day 71 CCl4 injection 
day 85 #1 /  63 4,5% 1955 101,9% 1373 72,1% 
 #2 716 35,3% n.d.  n.d. n.d. 2825 152,5% 
 #3 1688 75,7% n.d.  2004 96,4% 1430 96,5% 
 #4 dead  n.d.  /  dead  
 #5 1344 68,4%   805 35,0% /  
 #6 /    1551 76,9% /  
 average 1249,33 60,6% (63) 8,7% 1578,75 76,7% 1876 105,0% 
day 98 #1 /  n.d.  1140 59,4% n.d.  
 #2 422 20,8% n.d.  n.d.  682 36,8% 
 #3 1113 49,9% 32 3,3% 702 33,8% 859 58,0% 
 #4 dead  n.d.  /  dead  
 #5 811 41,3%   543 23,6% /  
 #6 /    n.d.  /  
 average 782 37,9% (32) 4,4% 795 38,6% 770,5 43,1% 
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5. Summary 
The PhiC31 integrase system represents an attractive tool for somatic integration of extrinsic 
genes or specific excision in applications such as therapeutic gene transfer or genetic 
engineering and transgenesis. In its most prominent role, the integrase mediates integration of 
plasmids carrying a therapeutic gene of interest and a specific attB site into pseudo attP sites. 
As a non-viral integrating vector, the PhiC31 integrase suffers from insufficient gene transfer 
and low integration efficiency. Additionally, aberrant events such as chromosomal 
rearrangements and deletions are known to occur at a given frequency of about 15 % within 
the host genome. 
Therefore, the goal of this study was to first optimise the PhiC31 integrase-mediated 
integration efficiency and second to optimise the specificity by performing site-directed 
alanine scanning mutagenesis for the first time within the DNA binding domain.  
In the course of this work, 22 single amino acid mutations were generated, which were then 
evaluated in antibiotic-selective integration assays in different human cell lines, based on co-
transfection of integrase encoding plasmid and substrate plasmid with attB and neomycin 
resistance marker. Initial screening revealed one mutant with 1.7-fold higher integration 
efficiency. Upon optimisation of the plasmid ratio and with the creation of double mutants, 
the integration efficiency of two double mutants could be enhanced above threefold in HeLa 
cells. A nearly twofold improvement of one particular mutant could be achieved in Huh7 and 
in HCT cells, indicating that integration efficiency is cell line dependent.  
Intramolecular plasmid-based excision assays were established leading to gene activation of 
the reporter. At native attB ×attP recombination sites, five mutants with about twofold 
enhanced integration efficiency compared to wt integrase were identified, whereas 
recombination activity in chromosomal context of a stably integrating GFP reporter cell line 
showed no improvement. Increasing integrase plasmid dose fivefold and replacing the native 
attP site within the substrate plasmid by three preferentially targeted pseudo attP sites found in 
mammalian genomes did not result in any improvement of the integrase-mediated excision 
activity of a polyA termination site beyond twofold.  
To evaluate integration efficacy of PhiC31 integrase in vivo in murine liver a human 
coagulation Factor IX (hFIX) encoding substrate plasmid and the respective integrase 
encoding plasmid were co-injected via high-pressure tail vein injection into C57BL/6 mice. 
Two integrase mutants, K457A and D470A, showed a similar hFIX expression profile 
compared to wt integrase as determined by serum hFIX levels. 
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6. Discussion 
6.1 Mutagenesis and other approaches to improve recombination of PhiC31 
integrase  
 
In order to improve non-viral gene transfer systems such as the PhiC31 integrase and the 
Sleeping Beauty (SB) transposase (Ivics et al., 1997), several mutagenesis techniques of their 
DNA sequences are widely used. Several studies aiming at identifying beneficial mutants by 
different screening assays have been carried out to improve integration efficiency and 
specificity on a protein level addressing the PhiC31 integrase (Sclimenti et al., 2001; Keravala 
et al., 2009) and the SB transposase (Geurts et al., 2003; Yant et al., 2004; Zayed et al., 2004; 
Mátés et al., 2009).  
The mutagenesis screening was based on a widespread technique termed alanine scanning by 
replacing charged amino acids with alanine. For the first time, the DNA binding domain 
roughly including amino acid positions 365-480 served as a template to generate 22 single 
mutants. Initial screening of the efficiency of the mutants resulted in an increase of 1.7-fold 
compared to the wild type integrase (Figure 4.7). An approximate threefold enhancement in 
integration efficiency could be achieved in HeLa cells upon further improvements (Figure 
4.11). The same method was used to change 95 single amino acids within the DNA binding 
domain of SB transposase resulting in 10 “hyperactive” mutants (10.5 %) with two- to 
fourfold enhanced transposition activity (Yant et al., 2004). Synergistic effects on the first 
generation transposases could boost the SB transposition up to a ninefold enhancement (Yant 
et al., 2004). Recent progress in improving stable gene transfer by a hyperactive version, 
created by a large-scale genetic screen of the SB showed 100-fold enhancement in efficiency 
(Mátés et al., 2009). As yet, such a breakthrough has not been achieved with the PhiC31 
integrase system. When the PhiC31 integrase was mutated for the first time, the integration 
frequency and specificity could be improved two- to threefold at a favoured pseudo attP site 
on chromosome 8, detected by quantitative PCR (Sclimenti et al., 2001). In a study published 
recently, the N-terminal catalytic domain was screened for positive residues and among 43 
mutants, only two (<5 %) showed up to 2.3-fold improvement in recombination efficiency in 
a “flipper assay”. These mutants were created by error-prone PCR, included up to eight 
mutations and a 33 amino acid-long N-terminal fusion sequence, which was involved to 
improve recombination activity further (Keravala et al., 2009). The transfected substrate 
plasmid contained inverse oriented native attB/attP sites, flanking a CMV promoter, located 
upstream of an eGFP reporter gene. The recombination activity was determined by the 
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inversion of the promoter, turning on eGFP, whose expression level was relative to the 
efficiency in the extrachromosomal “flipper assay” (Keravala et al., 2009). In concordance 
with the present study, their results demonstrate that double mutants do not consistently cause 
synergistic effects in respect to recombination efficiency. Increasing the number of mutants 
may result in a few beneficial mutants. Alternatively, specific amino acid residues can be 
replaced by others. However, limited data addressing structure, conformation, and enzymatic 
mechanism question this site-directed mutagenesis strategy.  
Several other site-specific recombinases as lambda, Cre, and FLP and resolvases as gamma 
delta and Tn3 have been subjected to mutagenesis approaches addressing recombination and 
in particular DNA-binding, cleavage and ligation (Buchholz et al., 1998; Bankhead et al., 
2003; Schwikardi and Dröge, 2000; Warren et al., 2005; Malanowska et al., 2009). 
Mutagenesis of lambda integrase and gamma delta resolvase can be designed more rationally 
and site-specific, since their putative protein structures are solved (Biswas et al., 2005; Li et 
al., 2005). The increasing number of studies addressing improvements of recombination and 
integration emphasise mutagenesis approaches still as a convenient method. 
To increase integration efficiency further, the effect of enhancing integrase plasmid dose on 
colony formation was investigated. Dose dependent studies showed that the molar ratio of SB 
expressing plasmid to transposon affected SB-mediated integration. Overproduction inhibition 
consequently reduced transpositional activity at critical transposase concentrations (Geurts et 
al., 2003; Zayed et al., 2004), however N-terminal fusion of zinc fingers to a hyperactive SB 
transposase attenuated overproduction inhibition (Wilson et al., 2005). This adverse effect is 
not yet documented in PhiC31 integrase-mediated gene transfer. Thus, the effect of a 
twentyfold increase of integrase plasmid dose on the recombination efficiency was 
investigated. Although improvements could be achieved in integration efficiency of particular 
mutants caused by a higher plasmid dose in different cell lines (Figure 4.8 and 4.14), no 
general correlation between integrase plasmid dose and colony formation was detected. 
Addressing the influence of lowering the integrase plasmid dose showed a diminishing effect 
on recombination efficiency according to lower colony numbers (Figure 4.9). These findings 
are contradictory to recent data suggesting low dose of PhiC31 integrase to mediate 
considerable integration events in human cells (Wang et al., 2009). The interaction of 
extrinsic integrase with endogenous proteins as TTRAP (TRAF and TNF receptor associated 
protein) as presented by yeast two-hybrid and co-immunoprecipitation assays resulted in 
reduced effects on PhiC31 integrase recombination efficiency (Wang et al., 2009).  
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Another strategy was to combine improved single mutants to double mutants to achieve 
synergistic effects. Again, this method did not reveal a higher integration rate, however low 
synergistic effects were found in one double mutant in HeLa cells (Figure 4.10). The 
combination of both the double mutant and the plasmid dose increase shows a trend of higher 
activity slightly above threefold compared to wt integrase (Figure 4.11). Since further 
increase could not be achieved, the threshold of this experimental approach has potentially 
been reached. A triple mutant generated by three recombination-improved single mutants 
within the C-terminal domain of PhiC31 integrase also revealed a rather poor synergistic 
effect on recombination activity (Keravala et al., 2009). In the first mutagenesis study 
addressing SB, the combination of beneficial transposase mutants could be enhanced from 
initially fourfold by the factor of two (Yant et al., 2004). Large-scale mutagenesis by in vitro 
evolution using DNA shuffling performed on the genetic sequence of SB transposase even 
resulted in hyperactive transposases with up to 100-fold enhancement in efficiency (Mátés et 
al., 2009). 
PhiC31 integrase fusion proteins with a nuclear localisation signal (NLS) 
(Kalderon et al., 1984) represent additional methods to enhance cell target specific delivery 
(Andreas et al., 2002). N-terminal tagged NLS to PhiC31 integrase reached almost the same 
recombination activity as NLS-Cre with an advancement of 1.74-fold compared to the native 
integrase (Andreas et al., 2002). Presumably, the addition of the NLS to our improved 
mutants might result in enhanced integration efficiency. The addition of NLS to the relatively 
large PhiC31 integrase is primarily associated with enhanced translocation through cellular 
membranes into the nucleus (Chen et al., 2006, Woodard et al., 2009). Surprisingly, the 
addition of the SV40 NLS had about fourfold decreasing effects towards integration 
efficiency in vitro in HeLa cells and in vivo upon hydrodynamic injection. Woodard et al. 
suggested that cell division was not required for integrase function in mouse liver and that 
nuclear localisation provided at most little benefits for PhiC31 integrase-mediated liver gene 
therapy (Woodard et al., 2009). Large fractions of enzymes in an unmodified state remain in 
the cytoplasm, since the nuclear membrane as pore complexes represent a limiting barrier for 
large proteins in size of 40 kDa and larger to enter the nucleus (Rolland, 2006; Bonner, 1978). 
A similar approach showed up more than threefold increase of targeted integration, when the 
combination mutants were fused with a 33 amino acid N-terminal sequence representing part 
of the bacterial/mammalian promoter. This sequence is present in the native plasmid 
backbone and was additionally fused to integrase mutants (Keravala et al., 2009). A codon-
optimisation towards a reduced number of CpG dinucleotides of the integrase in combination 
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with the C-terminal addition of the simian virus 40 (SV40)-derived NLS showed twentyfold 
improvements in episomal recombination assays (Raymond and Soriano, 2007).  
 
6.2 PhiC31 integration efficiency 
 
In the selection-based integration assays the efficiency of PhiC31 integrase to integrate 
plasmid DNA into the mammalian genome was determined relative to the quantity of G418-
resistant colonies. The integration efficiency is predominantly influenced by the chromosomal 
context due to the intrinsic influence of the genomic DNA flanking the integration site, on the 
promoter and the transgene within the substrate plasmid. The choice and design of the 
substrate plasmid and in particular the promoter influences efficiency and transgene 
expression. The huge diversity of the chromosomal context within the genome derived from 
different cell lines and organs reasoned the inconsistent integration efficiency among different 
cell lines (Section 4.5).This is supported by the finding that chromatin conformation and 
accessibility were suggested to influence PhiC31 integrase pseudo site selection (Portlock and 
Calos, 2003) and transgene expression levels. The frequency of integration by a related HIV 
integrase was shown to be influenced not only by the structure of the target site, but also by 
DNA curvature and flexibility (Pruss et al., 1994), thus proposing that features may also affect 
the PhiC31 integrase target site selection. Another parameter which influences integration 
efficiency refers to the transfection method (delivery into the nucleus). Since equal 
transfection conditions via lipofection were assumed throughout the experiments, beneficial 
effects on plasmid delivery, e.g. addition of nuclear localisation signals (NLS), are not 
considered further within the context of this work. The overall integration efficiency upon 
lipofection-mediated transfection in vitro is generally low, but still higher than integration by 
homologous recombination (10-6) for most mammalian cells (Vega, 1991). PhiC31 integrase-
mediated integration naturally accomplished an approximate 100-fold improved 
recombination rate in vitro compared to random integration (Chalberg et al., 2006).  
The constitution and the proficiency of the particular integrase likely play the most pivotal 
role in respect to integration efficiency. Since the crystal structure of the PhiC31 integrase has 
not been solved yet, homology modelling and secondary structure prediction (Yang and 
Steitz, 1995; Li et al., 2005) could support site-directed mutational analysis addressing 
recombination activity and in particular integration efficiency.  
In the initial screen (Figure 4.7), five mutants showed a slight improvement in integration 
efficiency between 1.2- and 1.7-fold, assuming a mild functional preference for alanine 
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instead of the large side chains of the charged amino residues (detailed structure in appendix). 
Single amino acid changes at these critical residues take certain effects on the overall 
enzymatic functionality e.g. by altering the charge and the conformation. However, replacing 
large side chains of amino acids, the methyl group of the small amino acid alanine does not 
necessarily lead to increased recombination efficiency.  
Seven mutants showed a fivefold decline of integration efficiency suggesting structural or 
functional importance associated with the native charged amino acid positions (Figure 4.7). 
The small side group of alanine abolishes integration activity likely at these particular 
positions. 
Ten mutants showed rather similar integration efficiency compared to wt integrase. Therefore, 
these amino acids were not critical to maintain the recombination activity at the level of wt 
integrase. Although the goal of this study targets to increase integration efficiency, it would 
be of great interest to determine, at which recombination step the mutant proteins are 
deficient, to gain more information and understanding about structure-function relationships. 
Initial experiments addressing synapsis, DNA cleavage and control of directionality during 
the PhiC31 integrase-mediated recombination reaction might gain additional knowledge 
(Thorpe et al., 2000; Smith et al., 2004). 
According to the secondary structure prediction (Figure 1.5) the DNA binding domain 
comprises three repetitive β-sheets within position D366-R392 and a long α-helix comprising 
position between M413 and E480. A putative coiled-coil region, which is a common 
structural motif in proteins, in length of about 28 amino acids with a periodicity of four 
heptads forming several supercoiled α-helices has also been observed within the binding 
domain (Rowley et al., 2008; McEwan et al., 2009). In the first β-sheet comprising amino acid 
sequence 365-MDKLYC-370, two mutants (D366A and K367A) were created in this study, 
showing totally diverse effects on integration efficiency. Removal of the acidic carboxy group 
(COOH) of aspartic acid (D) and replacing it with the methyl group gained slightly 
integration efficiency. The mutant K367A dropped integration activity about fivefold when 
the positive charge is removed. This might be due to the substitution of a large basic amino 
group by the small methyl group, which likely implies the importance of the polar side chain 
at that position to maintain hydrogen bonds between individual side chains of amino acids. 
The two mutants (E382A and E383A) showed both an approximate 1.3-fold increase. The 
residues are located between two connecting β-sheets. Mutations towards alanine at these 
positions might improve orientation and binding affinities between the second and the third β-
sheet. The side-chain of the positively charged amino acid arginine (R) at position 380 might 
Discussion 
 105 
be involved to maintain the β-sheet structure of the second sheet, since alanine reduced 
activity dramatically. The third beta-sheet included two amino acids changed to alanine; 
K386A and R390A. The mutation effects resulted in a drop to 60 % integration efficiency 
compared to the wt integrase. Removal of positively charged side chains might consequently 
abolish the disruption of native interaction between the sheets, as indicated by the fivefold 
loss of recombination activity in the mutants R393A and R394A. These findings suggest that 
positively charged amino acids found in structures forming β-sheets support stronger binding 
to negatively charged DNA.  
The most beneficial mutant D470A lies within the structural motif of a coiled-coil region 
between two alanine residues (Figure 4.5), in which four α-helices are coiled together in 
heptamers (Rowley et al., 2008; McEwan et al., 2009). By replacing the negatively charged 
side chain of aspartic acid (D) with alanine the protein interaction interface likely performs 
enhanced substrate recognition or improved α-helical propensity. The putative coiled-coil 
motif is strongly involved in substrate recognition and consequently in attB×attP synapsis 
(McEwan et al., 2009). The approximate tenfold decrease of mutants D417A and E432A 
suggests that the negatively charged sidechains of aspartic acid (D) and glutamic acid (E) are 
likely involved in protein active sites or cationic bonds rather than in DNA interaction. 
Whether or not the mutated residues in the double mutants are in close proximity in its active 
conformation could not be determined. Mutants showing improved efficiency were likely 
altered in specificity as well. However, it was not investigated whether and when integration 
efficiency is associated with integration specificity, assuming that no obvious coherency 
exists. 
 
6.3 Excision activity of PhiC31 integrase mutants  
 
Besides PhiC31 integrase-based gene transfer associated with chromosomal integration, site-
specific recombinases (SSR) are also capable of performing excision or inversion of DNA 
sequences when attachment sites are present within the same molecule, depending on their 
orientation to each other (Grindley et al., 2006; Sorrell and Kolb, 2005; Kolb, 2002).  
Our plasmid recombination assay was based on luciferase gene activation by the removal of 
the `expression blocking´ polyA sequence bringing luciferase cDNA in frame with the 
promoter. The intramolecular recombination assay carried out at native attB/attP sites 
revealed a few mutants with twofold improved recombination activity detected by luciferase 
expression (Figure 4.23 and 4.24). A time course of luciferase expression would nicely 
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investigate and compare “long-term” expression potential of selected mutants using 
intramolecular recombination activity (Aneja et al., 2007). Evaluation of mutant derivatives 
for excision activity within extrachromosomal context excludes epigenetic effects as 
chromatin structure and modification, if integration would happen in regions with limited 
gene expression as heterochromatin.  
In plasmids the promoter activity is stable, assuming transient recombination assays relatively 
reliable. Excision activities of integrase mutants at preinserted plasmid constructs within 
chromosomal context of 293 cells however revealed no improvements in recombination 
activity, detected by GFP expression levels (Figure 4.21). This might be due to affecting 
chromatin position effects, which are capable to relieve transgene expression. This 
phenomenon could be avoided by insulating the integrated DNA with tandem copies of 
chicken β globin HS4 insulators, as used in transgenesis (Allen and Weeks, 2005). 
Dimer interactions to form a synaptic complex with the substrate DNA (Rowley and Smith, 
2008) might be preferentially achieved when target attachment sites are either present within 
one episomal molecule or present on two different molecules, as plasmid and genome. 
Although the excision principle is similar, results of both assays are rather ineligible to be 
compared, since the differences in terms of reporter gene detection (luciferase/eGFP) and 
molecule (plasmid DNA/genomic DNA) are crucial. 
The excision-improved integrase mutants can be used in applications, where excision-based 
recombination is desired, e.g. removal of unwanted selectable markers. Excision-based 
recombination could be used for instance in transformed yeast cells, transgenic plants or 
embryonic stem cells, in animal transgenesis or conditional mutagenesis, to analyse specific 
gene function. These applications have been dominated by related recombinases as FLP and 
Cre recombinase basically due to bidirectional reactions and their improved mechanistic and 
structural knowledge (Buchholz et al., 1996; Guo et al., 1997).  
 
6.4 Specificity of PhiC31 integrase 
 
Integration specificity gained great attention since aberrant events as chromosomal 
translocations and large deletions were associated with the PhiC31 integrase system in vitro at 
a frequency of about 15 % (Ehrhardt et al., 2006; Chalberg et al., 2006). Additional studies 
demonstrated that the PhiC31 integrase induces chromosomal aberrations and DNA damage 
response in primary human fibroblasts (Liu et al., 2006; Liu et al., 2009). Whether the 
cytotoxic effects were assigned to prolonged integrase expression or to high integrase doses, 
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has not been investigated yet. Although the total number of potential integration sites was 
predicted to be in the range between 100 and 1000 due to a site-specific integration reaction 
(Chalberg et al., 2006), the risk of insertional mutagenesis still remains. In theory, the ultimate 
goal associated with PhiC31 integrase mediated gene transfer describes targeting the 
transgene containing construct with high efficiency into a limited number of integration sites. 
Ideally, these sites are safe in terms of avoiding unwanted intrinsic effects. Additionally, 
appropriate transgene expression levels should be achieved at these sites. Therefore, 
specificity analysis of integrase mutants using different methods were performed.  
(1) Excision based assay evaluated specificity in terms of binding activity towards attB and 
attP sites within the same molecule. Excision frequencies were compared between native 
attachment sites attB×attP and 3 different combinations of attB×attP´. These attP´ target sites 
were found to be preferentially targeted by the wild type integrase (Section 4.7.3, Figure 
4.26). 
(2) Integration assay based on plasmid rescue strategy aimed at detection of chromosomal 
sites of insertion (Figure 4.30, Table 4.3). Hence, this strategy produces more qualitative 
results. However, parameters such as design and size of substrate plasmid, selected restriction 
sites, and transfected cell lines bias the results (Ehrhardt et al., 2006; Chalberg et al., 2006). 
The transfer to in vivo analysis demands modifications in respect to selection.  
Intramolecular excision studies based on recombination at attB×attP only compared the 
targeting frequency between attP and selected attP´ sites. These sites might be preferentially 
targeted by the particular integrase mutants within genomic context as well. The evaluation of 
excision assays resulted in integrase mutants with about twofold improved specific 
recombination at selected pseudo attP sites. These slightly moderate improvements do not 
greatly support further applications of these mutants. Therefore, further trials to increase 
specificity need to be investigated, as shown in the next paragraph. 
Results obtained from the plasmid rescue strategy yielded only very few integrase-mediated 
insertion events in HCT cells. Only the insertion site at position 19q13.31, which was found 
in two independent clones, has previously been identified as a preferred integration site in the 
two extensive PhiC31 integration studies to date (Ehrhardt et al., 2006; Chalberg et al., 2006). 
Most likely due to problems in plasmid rescue per se (frequent contamination with the 
substrate plasmid) and aberrant recombination events, insertion sites could not be detected 
properly. This system seems also to be error-prone, since artefacts of the rescue procedure 
might lead to the identification of only one single integration site (Chalberg et al., 2006). An 
alternative method to determine and analyse the integration events represents the PCR-based 
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rescue by means of the “Genome walker” kit. This technique is based on linker ligation and 
nested PCR and determines only one site of the integration junction, being unable to detect 
rearrangements. Nested PCR could also introduce artefacts (Chalberg et al., 2006). The 
selection of restriction sites and the transfection method were influenced by the cell line to be 
analysed, due to the cell line`s composition. The qualitative and specific analysis of 
integration sites helps to evaluate safety issues addressing the risk of insertional mutagenesis. 
Since the enzyme requires significant DNA sequence recognition (39 bp) for integration 
(Chalberg et al., 2006), much lower potential sites than retroviral or transposase-mediated 
integration systems are targeted (Mitchell et al., 2004; Schroeder et al., 2002; Wu et al., 2003; 
Yant et al., 2005). Additionally, severe adverse events in clinical trials were reported, in 
which retroviral vector-mediated insertion caused the proliferation of a proto-oncogene 
leading to leukaemia (Hacein Bey-Abina et al., 2003b). No similar adverse event in in vivo 
studies has been observed so far with non-viral integration systems. This makes PhiC31 
integrase a potentially attractive tool for specific insertion into the genome, despite poor 
delivery. Attempts to combine efficient delivery (high transduction efficiency) and site-
specific PhiC31 integration were approached for the first time by the construction of a hybrid 
PhiC31 integrase adenovirus vector. The combination of both desirable properties leads to 
prolonged transgene expression in vivo, suggesting this system a new tool for gene therapy 
(Ehrhardt et al., 2007). Alternatives aiming at increasing specificity of SSRs represent the 
design of chimeric proteins as custom-made zinc finger nucleases (Alwin et al., 2005; Caroll, 
2008) in combination with the PhiC31 integrase to specifically target DNA double strand 
breaks for gene targeting. 
The precursor of the PhiC31 integrase referred to zinc finger fusion proteins has been the SB 
transposase, which was successfully linked to a zinc finger protein E2C, resulting in targeted 
integration into predefined sites in the human genome (Yant et al., 2007). These new 
generation transposases or chimeric proteins showed altered DNA-binding specificity and 
integration, however controlled DNA transposition is still far from being realised perfectly. 
 
6.5 Evaluation of integration efficiency in murine liver 
 
To move further towards gene therapy trials, the PhiC31 integrase system was transferred to a 
mouse model. A simple, safe and effective method to transfer naked DNA molecules is the 
hydrodynamic tail vein injection of plasmids into the mouse (Zhang et al., 2004; Zhang et al., 
1999; Liu et al., 1999). With a targeting frequency of at least 10 %, transgene expression via 
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hydrodynamic delivery is preferentially found in hepatocytes (Herweijer and Wolff, 2003). 
One of the most appealing disease-related model systems describes gene transfer of human 
blood coagulation Factor IX (hFIX) into mouse liver to treat haemophilia.  
First, hydrodynamic injections with the respective integrase encoding plasmid and the donor 
plasmid pBS-attB-hFIX at a ratio of 10:1 were carried out (Table 4.4). This vector was 
designed and optimised for hepatic uptake by the inclusion of a liver-specific promoter and to 
treat haemophilia in gene therapy trials (Ehrhardt et al., 2003). According to improved 
integration efficiency in CFAs, two mutants K457A+ D470A and D470A were transfected 
together with the substrate plasmid. In contrast to our expectations, that surplus of integrase 
expressing plasmids compared to the donor plasmid might cause a positive impact on 
integration efficiency in murine liver. Almost all hFIX serum levels were below detection 
levels. Potential reasons for minimal hFIX expression levels might be insufficient amounts of 
transfected substrate plasmid (2 µg) in a total volume of 20 µg per mouse or a large plasmid 
dilution in 2 ml NaCl. During delivery through the blood stream into hepatocytes, injected 
plasmids are exposed to degrading enzymes as DNases. Only a fraction reaches the target 
organ, which might have been to less for detection. Whether hFIX expression originated from 
extrachromosomally persisting plasmids or upon integration of the transgene was not 
determined, however appropriate expression at advanced time points are most likely 
associated with hFIX expression from integrated genes. The fate of the hFIX encoding 
plasmid (integration versus loss from the liver by out-dilution) is made within 48 hours post 
hydrodynamic injection (Woodard et al., 2009) and episomal plasmids are diluted out over 
time. 
In the second in vivo experiment, 20 µg of both integrase plasmid and substrate plasmid were 
co-injected in a 1:1 ratio per mouse, adequate hFIX levels could be determined by ELISA 
over time (Figure 4.33, Table 4.5). Long-term and sustained transgene expression levels 
represent main prerequisites for successful gene therapy trials. Hepatocytes, as rather 
quiescent cells, simply cause a moderate cell turnover, however the relatively harsh 
hydrodynamic delivery might initially increase proliferation of hepatocytes (Woodard et al., 
2009). Transient expression and potential readministration to deliver therapeutic genes might 
be an alternative.  
In murine liver, transient and acute toxicity was observed without any long lasting toxic 
effects (Miao et al., 2001). Whether the liver cells, which have taken up the hFIX expression 
plasmid, show different proliferation, must be speculated. The number of integration events 
per cell has been controversially discussed within one group. One integration event per cell 
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was proposed for wt integrase (Chalberg et al., 2006), whereas multiple integrations were also 
suggested for PhiC31 integrase mutants (Keravala et al., 2009), proposing elevated expression 
levels. 
Comparing hFIX levels between our study and the recently published one (Keravala et al., 
2009) revealed slight differences in hFIX serum levels at day 85 post injection, despite liver 
toxic CCl4 injection. hFIX levels revealed slightly higher concentrations of wt Int and mutants 
at day 85 post injection (Table 4.5) in our study. Differences in hFIX long-term expression 
between both in vivo studies are mainly associated with differences in vector components of 
substrate and expression plasmids. Compared to the hFIX encoding plasmid in our study, the 
plasmid in the study of Keravala et al. is missing the second promoter ApoE including the 
hepatic locus control region (HCR). This vector additionally contains a Tn5 transposon in 
combination with a kanamycin resistance marker (Keravala et al., 2009). The differences in 
vector size and composition of features might lead to differences in expression levels. 
However, individual routes of delivery, localisation of the extrinsic protein, nuclear uptake, 
metabolism, and particular target sites have also particular influence on the expression levels. 
Repeated administration was shown to boost hFIX expression levels (Miao, 2005) and might 
even increase expression levels in our in vivo study. Immunofluorescence stainings on 
specific liver sections by using hFIX specific antibodies contribute to more detailed analysis 
of integration and hFIX long-term expression (Keravala et al., 2009) and seemed appropriate 
to further evaluate and confirm long-term expression. The first study presenting therapeutic 
factor IX levels in mice could even detect prolonged survival of more than eight month of 
factor IX-expressing hepatocytes, suggesting no substantial immune response against 
integrase (Olivares et al., 2002). 
Parameters to be investigated and optimised further in hepatic gene expression range from 
liver-specific α-1 antitrypsin (hAAT) promoters (Hafenrichter et al., 1994) over hepatic locus 
control regions (Ellis and Pannell, 2001) to enhancers and insulators, being involved in 
improvements of gene transfer into haemophilia mouse models (Miao et al., 2005). 
 
6.6 Outlook and future perspectives 
 
Aiming at increasing the recombination activity of the PhiC31 integrase further, several 
strategies in combination with the improved mutants might contribute to achieve this goal. 
The construction and screening of additional mutants within the binding domain in 
combination with a detailed investigation of critical residues based on homology to related 
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SSR, e.g. by applying a different mutational strategy than alanine scanning may gain 
additional mutants with improved recombination efficiency.  
The determination of the crystal structure would definitely help to apply more rational and 
likely promising mutagenesis. A few common modifications on the protein level represent 
appropriate means to boost the PhiC31 integrase enzyme in particular. Combination of 
beneficial properties regarding delivery, nuclear uptake, and recombination will result in 
synergistic effects. A large-scale genetic screen involving gene shuffling, as successfully 
performed with the SB transposase (Mátés et al., 2009) will likely result in additional 
efficiency and specificity mutants. It would also be of interest to combine the construction of 
hybrid integrase adenovirus fusion proteins (Ehrhardt et al., 2007) with the new mutants 
found in the present study.  
A next step might represent the generation of custom-built recombinases including a chimeric 
fusion of the integrase with a specific DNA binding domain e.g. a zinc finger nuclease which 
leads to specifically targeted double strand breaks near the site of the desired recombination 
(Caroll, 2008). Hence, the fusion construct can be used for gene targeting to any sequence in 
question, however this technique is still in an early state of research. 
Vector improvements to prevent post integrative gene silencing and the steady decline in 
expression by exchanging promoters and polyA sites (Aneja et al., 2009) should also be 
introduced into the plasmids used in this study. The reduction or depletion of bacterial 
sequences or CpG islands (codon-optimisation) within the backbone vector of both the 
substrate and expression plasmids reduce silencing effects and can thereby prolong transgene 
expression. Approaches to guarantee transient presence of PhiC31 integrase or regulated 
integrase activity within a predetermined time window enhance the safety profile and are 
therefore worth performing (Sharma et al., 2008; Zhang et al., 2009). Binding assays as 
EMSA (electromobility shift assay) help to understand individual steps in the recombination 
reaction and evaluate further deficiency or proficiency of particular mutant proteins in 
combination with different attachment sites.  
Delivery and metabolism of foreign DNA in cells and animal models for the sake of 
researching and understanding human diseases better represents a high challenge for the 
future. Lots of efforts still need to be done to improve persistence of transgenes in a more 
controlled and safe manner in an existing complex biological network. 
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8. Appendix 
Appendix 1: Selection of amino acids discussed within this study. 
 
Table 8.1. Chemical and physical properties and further characteristics of selected amino 
acids are presented, which are involved in the mutagenesis approach. 
 
Amino acid Chemical and physical 
properties 
Further characteristics  
Alanine;  
Ala (A) 
aliphatic, non-polar,  tiny, ambivalent, can be inside or 
outside of the protein molecule 
Aspartic acid 
Asp (D) 
acidic, polar (negatively 
charged) 
Glutamic acid 
Glu (E)  
acidic, polar (negatively 
charged) 
play important roles as general acids 
in enzyme active centers, as well as in 
maintaining the solubility and ionic 
character of proteins 
Lysine 
Lys (K) 
Basic, polar (positively 
charged) 
Arginine 
Arg (R) 
basic, polar (positively 
charged) 
frequently involved in salt bridges 
1 
 
 
2 
Figure 8.1. Selection of amino acids discussed within this study. The four amino acids are 
shown, which were shifted to alanine in the selected mutagenesis approach alanine scanning. 
The amino group (-NH3+) is depicted in blue and the carboxy group (COO-) is depicted in 
green, respectively. The side chain for each amino acid is presented in red.  
 
Amino acid properties and structures were derived from the websites below: 
1.)  http://www.biology.arizona.edu/biochemistry/problem_sets/aa/aa.html 
2.) http://www.thescienceforum.com/viewtopic.php?p=204149 
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Appendix 2: Molecular size markers 
 
 
 
Figure 8.2.A. PeqGOLD 100 bp DNA marker. 
This molecular size marker was used for 
appropriate determination of DNA fragments 
on 1.5- 2 % agarose gels. The size in base pairs 
of each single band is indicated. One enhanced 
band is shown at 500 bp. Reprinted from peqlab 
Biotechnologie GmbH.  
 
Figure 8.2.B. PeqGOLD 1 kb DNA marker. 
This molecular size marker was used for 
appropriate determination of DNA fragments 
on 1 % agarose gels. The size in base pairs of 
each single band is indicated. Three enhanced 
bands (1000, 3000 and 6000 bp) are shown. 
Reprinted from peqlab Biotechnologie GmbH. 
 
 
Figure 8.2. Molecular size markers 
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